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CHAPTER 1 
GENERALINTRODucnON 

Genera/Introduction 
1.1 HISTORY 
In the past decades osteoporosis has been recognized as an important public health problem. 
Several causes for this problem can be pointed out. The most probable cause for the 
development of osteoporosis is the loss of ovarian function in women and the increasing age 
of people!", thereby increasing the incidence of osteoporosis. Other causes or risk factors for 
the development of osteoporosis are immobilization and dietary deficiencies'. Finally, the 
outcome of osteoporosis is an increased risk for the development of fractures (chapter 1.3). 
The terminology associated with osteoporosis was developed in the nineteenth century by 
German pathologists to distinguish diseases of bone. Pommer stated in 1926 that in 
osteoporosis the formation of bone by osteoblasts was not able to replace the bone resorbed 
by osteoclasts. Pommer performed extensive histomorphometric analysis of bone, thereby 
distinguishing various forms of osteoporosis (senile, immobility), osteomalacia and osteitis 
fibrosa cystica'. 
The first reports concerning calcium homeostasis and bone metabolism were published in the 
first decades of this century, especially studies performed in animals"'. In 1923 Robison 
postulated that alkaline phosphatase (AP) plays a role in bone formation' and a few years 
later an increased concentration of serum AP was described in Paget's disease9 • 
Early this century, the first radiological studies of bone were published. In the 1930s and 
1940s routine x-ray methods were used to detect osteoporosis lO• Osteomalacia and 
osteoporosis could not be separated by means of radiographic methods and both were often 
considered together. 
In 1941 Albright et aJ. brought Some clarification and defined osteoporosis pathologically as 
'a condition in which there is lack of bone tissue, but that tissue which remains is fully 
calcified'li. This clearly differentiated it from osteomalacia, a condition in which bone matrix 
mineralization is delayed or has failed. In the same article Albright reviewed the clinical 
history of 42 patients with osteoporosisll. In this paper he founded several etiologic factors, 
i.e. diet-related, disuse and postmenopausal state. He stated that the major argument for the 
existence of postmenopausal osteoporosis was the frequency in which osteoporosis occurred 
in women after the menopause. A few years later Albright et aJ. showed the reducing effect 
of estrogen substitution on calcium loss in the urine in postmenopausal woment2. It was 
concluded that osteoporosis of the postmenopausal state had to be attributed to the decrease 
in estrogen production following the menopause. 
The following years the diagnosis of osteoporosis was made by using bone biopsies of the 
iliac crest in which a decrease of cancellous (trabecular) bone was observed, while with the 
use of tetracycline labelling also an impression of bone remodelling was obtained ll . At 
present a standardized nomenclature for bone histomorphometry is used t4 • 
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In the sixties further progress in the diagnosis of the disease was made, as new diagnostic 
possibilities were made available. The first bone densitometric methods were able to measure 
bone mineral mass in the forearm"'''. These instruments were improved rapidly and at 
present several different devices with high precision are available to measure at various sites 
in tIle skeleton (see chapter 2). 
Similar progress has been made in the development of several biochemical markers of bone 
resorption and formation. Until 1970 only urinary hydroxyproline as a resorption marker" 
and serum alkaline phosphatase as a formation parameter could be measured, whereas 
nowadays a variety of different turnover parameters are available. The interpretations of the 
different markers are still controversial and the relationships to one another are not 
completely understood, but the use of a combination of several turnover parameters seems 
to be promising for identification of subjects at risk for fractures and for follow-up of 
treatment"·19 (see chapter 3). 
Associated with the progress in diagnostic possibilities) is the increase in therapeutical 
options. Until !O years ago, hormone replacement therapy was the most important treatment. 
The last decade different treatment modalities have been developed (see Chapter 4). 
Currently osteoporosis is recognized as an important health problem in the Western world 
and Asia. Osteoporosis is also seen as one of the most common age-related metabolic 
diseases. With a growing elderly population the problem will probably augment in the years 
to come in the Western world, but to an even greater extent in other parts of the world, i.e. 
the Asian countries". Even after correction for these demographic changes the incidence of 
hip and other osteoporotic fractures is steadily increasing. It has been calculated that the 
number of hip fractures in the whole world will increase from 1.7 million in 1990 to 6.3 
million in 2050, indicating the magnitude of the problem'!. 
1.2 DEFINITION OF OSTEOPOROSIS 
Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue, leading to an increase in bone fragility22. In 
contrast with earlier consensus definitions this definition does not longer state the presence 
of a non-traumatic fracture necessary for the diagnosis of osteoporosis. 
Two categories of osteoporosis can be distinguished: primary and secondary. Primary 
osteoporosis occurs in the absence of known causes (except for the estrogen deficiency of the 
postmenopausal state) that may affect bone structure and quality. The two main 
representatives of this group are: postmenopausal osteoporosis, in which Ule loss of ovarian 
function (and thereby loss of estrogen) leads to an exponential bone loss'3 and age-related 
osteoporosis24. Other representatives of primary osteoporosis are: idiopathic osteoporosis, 
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mainly occurring in young adult and middle aged persons and juvenile osteoporosis, 
occurring before pUbertyH. Secondary osteoporosis represents a state, in which another 
disease or condition, known to affect bone turnover and leading to bone loss, is present 
(Table 1.1). 
Table 1.1 Callses oj secolldary osteoporosis 
Hyperparathyroidism 
Hypercortisolism 
Hyperthyroidism 
Hypogonadism 
Connective tissue disorders 
Malabsorption, liver cirrhosis 
Calcium and Vitamin D deficiency 
Drugs, i.e. corticosteroids, ethanol 
Immobilization 
Myeloma 
1.3 RISK FACTORS AND EPIDEMIOLOGY 
1.3.1 Risk factors 
As our population ages, the number of people at risk for developing fractures increases. 
Furthennore, fracture risk is correlated with bone mass, which in tum is inversely related 
with age and menopausal state"'''. Low bone mass in the elderly is determined by the peak 
bone mass and the age-related bone loss. In women the accelerated postmenopausal bone 
loss, superimposed on the age-related bone loss, plays an important additonal role. In figure 
1.1 the factors associated with the development of a low bone mass are presented. They will 
be discussed in this paragraph. 
The peak bone mass is already achieved in early adulthood"'''. After the age of about 20 -
25 years no further increase in bone mass is observed. The bone mass at skeletal maturity 
differs between the sexes and is about 30 % higher in men than in women23,JO. The peak bone 
mass is largely determined by genetic factors, i.e. in dizygotic twins much greater differences 
in bone mass are observed than in monozygotic twins31,32. It has also been observed that 
daughters from women with osteoporosis have reduced bone mass in the lumbar spine and 
femoral neck33. Compared to daughters of non-osteoporotic women the loss was about 5 -
7 %". Recently, it has been shown that common allelic variants in the gene encoding the 
vitamin D receptor are correlated with the bone density3~. However. between an Australian 
populationJ-t and a European popuiationJ5 opposite results were obtained. This has to be 
worked out further, but vitamin D receptor polymorphism seems to be correlated with bone 
densityH.35. 
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Figure 1.1 FaclOrs associated with the developmelll of low bone mass 
and subsequent increased fracture riSJ!J·29,J6.J7,49.54, 
Also environmental factors are known to influence peak bone mass, such as diet and 
exerciseJ6 . So, if onc wanlS to increase the peak bone mass, in order to prevent osteoporosis 
from developing later in life, prevention programs have to be started early in life. Physical 
activity by itself has been shown to increase bone mass, especially those activities which 
require resislance to an external force". Increased dietary intake of calcium during puberty 
has shown to increase peak bone mass in young people already using approximately the 
recommended dietary allowance of calcium38 . The overall effects of these potential 
interventions are of about 20 - 30 %, in terms of increased peak bone mass, compared to 
controls. 
Shortly after peak bone mass has been reached age-related bone loss starts". Three patterns 
of age-related bone loss in women have been described. Riggs et al. demonstrated loss 
commencing in 'young adulthood' and continuing in a linear matter throughout life". A 
second model suggested that cancellous bone behaves in a similar way as cortical bone, i.e. 
it is maintained until the menopause, when bone loss commences4I . The third model describes 
that cancellous bone reaches a peak in the mid-30s, and is followed by a progressive loss""". 
This last model is considered to be the most accurate and shows a loss of bone which starts 
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between the age of 30 and 40 years, in men as well as women. Approximately 0.3 - 0.5 % 
of bone per year is 10st42~s. In a longitudinal study a progressive bone loss in the femoral 
neCk, in men as well as women over 60 years old, was found of about I % per year". In this 
study rates of loss in the femoral neck showed an increase in both sexes with age. However I 
no significant loss in the lumbar spine was found". A different pattern of bone loss between 
the appendicular and axial skeleton has been suggested, i.e. a more pronounced loss at the 
axial skeleton before the menopause". 
Next to the age-related bone loss, in women a super-imposed bone loss occurs as a result of 
the menopause. This is an exponential loss, which starts around or just before the menopause 
and continues until about JO years after the menopause. During this period an amount of 
bone of approximately 15 % of cancellous and cortical is 10st27•47.". After this accelerated 
loss, the rate of bone loss will return to its premenopausal level49,5o. Although numerous 
exogenous risk factors related to low bone mass have been identified, these factors only 
explain 30 % of the variation in bone massSl • The risk factors other than genetic, that are 
recognized nowadays are presented in Table 1.2. 
Table 1.2 Non-genetic faclors for developing low bone lIIass 
Nulliparity 
Underweight 
Inactivity 
Previous diseases that reduce bone mass 
High ethanol intake 
Cigarette smoking 
Low calcium intake 
(e.g. hypogonadism, byper(para)thyroidism, hypercortisolism) 
Next to a low bone mass, other parameters are of importance for the development of a 
fracture, i.e. the quality of bone and some non-skeletal factors (Fig. 1.1). 
The loss of trabeculae has been shown to occur more often in women than in men. In a 
transversal study of normal iliac bone, it has been shown, that the mean number of trabeculae 
declines with age in men as well as womenSl . It was concluded that the disappearance of 
entire elements is the main event in age-related bone loss. Furthennore, in the same 
population, a lower trabecular width in women, than in men was observed. This may partly 
explain the higher incidence of osteoporosis in women52 . 
A sedentary life style and the age-related increase in falls are the two main non-skeletal 
factors which are related to the development of fractures". It has been shown that even a 
moderate exercise program already has a positive effect on the incidence of fractures. This 
is probably only to a small extent related to increased bone mass"'5S, but more importantly 
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to improved dexterity and to increased muscle mass". 
Falls are a common feature as age increases and although only a minority of the falls result 
in a fracture, falls certainly are a risk factor for the development of fracture. There are 
several circumstances, which can increase the risk of falling, i.e. the use of sedatives 
(including alcohol), inappropriate footwear, impaired visual perception, travel under bad 
weather conditionsS3·51 , 
1.3.2 Epidemiology of osteoporotic fractures 
The vast majority of osteoporotic fractures occur in elderly women. These comprise vertebral 
compression fractures, Calles fractures at the distal radius, hip fractures, and to a lesser 
extent fractures at other sites".!n the United States about 1.3 million fractures each year are 
attributable to osteoporosis, including about 250.000 hip, 250.000 wrist and 500.000 
vertebral fractures". In the Netherlands the age-adjusted incidence of hip fractures in women 
50 years of age and over is about 3501100.000. For men an incidence of 1501100.000 has 
been reported59 . 
There are large differences in the incidence of osteoporotic fractures between various 
geographic areas. Fracture rates seem to be higher in the temperate zones than in the tropics, 
i.e. in the northern parts of Europe and of the United States higher rates of fractures are 
observed than in the southern parts. Within Europe the difference in incidence of hip fracture 
between the northern and southern countries is about eleven-fold for women and about seven-
fold for men (highest in the scandinavian countries). The ratio between men and women is 
similar throughout Europe"'. The explanation for these differences is not clear but may 
indicate genetic differences andlor environmental factors. Incidence rates of osteoporosis and 
fractures also are higher in whites than in blacks, indicating that the geographical variation 
may be related to race and thereby to genetic differences". 
At this moment the best available possibility to assess the fracture risk of an individual is the 
perfomance of a bone mass measurement. In several prospective studies an association 
between baseline bone mineral mass and fracture risk is observed53,62.63. 
Unfortunately a single bone mineral mass measurement is not always able to differentiate 
completely between nonnal and abnonnal tH • A measurement at one site even does not predict 
the bone mass at another site within the same patient, and it is suggested that a measurement 
at the site of interest is the best predictor for the fracture risk at that specific site65--67. 
The risk factor for the development of osteoporosis, given by the bone mineral mass or 
density (BMD), is expressed as T-score or Z-score, according to WHO consensus criteria. 
The T -score is defined as the difference in standard deviations compared to the mean peak 
bone mass. The Z-score is defined as the difference in standard deviations compared to the 
mean bone mineral mass of age-matched controls. A T-score of -I to -2.5 is considered as 
osteopenia. A T-score of < -2.5 is considered as osteoporosis, whereas a combination with 
18 
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a non-traumatic fracture is considered as severe osteoporosis. The expression in T -scores is 
the preferential way of expressing the risk of osteoporosis at this moment. In the past this 
risk was expressed in Z-scores, in which a Z-score of < -1 was considered to represent a 
person at risk for the development of osteoporosis68 • 
It is also possible to detemline bone turnover parameters in serum andlor urine. At this 
moment, however. no single measurement is available which can be used in the fracture risk 
assessment for an individual. In the future a combination of a single bone mass measurement 
with a combination of bone turnover parameters may be used for the fracture risk 
assessment, but several problems have yet to be solved (see chapter 3.1). 
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2.1 INTRODUCTION 
The measurement of bone mineral mass or bone mineral density (BMD) has been the subject 
of intensive research over the past decades. Bone mineral content (BMC) determines about 
70 % of bone strength'-'. Also breaking strength of bone appears to be linearly related to 
mineral content4 . However, bone mass is not the only determinant of bone strength. Also 
other bone-related parameters have a certain impact on the bone strength: (I) geometric 
changes affect the modulus of elasticity of bone, such as the increased circumference of long 
bones with age; (2) compared to compact cortical bone smaller changes in the cancellous 
bone mass may be required to reduce bone strength (loss of connectivity); (3) the bone 
marrow fat content increases with age and changes the mechanical behaviour of bon~. 
As there are no routine measurements to assess the strength of bone in an individual, and 
bone mass seems to be a major determinant of bone strength, bone mineral mass is measured 
and used to predict fracture risk6.8• 
The different measurement sites of bone are moderately related to one another. It has been 
shown that they show different changes with age and in their response to different factors 
which affect bone mass in general. Because of the variability in response throughout the 
skeleton it is difficult to extrapolate directly from one site, at which measurement is feasible, 
to another as to fracture risk9.Il . 
A large variety of non-invasive techniques are available for the assessment of bone mass. 
There are wide differences in precision and complexity. For example radiogrammetry has 
important methodological problems. which is reflected in poor precision12 • It has however 
been demonstrated to be a rather good method in a large population-based study with respect 
to prediction of fracture 13 • Neutron activation analysis has, because of its high costs and 
technical complexity, not found widespread implementationl4 . More attractive are 
measurements which are easy and fast to perform, with a good accuracy and a high 
reproducibility. It is also important to measure specific regions in the skeleton. The 
measurements of bone mineral mass by means of photon or x-ray absorptiometry or CT-
scanning have made this approach possible. In table 2.1 several aspects of the different non-
invasive bone mass measurement methodes are presented. Furthermore, a brief overview of 
the various techniques and instruments that are commonly used for bone mass measurement 
are presented in this chapter. 
25 
Table 2.1 Several parameters of the different bone mass measurement methods. 
Technique Precision Accuracy Radiation Measurement site Scan time Costs References 
(%) (%) (mrem) (min) 
SPA 1-2 2·5 5 Proximal forearm 10 in between 14-16.21.23 
Distal forearm 
Calcaneus 
DPA 2-4 3-5 10-15 Lumbar spine 15-25 in between 14,21.28,29 
Hip 
Total body 
DXA 1-2 1-2 Lumbar spine 3-10 in between 30.31.36-40 
Lateral spine 
Hip 
Forearm 
Total body 
Radiographs 1-10 All bones low 42.43 
Radiogranunetry 1-2 10-20 Metacarpalia low 13.52 
Radiographic ? 10-50 Phalanx low 53.54 
densitometry 
QCT 2-5 5-10 50-70 Vertebrae 10 high 55.56 
Ultrasound 1-2 1-3 Calcaneus 5-10 low 62.64.68.69 
Patella 
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2.2 ABSORPTIOMETRY 
2.2.1 Single photon absorptiometry 
Photons are absorbed by bone and, to a much lesser degree, by soft tissues. When a beam 
of photons passes through bone, the amount of photon energy that is absorbed is proportional 
to the amount of mineral in the bone, 
In single photon absorptiometry (SPA), which was first described in 196315 , a iodine-125 
source, emitting 28 keY X-rays is used to provide transmission measurements through the 
tissues of the selected site. In the case of SPA, usually the distal radius is measured. To 
make the soft tissue thickness constant throughout the scan, the limb is inunersed in water 
or surrounded by water bags; hereby the only remaining variable at each measuring point is 
the bone mass present in the beam path. The beam is passed in a linc across a part of the 
skeleton. The attenuated beam is detected by a NaI crystal-photomultiplier as light pulses and 
transformed into a digital read l6 . The result is expressed as arbitrary units (U) per unit of 
region of interest or after calibration as grams (g) hydroxy-apatite (Ha) per cm. By division 
of this result by the bone width (measured at individual scans) the data are expressed as U 
or g/cm2 and are thereby corrected for skeletal sizel1 , 
SPA can produce accurate measurements only at sites that have very little soft tissue. 
Therefore it can be performed at the calcaneus and the forearm. The latter is generally 
used l8, 
In the forearm, the cross-sectional arcas of the radius and ulna vary along their length and 
also the proportion of cortical to trabecular bone varies, particularly distally in the bones. 40-
50 % of bone in thc ultradistal site consists of cancellous bone, but this falls to 10 % within 
the next 2 cm proximally, To overcome this problem there is an automatic detection (of 8 
mm) used of the distance between radius and ulna; from there on measurements commence, 
distally as well as proximally. 
An important problem when measuring with SPA is thc percentage of fat surrounding the 
bone. The penctration of the beam through fatty regions is greater, and the transmitted 
intensities are therefore higher than expected l9 , This may become an even greater problem 
when therapy is started for osteoporosis which may induce body composition changes, It is 
therefore important to correct for the fat mass, which is perfomled by using an algorithm, 
which corrects the raw BMC value, based on various amounts of fat in the surrounding 
tissue20 . 
In our laboratory the coefficient of variation (CV) for this technique was determined by 
measuring 50 healthy subjects. It proved to be 1.9 % and 1.0 % for the distal and proximal 
site, respectively'l, similar to what others have found in healthy peoplc". Long-term 
reproducibility is also good, a CV of 1.8 % over a 7 year period has been found". As the 
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half-life of "'I is rather short, the source has to be replaced every 3 to 4 months to maintain 
an adequate intensity for good precision. 
2.2.2 Dual photon absorptiometry and dual X-ray absorptiometry 
Dual photon absorptiometry (DPA) and dual X-ray absorptiometry (DXA) permit the 
detemlination of bone mineral content at sites, where there is much surrounding soft tissue, 
notably the femoral neck, the lumbar vertebrae or even the whole skeleton. Sources emitting 
two different energies arc used. 
In 1975, the Gadolineuml53 ('53Gd) source, that emits photons both at 42 and 100 keY was 
introduced. These photon energies appeared ideal for measuring bone through thick soft 
tissue layers. The half-life of '53Gd is 242 days and the working life of the source is 12-18 
months. 
In the 1980's, DXA was introduced and has replaced DPA. DXA is based on the same 
principle as DPA but uses an x-ray tube instead of an isotope as the photon source2-1. X-rays 
at two photon energies arc generated, either by rapid switching of the generator voltage 
between high and low kV in synchrony with the main supply", or by using a constant 
potential generator with a rare earth filter (samarium or cerium), There appears to be no 
particular advantage of one of both approaches26,27. 
The absorption of photons is dependent on three variables; the photon energy, the kind of 
absorbing material and the thickness of the absorber. With bone mineral mass measurement, 
the absorber consists of soft tissue and bone mineral in bone tissue. To eliminate the effect 
of the soft-tissue mass on the results of bone mineral measurement, two different 
measurements (one with low and one with high energy) are performed. The underlying 
principle is that the mass attenuation coefficients of two different tissues (i.e. soft tissue and 
bone) differ as a function of photon energy. By using two photon energies it is possible to 
calculate the attenualion in bone independent from the attenuation by the soft tissue. After 
calibration the BMC is calculated as gHa. BMD is calculated by dividing BMC by the 
surface of the projected regions of interest (gHa/cm'). 
DPA of the lumbar vertebrae has a high precision, with a CV of 1-4 %" for the lumbar 
spine, but is limited by the need for exacl relocation for reproducibility. In our laboratory 
the CV in osteoporotic women proved to be 3.7 and 2.3 % for BMC and BMD 
respectively". The precision may be influenced by source change. 
The precision of DXA is higher than with DPA, with an error of about I %. In our 
laboratory the coefficient of variation for normal women is 1.1 + 0.2 % for the lumbar 
BMD and 1.4 ± 0.2 to 2.3 + 0.3 % for the various regions in the proximal femur". 
Because of the higher photon fluxes in the X-ray tube, the radialion beam can be highly 
collimated, resulting in high resolution images, improved study precision, shorter scanning 
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times and reduced radiation dose to the patient". 
Besides the problem of precision, DPA and DXA measurements in the lumbar spine may be 
affected by aortic calcification and osteophytesll.29."-". 
With the increased photon flux with DXA, lateral projection of the spine became more 
accessible. The advantage of a lateral projection measurement is that it is possible to perform 
isolated measurements of the vertebral body without inclusion of the posterior spinal elements 
and of possible aortic calcifications". However, differences in overlying fat amount may 
introduce another bias in the lateral projection35 • 
Next to measurements of the lumbar spine (anteroposterior and lateral) it is also possible to 
measure the proximal femur at three regions of interest; the femoral neck, Ward's triangle 
and the trochanteric region". The femoral neck represents an area with predominantly 
cortical bone, whereas the Ward's triangle represents an area with mainly cancellous bone. 
h has also been shown that DXA-measurements can be used to assess bone mineral mass in 
the forearm with comparable results as SPA measurements (correlation r=0.99)". 
Besides the measurements of bone mineral mass in the various regions of the skeleton it is 
also possible to measure total body bone mineral and determine soft tissue composition, 
showing a higher precision with DXA than with DPA for bone density as well as fat mass 
and lean body mass. With DXA a three-compartment analysis of the total body is made, 
consisting of total body mineral content (TBMC), total body lean tissue mass (TBLTM) and 
total body fat mass (TBFM). TBLTM is largely a combination of total body water and total 
body protein. Fat free mass is the sum of TBMC and TBLTM. It is concluded that DXA 
provides precise composition analysis with a low radiation exposure (1-3 mrem) and a 
scanning time of about 20 minutes". The coefficient of variation for the various total body 
measurements has been reported to be around 0.8 + 0.5 %". Correlations between these 
measurements and olher body composition measuring methods have been found with an c-
value of about 0.80"'. 
2.3 RADIOLOGY 
Radiographic methods for the evaluation of osteopenia are divided into three categories: (I) 
qualitative, (2) semi-quantitative and (3) quantitative. The qualitative methods include plain 
radiographs and are usually the initial techniques used in the clinical diagnosis of osteopenia 
or osteoporosis. Semiquantitative methods are those that are based upon a grading system. 
Quantitative methods include radiogrammetry and radiographic densitometry. 
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2.3.1 Radiographs of Ihoracal and lumbar vertebrae and femoral neck 
The normal vertebral body is homogenous in its opacity as seen on a lateral x-ray. As 
vertebral osteoporosis develops, there is a loss of density in the centre of a vertebral body 
more than in its cortical shell. Because of the preferential loss of the horizontal trabeculae, 
the vertical trabecular pattern appears to be accentuated. The advantage of using radiographs 
of the vertebrae is that it is a rather simple technique, which is widely available. An 
important disadvantage is that changes are only seen as already a substantional amount of the 
bone mineral (more than 30 %) has disappearedll . On the other hand, vertebral radiographs 
remain the best method for assessing the presence of vertebral fractures. For screening 
purposes, however, in a prevention or an early intervention program there is no place for the 
use of radiographs. 
Changes in height of vertebrae have been used as an index of progressive bone loss and 
various grading schemes have been proposed". It is important to be informed about the 
lateral view of both thoracic and lumbar spine. The radiographs have to be performed in a 
standardized position43 • 
Until recently there were no agreed-upon criteria for the variability in normal vertebral shape 
or in the transition from nonnal to vertebral defonnation and vertebral fractures. However, 
recently a consensus meeting has given guidelines for the procedure for taking the 
radiographs as well as for special considerations with respect to longitudinal studies44 . In the 
same consensus report criteria for the diagnosis of prevalent fractures as well as incident 
fractures are described4-J. 
For quantitative measurement of vertebral bodies, typically six points are marked, defIning 
the anterior, middle and posterior heights of each vertebral body". 
Several defInitions have been suggested to defIne normal vertebral bodies and fractures"''', 
leading to a (semi-)quantitative measurement. With this method normal values are obtained 
from a representative sample of groups that have a very low prevalence of vertebral 
defonnity (e.g. premenopausal women). The relative vertebral heights of patients with 
osteoporosis are compared to the relative vertebral heights of the normal subjects. This 
comparison allows the identifIcation of deformed vertebrae, as well as a quantifIcation of the 
extent of deformation due to these fractures, which is expressed as spine defonnity index 
(SDI)". An important disadvantage of this technique is that it is very time-consuming and 
therefore expensive. Recently McCloskey et aJ. developed another semi-quantitative technique 
for assessing vertebral deformities based on lateral spine radiographs, which showed a high 
specificity. This technique is based on differences in the ratio within a vertebra of anterior I 
central and posterior heights, which are compared to reference values, obtained in controls. 
In patients a cut-off of -3 standard deviations was used in assessing the number of vertebral 
fractures". On the other hand, it has also been shown that a rather simple approach of a 
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semiquantitative grading of vertebral fractures, i.e. visual inspection without direct vertebral 
measurement showed a good correlation with quantitative morphometry". As the different 
quantitative techniques for the assessment of vertebral deformities are very time-consuming, 
the only application of these techniques at present are the use in population studies and 
clinical trials. Also in these studies quantitative vertebral morphometry should be compared 
with simple visual grading". 
Recently it has been shown that the hip axis length (HAL) (i.e. the distance from the greater 
trochanter to the inner pelvic brim) is correlated with the risk for developing a hip fracture. 
With every standard deviation increase in HAL, nearly a doubled risk for hip fracture was 
observed, independent of other known risk factors49 . In this group there was no correlation 
with height. The increased risk of hip fractures in white women, compared to asian and black 
women may also be related to the HAL, as it has been shown that white women have 
significantly longer HAL's. Also body composition may be related to this difference". One 
can speculate about the possibilty to use the HAL in combination with BMD. For instance 
one may decide not to start prevention therapy, because of a short HAL in combination with 
a modest decline in BMD, whereas on the contrary a longer HAL may be of decisive value 
to start preventive therapy with a similar BMD. Whether this rather simple technique can be 
used in ti,e risk assessment for future development of a hip fracture has yet to be established. 
2.3.2 Radiogranffiletry and radiographic densitometry 
In radiogrammetry the midshaft of the second metacarpal of the nondominant arm or of 
several metacarpals of one or both hands are measured". The method requires a high quality 
radiograph taken under standardized conditions. The outer and inner diameters of the 
metacarpal cortex are measuredsi . The correlation with other measurements of bone mass is 
reasonable. The main advantage of this techniques are the low cost, the reproducibility and 
the easy performance of the teclmique in large groups of patients or normal persons l ).". 
In radiographic densitometry or quantitative radio-microdensitometry (QMD) standardized 
radiographs of a phalanx provide a measure of BMD. The density of the bone on the 
radiograph is analyzed with an optical microdensitometer together with a simultaneously 
radiographed aluminium reference wedge53.S4 . 
2.3.3 Quantitative CT-scanning 
Quantitative CT-scanning (QCT) is the only technique which can measure a real bone mineral 
density expressed per unit volume of bone. It is also the only technique that is able to distin-
guish the density of cortical and cancellous bone. Standard CT-scanners are all potentially 
capable to measure at the level of the lumbar spine. With QCT, a standard phantom is 
measured along with the lumbar vertebrae. The value of the attenuation of the radiation by 
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the bone, which is compared to that of the phantom, is expressed as mg K,HPO,/cm'. These 
values are used as a true measure for bone mineral density. 
The precision with this measurement is in phantoms about 1-2 %, but less favourable in vivo. 
In our institute a precision of about 2.5 - 2.7 % in osteoporotic women was found at the 
level of the lumbar spine". 
The accuracy of the QCT measurements is between 5 an 10 %55, The amount of marrow fat 
is for a great deal responsible for this low accuracy. \Vith age, the amount of intravertebral 
fat increases and bone red marrow mass falis, leading to an underestimation of the bone 
mineral mass. This problem can be overcome by using dual energy QCT, in stead of single 
energy QCT,,·17. 
In the past, an important disadvantage of QCT, was the high radiation dose of about 200 
mrem, which has been reduced to about 50 mrem. However, this is still a much higher 
radiation dosage, when compared with DXA. 
Nowadays high resolution CT scanning with a resolution of about 0.25 mm (as opposed to 
I mm) is under investigation. With this high resolution it may be possible to quantify 
cancellous bone structure in a more precise manners. With micro CT -scanning it is possible 
to measure also structure of bone and not alone bone mass, but this technique is only 
available for in vitro studies59 . 
In the future it may be possible to perform bone mass measurements and even get an 
impression of bone structure by using magnetic resonance imaging (MRl). The main 
advantages of this technique are the high resolution and the fact that no radiation is used. 
However, at present this technique can only be used in in vitro situations59.60• 
2.4 ULTRASOUND MEASUREMENTS 
In recent years a new technique for the non-invasive measurement of bone has been 
developed. This technique is based on the use of ultrasound waves, which means that it is 
a non-ionizing technique. Media for which the velocity of ultrasound are not equivalent 
throughout the medium, are known as dispersive. Bone is an example of a dispersive 
medium, and cancellous bone is more dispersive than cortical bone. Because ultrasound is 
a mechanical wave, its attenuation is suggested to depend on both the structural and material 
properties of the propagating medium61 • There are two sites, which are attractive to measure, 
i.e. the os calc is and the patella. Most often the as calcis is rneasured62 . 
Two types of measurements are perfonned, speed of sound (SOS) and broadband ultrasound 
attenuation (BUA). The system consists of a tank with water or a coupling gel is 
administered around the as calcis. Two broadband ultrasonic transducers (emitting and 
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receiving) are present. The heel or knee is positioned between the transducers, in which the 
calcaneus or patella acts as a frequency selective absorber for the ultrasonic waves. After 
scanning, the SOS and BUA are calculated by a computer program, correcting for the 
influence of water". SOS is expressed in mlsec and BUA in dB/Hz. The in vivo 
reproducibility is about 3-4 %. One of the main problems with this new technique is related 
to the inhomogeneity of the os calcis and to the sensitiviy of BUA to small changes in density 
and structure". A high variability of the measurements is related to the position of the 
transducers64 . One of the most critical steps therefore is correct foot positioning. Because this 
influences reproducibility due to interindividual anatomical variations and variable amounts 
of soft tissue below and behind the heel, the site of measurement may vary from one subject 
to another. A new technique. BUA imaging, may diminish these variances65 • 
Ultrasound measurements are suggested to be related to the compressive strength and load 
bearing capacity. If these measurements are able to characterize the complex. mineral and 
nonmineral properties of bone, it might be useful in predicting fracture ris~2. Ultrasound 
measurements might therefore be complementary to BMC and/or BMD measurements 62. 
Calcaneal BMC has been found to predict spine mineral content and spine fracture incidence. 
although the calcaneus is a mainly cancellous bone and not a common fracture site66 . 
A correlation of about 0.6-0.7 between calcaneal ultrasound measurements and 
absorptiometry of the femoral neck andlor lumbar spine has been reported"'''. In another 
cross-sectional study, however. only weak correlations of 0.3-0.5 between ultrasound 
measurements and femoral neck and lumbar spine BMD were observed". In this particular 
study it was also not possible to identify subjects with low BMD by means of ultrasound 
measurement. A correlation of 0.99 between DXA- and ultrasound measurements has been 
observed in calcaneal bones, obtained from deceased people (personal communication J.W. 
Kuiper). Recently also high correlations of ultrasound of the calcaneus and densitometry of 
the proximal femur with the failure loads of cadaveric femurs have been found". No extra 
infonnation was obtained with the ultrasound measurement as compared to densitometric 
methods69 • 
The main question at present is, whether this ultrasound technique offers information on bone 
quality 1 additional to the results of bone mineral mass measurements. Present data indicate 
that ultrasound is another density measurement. 
The main advantages of this technique at this moment, are the short scanning time, the low 
cost and no use of radiation. 
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BONE TURNOVER PARAMETERS 

Bone Tumover Parameters 
3.1 INTRODUCTION 
Research has been focused on the identification of markers of bone mineral metabolism, 
which can provide more insight in the process of bone turnover, and may therefore be used 
in the identification of disease. 
The bone turnover markers, which can be determined in serum or urine samples, are the 
easiest to collect, since other parameters of bone turnover are more difficult to assess, i.e. 
bone histomorphometry or radiokinetic methods!. 
Bone remodelling or turnover refers to the sequential processes of resorption and subsequent 
formation, which is essential for the maintenance of bone mass. This bone remodelling 
process was first described by Frost'. Bone is remodelled by osteoclasts and osteoblasts, 
working in combination in a cycle of activity that lasts between 3 and 6 months'. In 1899, 
it was already recognized that bones remodel in response to the forces applied to them'. The 
resorption of bone by osteoclasts and its replacement by osteoblasts are normally 'coupled', 
which ensures that the processes of bone destruction and formation are more or less 
matched'. Both are subject to local and humoral regulation, by which bone resorption and 
formation can be stimulated or inhibited6. This coupled process is altered in the period 
between midlife and older age: resorption exceeds formation, leading to a reduction of 
skeletal mass. This proces has been extensively studied by means of bone histomorphometry 
7·9 and by recording changes in biochemical markerslO . In the cancellous bone much more 
remodelling sites are present than in the cortical bone, because of the higher surface to 
volume ratio in cancellous bone. Consequently, disorders of remodelling become earlier 
manifest in cancellous bone than in the conical regions. 
It is possible to assess bone turnover by measuring in serum and/or urine markers of bone 
fOffilation and resorption. In figure 3.1 and table 3.1 the various markers of bone turnover, 
which are available, are listed. 
These markers will be discussed in the following paragraphs, in which they will be divided 
into fonnation and resorption markers. Despite this separation into two groups, it should be 
borne in mind, that in disease states in which both events remain coupled, either of these 
groups of markers will reflect the overall rate of bone turnover. 
The biochemical markers can be used for two purposes; follow-up of treatment and the 
prediction of the rate of bone loss. In postmenopausal osteoporosis changes up to 50-100 % 
in biochemical markers of bone turnover have been reported. The reproducability of the 
different assays are in the order of 85 to 95 %. As the changes in biochemical markers occur 
earlier during treatment, compared to the changes of bone mass measurements, they might 
be used as early indicators of a therapeutic response. 
The other purpose for which biochemical markers can be used is the prediction of the rate 
39 
CHAPTER 3 
organic 
matrix 
minerai 
non 
collagenous 
protein 
collagen 
bone-specific 
alkaline 
phospalase 
praleoglyean 
Qsleoca[cln 
osteonectln 
etcetera 
Figure 3.1 Biochemical composition of bOlle. 
Table 3.1 Biochemical markers of bOlle tUn/over. 
Formation 
(Bone specific) alkaline phosphatase 
Osteocalcin 
Pro·collagen type-I 
Osteoneclin 
Bone siaioprotein II 
Resorption 
Urinary hydroxyproline 
Tartrate resistant acid 
phosphatase 
Urinary pyridinoline and 
deoxypyridinoline crosslinks 
Telopeptides of collagen type-I 
Fasting urinary calcium 
of bone loss, and therefore indirectly the fracture risk. It has been shown tllat biochemical 
markers reflect the rate of bone loss in postmenopausal womenll-13 • In the study of 
Christiansen et a!., the biochemical parameters were only related to the bone loss at the 
proximal foreann l2 . 
The rate of bone loss may also be a determinant of bone quality, i.e. a fast bone loss may 
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result in a deterioration of the bone structure of the cancellous bone, which will not be 
reflected in bone density measurement. On the other hand, biochemical markers reflect 
turnover states throughout the skeleton, and might therefore be less predictive for bone loss 
at specific skeletal sites'''. 
There are a number of other potential problems in using biochemical parameters. Different 
assay methods have different perfonnance characteristics. Accuracy and precision may differ 
within and between laboratories. Another problem is that these entities vary from day to day, 
and also show distinct seasonal and circadian fluctuations's. 
Theoretically, a combination of multiple biochemical measurements may offer greater 
efficiency but is also more complicated to apply. However, because of the correlation 
between the various bone turnover parameters, it is not clear whether different markers 
provide different infonnation. The relative levels of specific markers of bone fonnation and 
bone resorption may also be of importance l6 . 
3.2 BIOCHEMICAL MARKERS OF BONE FOfuvlATION 
3.2.1 Total and bone specific alkaline phosphatase. 
Serum total alkaline phosphatase activity (sAP) is the oldest known biochemical marker of 
bone tumoverl7. Already in 1923, it was postulated that sAP reflects bone formation" and 
a few years later an increased level of sAP in Paget's disease of bone was described". 
Because sAP is not only produced in osteoblasts but also in other tissues, for example liver, 
kidney. intestine and placenta, its measurement lacks specificity2o,2l, In older people changes 
in sAP levels frequently represent liver disturbances because of medications. Changes in sAP 
levels therefore do not always represent metabolic bone disease20 . 
In osteoporosis the lack of sensitivity and specificity is of great importance because the 
majority of the patients have normal values of sApn. In other bone diseases a better 
correlation between severity of the disease and value of sAP is found. In primary and 
secondary hyperparathyroidism sAP correlates positively with radiological and histological 
involvement of the skeletonB . Also in Paget's disease of bone a positive correlation between 
radiological changes and sAP has been found24.25 . 
Because of the rather low sensitivity and specificity of sAP measurement, several attempts 
have been made to differentiate the several isoenzymes of sAP, especially bone and liver 
sAP. The isoenzymes arc encoded by a single gene and differ therefore only in their 
posttranslational modifications26 . 
Initially, the activity of the various iso·enzymes was assessed with the use of differentially 
effective activators and inhibitors (heat, phenylalanine and urea), electrophoresis or 
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separation by polyclonal antibodies'~28. These methods did only slightly improve specificity 
compared to total sAP. 
Recently monoclonal antibodies, recognizing only the bone sAP have become available. This 
new technique is based on a two-site immunoradiometric assay (IRMA), which involves 
specific monoclonal antibodies to measure bone specific AP in serum29 . The first clinical 
reports suggest that this approach results in a higher sensitivity and specificity'". 
3.2.2 Serum osteocalcin (Bone Gla-protein) 
Osteocalcin (OC), also called bone Gla protein (BGP) is a small non-collagenous protein that 
is specific for bone tissue and dentin. OC was discovered in 1975". At first ganuna-
carboxyglutamic acid (Gla) residues were found in coagulation factors derived from liver 
tissue, in which under the influence of vitamin K, glutamic acid (Glu) was carboxylated to 
Glan. Later on these Gla residues were also discovered in non-hepatic tissues. In mineralized 
tissues, a protein rich in Gla residues was found, named osteocaicin3[,3J. OC contains three 
residues of gamma-carboxyglutamic acid"''', which have a high affinity for Ca'+. 
OC is synthesized de novo only by odontoblasts" and osteoblasts,,·J7. Its synthesis is directly 
stimulated by 1,25-(OH), vitamin D,"-". In mature bone, OC is the most abundant non-
collagenous protein, comprising 1-2 % of the total protein content of bone and about 25 % 
of the non-collagenous matrix proteinsH .)9. 
A small fraction of the newly synthesized OC is released into the circulation ("leakage"), 
where it can be measuredW.41 • 
Until now the exact function of OC is unknown although it has been postulated that OC may 
playa regulatory role in both bone resorption and mineralization". The involvement of OC 
in mineralization is illustrated by its expression in bone at the time of mineralization42-45 . 
OC levels are valid markers of bone turnover when coupling between fonnation and 
resorption is present and are a specific marker of formation when turnover is uncoupled. This 
is best illustrated in patients with multiple myeloma (M. Kahler), in which an inverse relation 
between OC and severity of the disease has been found, i.e. the lowest values of OC in the 
patients with the most extensive lytic lesions". After treatment, OC showed a rise, correlated 
with diminishment of the disease activity and an increase in osteoblastic activity%. 
In hyperparathyroidism a positive relationship between disease activity and OC has been 
shown. The level of OC correlates with levels of PTH, serum calcium and adenoma mass". 
With "Ca kinetics" or bone histomorphometry the OC level has been shown to correlate with 
bone fannation and mineralization rates47• 
In postmenopausal osteoporosis OC is a valuable marker of bone turnover with high 
correlations between DC values and histornorphometric measurements of bane fonnation48.49. 
OC is in the lower range in patients with low turnover and is significantly increased in the 
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patients with higher turnover5°. In untreated postmenopausal women, a single measurement 
of OC in combination with urinary excretion of deoxypyridinoline has been reported to 
reflect spontaneous rate of bone loss as assessed over a follow-up period of 2 years 
(r=0.77)50. 
Because vitamin K is essential for the carboxylation of DC and, thereby for its ability to bind 
Ca2+. vitamin K antagonists (anticoagulants) are able to increase the proportion of 
noncarboxylated OC relative to carboxylated OC51 .52. There are some experimental indications 
that the use of vitamin K antagonists may induce slower bone formation and even slower 
fracture healing52.". Nevertheless bone mass appears not to be affected". It has also been 
shown that administration of vitamin K increases the total OC concentration as well as the 
DC-hydroxyapatite binding capacity". 
In elderly women, an increased level of serum undercarboxylated DC (ucOC) has been 
found, despite nonnal levels of vitamin K". Recently it has been shown that ucOC is a 
marker for the risk of hip fracture in healthy elderly women, suggesting that serum ucOC 
reflects some changes in bone matrix associated with increased fragiliry56. The exact 
mechanism of this undercarboxylation is still unclear, but a relationship with vitamin D 
seems likely, as ucOC was negatively correlated with 25-0H vitamin OJ and administration 
of vitamin D induced a reduction of UCOC56 . 
Taken together, OC is a useful biochemical marker, in characterizing patients with changes 
in bone turnover, as well as in monitoring treatment. 
3.2.3 Carboxylerlllinal propeptide of type I collagen 
Type I collagen represents 90 % of the organic matrix of bone and is produced by the 
osteoblastss7 • Therefore, markers of collagen synthesis, may be of relevance as biochemical 
Illarkers of bone fonnation. During fonnation the carboxytenninal propeptide of type I 
collagen (PICP) is split off from its precursor, procollagen, in a I : 1 molar ratio of newly 
formed collagen. PICP is not incorporated in bone but is released into the extracellular 
fluid". In contrast, part of the aminotenninal extension peptide of collagen type I (PINP) is 
incorporated into bone matrix, where it has been identified as the 24 Kd phosphoprotein of 
bones9 . 
Recently radioimmunoassays for the measurement of PICP and PINP have been developed 
"'62. Although assays for PICP and PINP both measure native procollagen similarly, the 
serum concentration for PINP is almost a IOO-fold higher than that of PICP". This strongly 
suggests that there is a preferential release of PINP from bone andlor that the clearance of 
PINP is retarded compared to PICP, or both"'. 
Measurement of PICP seems to give more representative results than do PINP assays in 
primary hyperparathyroidism and Paget's disease""". 
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In a recent study an increase of PICP shortly after the menopause was observed, indicating 
an increased bone turnover. This increase could rapidly be reversed by adminislralion of 
honnone replacemenllherapy"'. The same sludy, however, did nol show any advanlage for 
PICP compared to measuremenl of oSleocalcin. Charles el al. sludied several groups of 
patients, i.e. thyreotoxicosis, osteoporosis and nonnals and found a significant correlation 
between the measurement of PIep and 47Ca kinetic studies65 . This correlation, however was 
ralher weak wilh a r-value of about 0.50. 
PICP and PINP are resislenl to defrosling, whereas osteocalcin is not. Olher advanlages for 
Ihe measurement of PICP or PINP are nol present. 
3.2.4 Other bone proteins 
Next to the above mentioned markers of bone fomlation, two other bone-related proteins: 
osleonectin and bone sialoprolein II (BSP), are secreted by Ihe osleoblasls and are potential 
markers of bone fconation. Both can be measured by RIA 66,61, These measurements however 
do not reflect bone turnover in a precise manner because significant amounts of both proteins 
are produced in olher cells, i.e. plalelels and fibroblasls, which conlribute to the 
concentrations measured in serum63 . Currently, no monoclonal antibodies, which detect only 
osteonectin and BSP from bone, are available. 
3.3 BIOCHEMICAL MARKERS OF BONE RESORPTION 
3.3.1 Urinary hydroxyproline 
A commonly used measurement of bone resorption and, indirectly. of bone turnover is the 
urinary excrelion of hydroxyproline (OH-P). OH-P is found only in collagen and represenls 
about 13 % of the total amino acid content of mature collagen69 • 
OH-P once released from collagen is not reused for collagen biosynthesis and is released into 
the urine 17 • Since the bone matrix contains half of human collagen, and has a rapid turnover 
compared 10 olher collagen pools, like Ihe skin, urinary OH-P is ulilized as a marker of bone 
resorption. 
Despite the infonnationprovided by urinary OH-P. il has several disadvantages. OH-P is not 
specific for collagen-Iype I, which is Ihe bone specific collagen. In praclice, urinary OH-P 
also originates from other sources such as diel (gelalin), the Clq fraclion of complement, 
turnover of soft connective tissues and degradation of the aminoterminal propeptides from 
collagen biosynlhesis70 • Only aboul 10 % of Ihe OH-P released by the breakdown of collagen 
circulales in Ihe peplide-bound fonn, and Ihese peplides Ihal conlain OH-P are filtered and 
excreled in the urine wilhoul further melabolism. The olher 90 % of the OH-P, released 
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during breakdown is degraded to free amino acids (serine and glycine) that circulate in 
plasma and are almost completely reabsorbed in the kidney after filtering. Finally it is 
completely oxidized in the liver71 • 
OH-P is usually measured in a 24 h urine collection, and the patient is ordered to avoid food 
wilh a high gelatin contenl for at least Iwo days before the collection. Because this has led 
to problems with patient compliance and interpretation of the results nowadays the OH-
P/creatinine ratio in an early 2-hour morning specimen after an overnight fast is measured72 . 
With this measurement OH-P is a good parameter of bone resorption. In the same sample 
also calcium excretion as a marker of resorption can be measured. Despite the easier 
collection of urine, the olher above menlioned problems with respect to OH-P still exist. 
\Vhen the OH-P excretion in urine is used in the evaluation of postmenopausal osteoporosis 
it seems important to look also at the other parameters of bone turnover. It has been claimed 
Ihat urinary OH-P values together with body mass index, serum alkaline phosphatase, and 
urinary calcium measurements can designate nearly 80 % of postmenopausal women with 
accelerated bone loss73. In this study J however only the foreann was taken into account. Data 
with respect to the same variables and the lumbar spine are not available. 
3.3.2 Tartrate-resistant acid phosphatase (TRAP) 
Acid phosphatase is a lysozomal enzyme that is present primarily in bone, prostate, platelets, 
erythrocytes and the spleen. The different isoenzymes can be separated by electrophoretic 
methods. In serum two main isoenzymes are present, isoenzyme 5 is produced by osteoclasts, 
and is resistant to tartrate (TRAP), whereas isoenzyme 3 is inhibited by tartrate'. The 
function of TRAP is still unknown. Plasma TRAP levels are elevated in a variety of 
metabolic bone diseases, for example in Paget's disease of bone7s , in vertebral osteoporosis76 
and certain categories of osteopetrosis77 . These elevations correlate well with other markers 
of bone tumover75 • At this moment it has not been shown that TRAP is a more sensitive 
marker for bone resorption than urinary OH_p78 . As there is currently no monoclonal 
antibody against the bone isoenzyme of TRAP available, there is no place for the 
determination of TRAP as a marker of bone resorption. 
3.3.3 Urinary excretion of the collagen pyridinium crosslinks 
Pyridinium crosslinks are products of a unique series of reactions during the maturation of 
collagen fibrils that lead to the fonnation of pyridinoline (Pyr) and deoxypyridinoline (dPyr) 
also called hydroxylysylpyridinoline and lysylpyridinoline, respectively. Bone collagen 
contains both Pyr and dPyr. Release of these components from bone undergoing resorption 
constitutes the main source of both crosslinks in urine79.8o . Pyr as well as dPyr have been 
identified in many connective tissues, such as bone, cartilage, and, to a lesser extent, other 
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connective tissues, except skinsl , Pyr is present in greater amounts than dPyr most of these 
tissues (molar ratio Pyr:dPyr 10: I), whereas dPyr is present in a higher proportion especially 
in bone tissue (molar ratio Pyr:dPyr 3.5:1)81. 
Because, compared to other connective tissues, bone tissue has a high turnover, it is believed 
that the pool of pyridinoline crosslinks in the urine is mainly derived from bone. The 
crosslinks can be measured by fluorometry after reversed phase high pressure liquid 
chromatography (HPLC) of cellulose bound extracts of hydrolyzed urine". 
Compared to the measurement of urinary OH-P, the measurement of the crosslinks seems 
to have some advantages: they are relatively specific for bone, they are not metabolized 
further before their urinary excretion and they are not influenced by dietary denatured 
collagen8~ . 
In early postmenopausal women an increment of the crosslinks in urine has been shown, 
whereas a decline after honnone replacement therapy was observed l1 ·22.85, Also in other 
(non-) metabolic bone diseases, such as primary hyperparathyroidism and neoplastic bone 
disease. an elevated excretion of both crosslinks has been found86,81, 
Since the current method of measuring both crosslinks in the urine (HPLC) is rather 
complicated, several methods have been developed to measure the pyridinoline crossIinks 
more directlys.s. 
3.3.4 Telopeptide of collagen type I 
The cross-linked carboxy terminal telopeptide of collagen type I (ICTP) is a 9 kD fragment 
of type I collagen which is released into the extracellular fluid during the resorption of 
mature bone collagen. Its concentration in serum has been reported to correlate with 
histomorphometric measurements of bone resorption89 . However. in another study this was 
not confirmed90, Charles et al. found weak correlations in high and low bone turnover states 
between ICTP and 47Ca kinetics65 . The use of ICTP as a marker of bone resorption in serum 
has to be evaluated further. before it can be used in clinical practice. 
Recently, urinary levels of the cross-linked N-terminal telopeptide of type I collagen have 
been reported to be a more specific and sensitive marker of bone resorption91 , The peptide 
which is measured in this assay appears to be unique for bone collagen degradation and 
seems to be promising92. Also a urinary marker with a peptide sequence specific for the C-
telopeptide a 1 collagen chain (Crosslaps) has been introduced recently and is under 
investigation for the use as marker of bone resorption. 
3.3.5 Fasting urinary calcium 
The total daily excretion of calcium is dependent on calcium intake during day-time. The 
fasting urinary calcium, however, does not come from the diet but is derived from the 
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tissues, presumably bone or bone cells93 • For this reason it can be used as a marker of bone 
resorption. An elevated value generally means an increase in net bone resorption and is seen 
in postmenopausal osteoporosis and hyperparathyroidism93 • As also OH-proline in urine is 
measured in a 2 hours fasting urine sample, both measurements can be performed in the 
same sample. 
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TREATMENT MODALITIES 

Treatmelll Modalities 
4.1 INTRODUCTION 
In the discussion of the treatment of osteoporosis, two situations have to be distinguished. 
First, the early detection of those at risk for developing osteoporosis (secondary prevention) 
and secondly the treatment of established osteoporosis (tertiary prevention). The goal of 
primary prevention is to prevent a disease from developing at all. Prevention of bone loss 
is most effective in the earliest stages of osteoporosis (secondary prevention), i.e. before 
perforation and removal of cancellous bone structures has led to irreversible destruction of 
bone microstructure1, However, it has been shown that arrest of further bone loss also in 
patients with established osteoporosis reduces the number of further fractures. The ultimate 
goal of the several different treatment strategies is to decrease the incidence of new 
osteoporosis-related fractures. 
As osteoporosis is considered to be a consequence of a disbalance between resorption and 
formation, drugs used to treat osteoporosis can be grouped into those that decrease bone 
resorption and those that increase bone formation. In table 4.1 the drugs, currently used or 
under investigation. are listed. 
Table 4.1. Medications llsed in the prevention and treatment of osteoporosis. 
Antiresorotive drugs 
Estrogen or 
hormone replacement therapy 
Anabolic steroids 
Bisphosphonates 
Calcitonine 
Unknown or complex action 
Calcium 
Vitamin D derivatives 
Growth hormone? 
Fonnation inducing drugs 
Fluoride 
Parathyroid honnone 
Growth honnone ? 
In table 4.2 the proposed working mechanisms for the various medications are presented. It 
is striking to observe, that the treatment that is used most often, i.e. estrogen substitution 
does not have a fully understood mechanism of action. 
Recently, the impact of bone resorption inhibitors on the so-called "bone-remodelling 
transient" has been reviewed by Heaney'. The gain of bone induced by an inhibitor of bone 
resorption will only be transient because the associated rate of change in bone mass persists 
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Table 4,2 Proposed mechanism of action of the variolls treatment modalities. 
Medication 
Estrogen 
Calcitonin 
Bisphosphonates 
Anabolic steroids 
Fluoride 
Parathyroid hormone 
Growth hormone 
Calcium 
Vitamin D 
1,25- (OH),D, 
Proposed working mechanism 
Reduction of activation frequency and remodelling mechanism via 
an unknown mechanism, maybe via local mediators, i.e. TGF-/3, IGF's, 
IL-6, IL-ll, elc. 
Inhibition of osteoclast recruitment and osteoclastic activity 
directly 
Induclion of changes in the membrane permeability of the osteoclast, 
which may account for structural changes al the ruffled border 
or cytoskeleton 
Decrease in acid production by the osteoclasIs 
Decrease hone resorption and increase muscle mass, and may 
increase collagen synthesis 
Stimulation of osteoblastic activity with incorporation of 
fluorapatite crystals in the bone hydroxyapatite 
Induction of bone fonnation in low dosages, probably via IGF-I 
Via IGF-I effects, locally or systemically. 
Diminishment of PTH release 
Correction of subclinical calcium deficiency 
Correction of subclinical deficiency 
Increased intestinal Ca-absorption 
Increased calcium absorption 
References 
3-6 
7 
8,9 
1O,l! 
12 
13,14 
15 
16 
17 
18 
19,20 
for only one remodelling cycle. After resorption has been diminished, also fonnation will be 
reduced, leading to a lower level of bone tumover'. It was calculated, that dependent on the 
rate of bone tumover an increase in bone mineral mass of about 5 - 10 % could be obtained 
in the first 6 to 12 monUlS after treatment with a bone resorption inhibitor was started. So, 
with an anti-resorptive agent, in patients with high bone turnover a higher increase in bone 
mineral mass will be obtained compared to those with a low bone tumover (see also Fig 4.1). 
However, after the remodelling space has been filled in, age-related bone loss will eventually 
continue. 
The restricted effect of an anti-resorptive agent fonns also the basis of the so called "activate-
depress-free-repeat (ADFR)" schedule. In this schedule initially an activator of bone tumover 
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is given, followed by a depressor (or inhibitor) of bone resorption. After a period in which 
no medication is used, this schedule is repeated. The theory behind this approach is that a 
sequential or intermittent therapeutic schedule results in an uncoupling of bone turnover with 
ultimately a more pronounced increase in bone mass. 
The ideal agent or combination of agents should not only induce a substantial increase in 
bone mass but also have to induce the development of new trabeculae. Only an increase of 
the thickness of the cortex and available trabeculae, together with a restoration of 
connectivity would lead to a considerable increase in bone strength. However, such a 
restoration of connectivity has not been observed up to now. 
Until now, no good formation inducing agent is available. Only fluoride has been shown to 
cause impressive increases in lumbar bone mass. However, this has not resulted in a decrease 
of fracture rate. On the contrary a small increase in the number of hip fractures was 
observed". However, this might have been related to the dosage of fluoride used. In an 
additional analysis of the same group of patients, 6 years after start of treatment it has been 
shown that a decrease in vertebral fractures was related to the serum fluoride level". It is 
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Figure 4.1 PattenlS of change of BMD in Ihe lumbar spine in womell wilh osteoporosis 
during treatment with various regimens (Modified from Riggs et al. 26). The dashed /ine repre· 
sellfs no change. WIlen no treatment is given (1), bone loss cominues. With all Gnti-resorptive 
dmg (2 and 3) an increase of about 3 . 10 % can be reached with a walling effect after 2 . 
3 years. With low tumover (2) a lower increase is reached, compared to high bone tumover 
(3). With a fonnation stimulator (possibly in combination with all anti·resorptive agent) 
higher positive changes might be obtained (4). 
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concluded that lower dosages of NaF, than presently used, may be indicated in the treatment 
of postmenopausal osteoporosis22,23. This implicates that fluoride has a rather narrow 
therapeutic window. 
The other available fomlation inducing agent is parathyroid honnone (PHI), which has been 
shown to increase bone formation when administered intermittently13. However, this may be 
an indirect effect, via insulin· like growth factor I (lGF-I), which has been shown to increase 
during intennittent, but not during continuous administration of PTH24. In an animal model 
(sheep) PTH has been shown to increase bone turnover in elderly sheep, but this effect was 
completely blunted in the presence of an anti-resorptive agent, tiludronate". In this study, 
the hypothesis has been made that an increased resorption is a prerequisite for the anabolic 
effect of PTH. As IGF-I may be important in the local environment of the osteoblast, the 
administration of growth honnone (GH) may be another attractive agent for fomlation 
induction. 
In figure 4.1 the potential gain in bone mineral density for different treatment modalities is 
shown 26, 
Osteoporosis is most frequently seen in postmenopausal women. However, also in men and 
in patients using corticosteroids or suffering from diseases interfering with the bone turnover 
(see also Table 1.1) it is frequently observed. In table 4.3 the medications most often used 
for the different patient-groups are mentioned. 
Table 4.3 Medications used in different groups of patients. 
Postmenopausal 
HRT 
Calcitonin 
Bisphosphonates 
Fluoride 
Anabolic steroids 
2S·(OH)D,. 1.2S·(OH),D, 
PTH· 
Growth hormone· 
Calcium 
Thiazide diuretics 
(" Under investigation) 
Corticosteroid·induced 
Bisphosphonates 
HRT 
Calcitonin 
Anabolic steroids 
1.2S·(OH),D, 
Calcium 
Thiazide diuretics 
Male 
Bisphosphonates 
1,2S·(OH),D, 
Calcitonin 
Calcium 
In the next chapters the various therapeutic options for prevention of developing and 
treatment of established postmenopausal osteoporosis will be discussed. However, first a few 
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general remarks about some of the medications and their administration will be made. 
At present a wide variety of estrogen preparations are available. Estrogen replacement 
therapy can be given as unopposed or opposed therapy. In opposed therapy the estrogens can 
be given cyclically or continuously, with cyclic progestagen, inducing regular monthly 
bleedings, Of estrogenlprogestagen can be given as a continuous treatment, thereby avoiding 
bleedings. This also prevents the increased risk of the development of endometrial carcinoma 
found in patients treated with estrogen alone27 • So far. no sufficient data are available with 
respect to continuous treatment and its impact on endometrial carcinoma21 , 
The measured effects of the various treatment schemes, based on estrogen therapy. on bone 
mass and bone turnover are more or less alike. 
With respect to the bisphosphonates it may be important to make a differentiation between 
the amino bisphosphonates and the non-amino bisphosphonates. Pamidronate and alendronate 
are representatives of the fonner group, whereas etidronate, clodronate and tiludronate 
represent the latter. The non-amino bisphosphonate, etidronate, has been suggested to prolong 
the total remodelling time, which may induce osteomalacia". The spatial distribution of 
etidronate in bone has been suggested to differ from that of an amino bisphosphonate. 
Autoradiographic studies were done with the amino bisphosphonate alendronate in animals, 
in which bone remodeling was accelerated by injections of PTH-related peptide. After 24 
hours the alendronate was concentrated on the bone surface in the vicinity of osteoclasts. It 
seemed as though the drug only bound to regions where bone remodeling existed". 
No comparable studies with etidronate were perfonned, but because of the more polar 
structure of etidronate it is possible that it penetrates the bone cell lining bener, and thereby 
is deposited throughout the bone surface. No indication for impainnent of bone 
mineralization and the subsequent development of osteomalacia have been observed in a long 
teml clinical study of osteoporotic patients with etidronate 3o. However, in patients with 
Paget's disease, treated with low dosages of etidronate, focal osteomalacia and increased 
incidence of pathological fractures have been reported3,. This complication was dose-
dependent. For the other non-amino bisphosphonates c1odronate and tHudronate no such data 
are known. In general they produce little or no inhibition in mineralisation at doses which 
show antiresorptive action32 . 
4.2 PREVENTION OF DEVELOPING OSTEOPOROSIS 
Prophylactic regimens aim at preserving bone mass at a given level. This is not comparable 
to the intention of reaching an optimal peak bone mass, which can be considered as primary 
prevention. It has been shown, that for reaching a maximal peak bone mass exercise as well 
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as a sufficient calcium intake at a young age arc important determinants. Moderate weight 
bearing exercise induces a higher peak bone mass3J , whereas extreme exercise may induce 
amenorrhoea with negative effects on the bone mass3-1.35. Also an adequate calcium intake 
seems to be necessary to obtain a maximal peak bone mass. In nonnal women, aged 20 - 30 
years, the gain of bone mass in the third decade depended for a large part on the daily 
calcium intake, i.e. with a daily intake of 200 mg Ca no change in bone mas was found, 
whereas with an intake of 1500 mg an increase of about 15 % during the third decade was 
observed36 . This amount of calcium intake seems mandatory. also for older women, at risk 
for, or with osteoporosisI7,)7. Most of the treatment regimens, used in the prevention or 
treatment of postmenopausal osteoporosis, do make sure this amount of calcium intake is 
reached. However, during the first years after the menopause no real effects of extra calcium 
supplementation have been observed"'''. A possible explanation for this observation is, that 
the increased calcium released by the bone itself, meets the requirements for bone fonnation. 
The aim in a prophylactic regimen (secondary prevention) is generally different from 
regimens used in the treatment of established osteoporosis, which focus on increasing bone 
mass to a level above the fracture threshold. Prophylaxis aims at preserving bone mass and 
structure after the menopause, thus preventing desintegration of the trabecular network and 
cortical thinning. Phannacological intervention to decrease postmenopausal and age-related 
bone loss should be undertaken in persons who, because of low or relatively low bone 
density, are deemed to be at increased risk for osteoporosis. 
After the menopause, it seems obvious to use honnone replacement therapy to counteract 
estrogen deficiency. Estrogen treatment indeed was the first prophylactic agent and has been 
used for over 20 years. Actually it is the only compound used on a large scale. As there is 
an increased risk of the development of endometrium carcinoma27. when using estrogen 
alone, many schemes use a combination of estrogen with a progestagen. Also various ways 
of administration are available and show comparable results with respect to bone mass (Table 
4.5). When estrogen therapy is started at the menopause it is unclear how long it has to be 
continued to maintain the positive effects on bone density. However it has been calculated 
that for long-teon preservation of bone mineral density, at least a period of seven years is 
warranted in which estrogen therapy is used40 . Discontinuation leads to accelerated bone loss 
like that which follows the natural menopause'I,,,. 
Next to the beneficial effect of estrogens on preserving bone mass, it is important to take into 
account other effects of long-term administration of estrogens in postmenopausal women. The 
adverse effect with respect to increased endometrium carcinoma, when administering estrogen 
alone has already been mentioned. Uncertainty exists with respect to breast carcinorna43 .46 , 
An increased incidence appears to be observed", which is not reduced with the addition of 
progestagens. Results on mortality are contradictory, some studies show no increased 
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mortality, probably because of more frequent surveillance", whereas another study showed 
a relative risk of 1.45 among women who had used estrogen for a period of 5 year or more"'. 
Another important and maybe even more important effect than the one on bone mass, is the 
beneficial effect of estrogen on cardiovascular disease". This effect can partly be explained 
by the decrease of LDL-cholesterol and the increase of HDL-cholesterol". Another 
pathogenetic mechanism may be the direct relaxing effect of estrogen on the arterial wall~s 
or by a direct inhibition of cholesterol deposition within the arterial wall". 
Although these positive effects are more impressive in women using estrogen alone, they also 
can be found in women treated with a progestagen in combination with estrogen. In a meta-
analysis of the recent literature, relative risks have been calculated for the above mentioned 
factors". These are depicted in Table 4.4. With addition of a progestagen the beneficial 
effect of estrogen on cardiovascular disease is moderately diminished, according to the 
somewhat higher relative risk values. 
When looking at these figures, one might speculate whether the most important reason for 
the administration of estrogen would not be to decrease cardiovascular events, 
Table 4.4 Calculated relative risk of several diseases for a 50-year-old white WOlJlall 
treated lVith long-tenn honnone replacemellt (modified from Grady et al. 50). 
Disease 
Coronary heart disease 
Stroke 
Hip fracture 
Breast cancer 
Endometrial cancer 
Estrogen therapy 
0.65 
0.96 
0.75 
1.25 
8.22 
Relative risk 
Estrogen plus progestagen 
0.65 - 0.80 
0.96 
0.75 
1.25·2.00 
1.00 
thereby also reducing the incidence of hip fracture. For the Netherlands an increase in the 
age-adjusted incidence of hip fractures in a cohort analysis of 15 years (1972-1987) has been 
found in women as well as menS!. Some data indicate a decrease of up to 50 % in the 
incidence of osteoporosis related fractures with the postmenopausal use of HRTs2• 
Also bisphosphonates and calcitonin are used in the prevention of osteoporosis, but until now, 
only on an experimental basis. The effects of these medications on fracture risk have yet to 
be evaluated. 
In Table 4.5 the various treatment modalities are presented, especially with respect to their 
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Table 4.5 Effects of preventive treatment ill osteoporosis. 
Treatment Duration of treatment Subjects. Design Number Years since Ag' 
or foHow-up (treatedlplacebo) menopause (range) 
Estrogen: 
MeslrallO! UplO .5 years oophorect. db-bl 63/51 0-6 
23.3 pg women 
Mestranol 6·12 years oophortcl. db-hi 58/42 3-9 
23.3 JIg women 
* Conj. estrogen 2 years postmenop. rand 20118 1~32 55--65 
0.625 mg + .5 mg women 
methyltestosteron 
Ethinyl-estradiol 2 years posrmenop. ",d 19/18 mean 5.4 33-62 
25 pg or 50 pg + oophoreci. 
women 
.. Conj. estrogen JO years poSlmenop. ""d < and> 3 yr postm . <or>3),T 
2.5 mg + Wmg women < 3 yr 30m 
medroxyproge 5te lOne > 3 yr 37141 
17~-estradiol gel 2 years postmenop. db-bl 11ft 1 0.5-3 41~54 
3 mg percutaneously women 
17,8-eSifadiol 1 year poslmenop. ""d 17117 2-4 43-58 
50 ug/day transdermal women 
+ to mg 
medroxyprogeslerone 
Calcitonin: 
Calcitonin 50 IUlday 1 year pos/menop. ",d 30/30 < 3 
5 dayslwk, inlranasally women 
Calcitonin 2 )'ears postmenop. db-bl 19/20 2.5-5 48-55 
100 IU/day, women 
inlranaully 
nlsl2hosl2honate: 
Tiludronate 100 mg 1 year postmenop. db-hi 28/31 3-10 50-60 
6 monlhs, daily women 
Etidronale 400 mg 6 months oophorecl. db-hi 10110 0 M-51 
3 months, daily women 
Thinide diuretics: 
Ch!orth:lIidone 2.6 years elderly v.omen ",d 43170 not memioned mean 72 
12.5 • 25 rug day 
oophorec., oophorec/omised; postmenop., postmenopausal; db-hI. double blind; rand., fandomised. 
* The combinalion of an estrogen with a progestagen was gi\·en cyclically, i.e. 21 days OUt of 28 the estrogen and from day 14-21 
Ihe progestagen was added. Bone mass measurement in the various studies compared 10 initial values. 
When I is menlioned in bone lumO\W parameters, these represent signifkanr changes. 
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Site of measurement Bone mass Bone turnover parameters References 
Therapy Placebo Therapy Placebo 
bmc metacarpalia + t %/Yf - 2 %/yr OH-Proline J no change 53 
Ca in urine' 
bme metacarpalia no change ·1 'lol'lr not mentioned 54 
bme radius no change - 2.7 '!olye not mentioned 55 
bme metlcarpalia - I %Iyr - 1.3 'lo/yr 
bmc proximal radius no change - 2.5 %/)'r not mentioned 56 
bme 3rd metacarpal < 3 yr postmenopausal: not mentioned 57 
+ 10% ·10 % 
> 3 yf postmenopausal: 
no change -10% 
bme pro"imai radius no change - 4 %I'lr OH-Proline , no change 58 
bme distal radius no change - 4 %/yr All::. Phosp , no change 
bme L2-4 + I 'lo/ye no change Oste!Xalc. I no change 
bme forearm + 4.3 % - 3.5 % OH-Proline , no change 59 
Alk. Phosp , no change 
Ca in urine I DO change 
bme L2-4 + 1.4 %/yr -3.2 %fy! no changes no changes 60 
bme proximal radius - I.S %/)'r -1.5 '!elyr All ... Phosp. no change no change 61 
bmc distal radius -I 'fc/yr -1.5 '!elyr Omocalc. no change I 
bmc L2-4 + 1.5 %/yr -3 %I,/c OH-Proline j 
bmc L2-4 + 1.5 %/,/c -2.5 %/yr OH-Proline I no change 62 
Alk.Phosp no change no change 
bmc pro:dmal radius no change no change OH-Proline no change no change 63 
Ca in urine' no change 
Alk. Phosp. no change no change 
Osteoca.lc, I no change 
bmc proximal radius - 0.3 %/yr - 0.9 %/yc not mentioned 
bmc distal radius + 1.5 'lory + 0.4 %/yr 
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Table 4.6 Effects of treatmel/l in postmenopausal osteoporosis. 
Anti-resorptive agents. 
Treatment Concurrent Duration of Design Number Years since 
treatment treatment (treated/placebo) mcnopJuse 
Estrogen: 
Conjugated estrogen none I year db-bl.pc 11110 mean 6 
1.25 mg/day 
17,B--estradiol, 0.1 rug patch, none I year db-bH)c 36/39 5·28 
day 1-21, + 10 rng medroxy-
progestefOn, day 11-21 
cycle of28 days 
17,B-estradioI2 mg + Ca, 500 mg daily 1 year db-bl-pc 16115 mean 16 
I mg norethisterone 
continuously 
Anabolic steroids: 
Nandrolone dennoate Ca, 500 mg daily t year db-bl-pc 19117 nOI mentioned 
50 mgl3 weeks, Lm. 
BLsl2hosQbonate: 
Etidronate, 400 mg. 2 weeks on, Ca, 500 mg daily 150 weeks db-hl.pc 33133 ,.,.. 
13 weeks off treatment ViI D 400 IU, daily 
Etidronate, 400 mg. 2 weeks on, Ca, 500 mg, 2 years db-bl-pc 105/104 mean 19 
13 weeks off treatment day 18-91 
Elidronate 400 mg, 2 weeks on, Ca, 500 mg, 3 years db-hi-pc 77178 mean 19 
13 weeks off treatment day 18-91 
Pamidronate ISO mg/day Ca, I g daily 2 years db-hi-pc 26m mean 18 
Pamidronate ISO mg/day Ca, 500 rng daily I year randomised 10/11 5-21 
(GH + Pam "'5 Pam) 
Calcitonin: 
Salcatonin 50 IU/day Ca, 500 mg daily 2 years db-hi-pc 40 mean 21 
Salcatonin 100 IUfday randomized 4J 
Salcatonin 200 IU/day group 41 
Placebo comparison 40 
All patients suffered from posnnenopJusal osteoporosis with osteoporotic fractures. The concurrent treannent was also gi\'en 
to the placebo·treated patients, Bone mass measurement in the \'arious studies compared to initial ,·alues. Bone mass changes during whole study period. 
YSM, yean: since menopause: FR, new vertebral fracture rateflOOO p3tient years; SOl, spine defonnity inde.~: 
db-bl-pc, double blind p!acebo-controlkd: FN, femoral neck; TB, total body. 
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Ag' 
(mean or range) 
mean 6-1 
54.6 -72.1 
mean 6-1 
mean 66 
57-75 
mean 65 
mean 65 
mean 66 
55-72 
mean 70 
Site of 
measurement 
bme L24 
bme FN 
bme L2-4 
bme FN 
bmc mid radius 
bme L24 
bme distal radius 
bmc proximal radius 
bme distal radius 
bme proximal radius 
bme L24 
bmc distal radius 
bme L24 
bme FN 
bmc L2-4 
bme FN 
bme L2-4 
bmeFN 
bmeTS 
bme L2-4 
bme FN 
bmc distal radius 
bme proximal radius 
bme L2-4 
Treatment Modalities 
Bone mass FR or SDI References 
Therapy Placebo Therapy Placebo 
+ 8.3 % -5.0 % not done 68 
+ 2.6 % -2.0 % 
+ 5.3 % + 0.2 % FR: 230 580 6. 
+ 1.0 % + LO % 
+ 1.0 % -2.6 % 
+ 8.0 % no change not done 70 
+ 8.0 % no change 
no change no change 
+ 3.0 % no change not done 71 
+ 3.0 % + 1.0 % 
+ 5.0 % -5.0 % SOl: -0.1 - 0.25 72 
no change - 4.0 % 
+ 4.0 % + 1.0 % FR: 44 68 7J 
+ 2.0 % no change 
+ 5.0 % +1.5% FR: 59 132 74 
+ 2.0 % no change 
+ 7.0 % - 1.5 % FR: 130 240 75 
+ LO % - 1.0 % 
+ 2.0 % -1.0 % 
GH+Pam: Pam: 
no change + 5.0 % not done 76 
no change no change 
no change + 4.0 % 
no change no change 
+ 2.2 % FR: 43 146 77 
+ 2.2 % 
+ 3.6 % 
+I.l% 
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Table 4.7 
Treatment 
50 - 60 mgfday 
7S mg 
no placebMoflt[olled studies 
1.25 (OHl,O!! 
2 dd 0.25 pg 
2 dd 0.25 pg 
Growth hormone: 
7 lU, daily for 2 months 
after 5 months (2 + 3), 
3 months reSI period. 
Schedule repealed 3 rimes 
Effects of tremll/elll ill postmenopausal osteoporosis. 
Fonllation inducillg dntgs and dntgs with ullknown action. 
Concurrent 
treatmenl 
Duration or 
treatment 
Ca, 1500 mg, daily 4 years 
ViI D 400, JU, daily 
Ca, 1500 mg. daily 4 years 
Vit D, 400 lU, daily 2 years 
none 3 years 
placebo·group 
1 g Ca, daily 
Caldtonin 100 IU 
months 3 -5 
2 years 
Design 
randomized 
db-bl-p: 
db-bl-pc 
prospective 
single blind 
randomized 
Number 
(mated/placebo) 
33/27 
66/69 
12115 
314/308 
717 
Years since 
menopall5e 
not mentioned 
9-33 
mean 17 
mean 15 
not mentioned 
All patients suffered from postmenopausal osteoporosis with osteoporotic fractures. The concurrent treatment was also gi\'en 
to the placebo· treated palients. Bone mass measuremenl in the various studies compared (0 inilial values. Bone mass changes during whole study period. 
YSM, years since menopause; FR, new vertebral fracture ralellOOO patienl years; SDI, spine deformity index; 
db-bl·pc, double blind placebo--<:olllrolled; FN, femoral neck. 
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Ag' 
(mean or range) 
50-81 
58·74 
mean6.j. 
mean 6.j. 
mean 63 
Sile of 
measurement 
not do~ 
bme L1-4 
bme FN 
bme radius 
bme L2-4 
bme distal radius 
not done 
bmc radius 
TB neutron 
activation analysis 
Bone mass 
Therapy Placebo 
+ 8.2 %/'1r 
+ 1.8 %/'1r 
- 1.8 %/'1r 
no change 
+ 2.6 % 
no change 
+ 4.6 % 
+ 0.4 %fyr 
- 0.9 %/'1r 
- 0.7 %/'1r 
- 8.0 % 
-3.2 % 
no change 
-1.0 % 
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FR or SOl References 
Therapy Placebo 
FR: 304 419 
" 
FR: 446 .525 21 
Tow new nOD-vertebral fractures; 
61 24 
FR: 250 333 19 
FR: 88-99 103-31S 80 
not done 81 
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effects on bone mass and on biochemical markers. In all studies mentioned in table 4.5 the 
subjects used a calcium intake of about 1000 mg per day. 
As can be seen in table 4.5 estrogen, calcitonin and bisphosphonates all are able to prevent 
bone loss in the early postmenopausal years. It has also been shown, however, that when 
treatment is started several years after the menopause a reduction of further loss can be 
obtained but not a gain of bone mass towards premenopausal values. The most illustrative 
study has been performed by Lindsay et al. in oophorectomised but otherwise normal 
women, where treatment with estrogen was started immediately, 3 and 6 years after 
oophorectomy respectively53. In the women in whom treatment was started within 3 years of 
oophorectomy an increase of bone mass towards the values obtained in women who started 
treatment immediately after oophorectomy was observed. In women started 6 years after 
oophorectomy no further loss, nor an increase was observed"'''. This indicates that the best 
period of initiating treatment with the intention of preventing bone loss is within 3 years after 
the menopause. 
Most of the earlier studies have used rather high dosages of estrogen. In later on studies 
0.625 mg of conjugated equine estrogens, 25 p.g of ethinyl estradiol or 1 mg of estradiol 
valerate turned out to be the minimum dosages needed to reduce bone turnover 
effectively"'''. It has also been shown that circulating levels in serum between 60 and 90 
pg/ml are capable of reducing bone turnover efficiently". 
4.3 TREATMENT OF ESTABLISHED OSTEOPOROSIS 
Treatment of established osteoporosis remains a problem. In the introduction several remarks 
have been made with respect to the theoretical basis of various treatment schemes. The 
ultimate goal of treatment is to achieve a reduction in (further) fractures. It is important to 
take into consideration that an increase of bone mass, does not peese indicate a reduction in 
fractures. The skeleton in postmenopausal osteoporosis is reduced in mass, and the tissue 
may be qualitatively abnormal. It is clear that the loss of tissue in cancellous bone produces 
important architectural changes, with elimination of complete trabeculae l , 
Most available agents inhibit resorption on the surface of the existing trabeculae, the hope 
being that the outcome will be an increase in the size of the individual trabeculae, and to 
decrease further loss of "COnnectivity. Thereby the bone tissue would be capable of 
withstanding stress more effectively. 
In the following tables some of Ow results, which are available, of anti-resorptive regimes 
as well as of some of the formation inducing agents are shown. In several studies also 
fracture rates have been calculated. It is, however, important to take into account the small 
68 
Treatlllelll Modalities 
size of several studies. This may introduce an important bias, i.e. small differences in 
number of new fractures observed in small groups are represented as more impressive 
absolute differences, when they are calculated as new fractures! 1000 patient years. 
4.4 CORTICOSTEROID INDUCED OSTEOPOROSIS 
As this subject as well as osteoporosis in men (chapter 4.6) are beyond the scope of this 
thesis, only some brief remarks with respect to the various treatment options will be made. 
Glucocorticoid-induced osteoporosis has been recognized since 1932 when Cushing first 
described skeletal decalcification as a characteristic feature of adrenal hyperplasia secondary 
to adrenocorticotrophic honnone production by pituitary tumours81. Glucocorticoid-induced 
bone loss became a significant problem as therapeutical corticosteroids became available83 . 
The metabolic effects of corticosteroids on bone and mineral metabolism are extensive. 
several pathogenetic factors, which can be divided in systemic and skeletal effects are 
mentioned in table 4.8. The secondary hyperparathyroidism which occurs after long-tenn 
administration with glucocorticosteroids is considered to be onc of the most important 
pathogenetic factors". The risk of hip fracture has been calculated to increase 50 % in 
patients using long-tenn corticosteroids compared to non-users. 30 to 35 % of the patients 
using long-ternl corticosteroids have vertebral fractures. 
Because corticosteroids are used for a variety of diseases, the corticosteroid-induced bone 
loss is an important problem. For this reason various schemes for prevention and treatment 
have been studied. No sufficient data do exist to allow recommendation of any definite 
treatment protocol. 
Table 4.8 Pathogenetic Jactors in the pathogenesis oj glucocorticoid osteoporosis"·85. 
Systemic effects Skeletal effects 
Decrease gastrointestinal calcium absorption 
and increase renal excretion leading to 
secondary hyperparathyroidism. 
Decrease gonadal honnone secretion 
Inhibit IOF-I production and action 
Cause muscle wasting 
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Direct inhibition of osteoblast function: 
decrease replication, differentiation 
and life span. 
Decrease production of prostaglandin El 
and IGF·I 
Increase sensitivity to parathyroid 
honnone and 1,25(OHhD)_ 
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As bone loss in palienls receiving glucocorlicosleroids is dose relaled, il is pruden! 10 
describe Ihe lowesl effeclive dose and 10 use lopical preparalions when possible. Many 
attempts to prevent bone loss associated with glucocorticosteroids have been carried out to 
improve calcium retention by increasing calcium absorption and decreasing urinary excretion, 
Ihus reversing secondary hyperparalhyroidism. Wilh 1,250H,D, adminislralion in 
combinalion wilh calcium bone loss allhe lumbar spine was prevenled bul nol allhe femoral 
neck8S • where it was increased by the addition of intranasally calcitonin86 . 
During glucocorticoid treatment thiazide diuretics have been shown to improve 
gastrointestinal absorption of calcium and to decrease urinary calcium excretion without any 
clear effects on bone rnass87,g8. 
The use of gonadal hormones to prevent and treat glucocorticoid osteoporosis has not been 
adequately studied. In postmenopausal women, however. it seems a logical treatment to 
apply. Also premenopausal women, who have become amenorrheic during Irealmenl wilh 
glucocorlicosleroids could benefil from Ihis Irealmenl, as eSlrogen is inlensely relaled 10 bone 
mass. As serum levels of testosterone can be reduced in men during glucocorticoid therapyS9 
and testosterone deficiency can cause osteoporosis9<1, testosterone replacement may be 
indicated. Nandrolone decanoate has been shown to increase foreann bone· density in 
glucocorticoid-treated male and female patients91 , Also calcitonin has been used in the 
treatment of glucocorticoid-induced osteoporosis with only small positive effects on bone 
mass92, 
The most promising agents with respect to the use in glucocorticoid-induced osteoporosis are 
the bisphosphonates. Significant increases in spinal bone mass with oral pamidronate after 
one year of treatment have been found, which were maintained after two years93 , Also with 
intermittent etidronate positive results with respect to prevention of bone loss at the lumbar 
spine have been observed94 , However, no effects on the femoral neck have been observed, 
moslly in unconlrolled, shorl lerm sludies in fairly small palienl populalions. Therefore 
longer conlrolled sludies are needed 10 clarify Ihe place of bisphosphonales in Ihe Irealmenl 
of corticosteroid-induced osteoporosis. 
4.5 OSTEOPOROSIS IN MEN 
Although fractures related to osteoporosis are more frequent in women, also in men an 
increased incidence of osteoporotic fractures occur with advancing age95 , ]n men, of the age 
of 65 and more, Ihe incidence of hip fracture is 4-5/1000, compared wilh 8-10/1000 in age-
matched women95 ,%. 
The reasons for the difference in fracture incidence between men and women are 
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multifactorial. First, men obtain a greater skeletal mass during puberty, leading to a higher 
peak bone mass, a greater diameter of the bone and greater cortical thickness". Secondly, 
women loose more bone with age than do men, partly because of the loss of estrogens at 
menopause. Thirdly, a sexual difference in the character of age-related changes in cancellous 
bone stmcture contributes to a greater fracture risk in women97• 
Compared to women, where estrogen loss is an important pathogenetic factor for the 
development of osteoporosis, in men causes of secondary osteoporosis can be identified in 
a majority of the patients". In Table 4.11 the various forms are presented. 
Age-related bone loss is an important feature of osteoporosis in men as well as women. In 
some men, this age-related bone loss may suffice to cause non-traumatic fractures, but 
Table 4.11 Osteoporosis in men 
1. 
2. 
Primary 
Secondary: Hypogonadism 
Glucocorticoid excess 
Alcoholism 
Gastrointestinal disorders 
H yper(para-)thyroid ism 
Immobilization 
Rheumatoid arthritis 
Osteogenesis imperfecta 
Systemic mastocytosis 
Homocystinuria 
frequently other conditions may adversely affect fracture risk. A low peak bone mass, 
deficient calcium intake, and a lack of physical activity are some of the factors 
mentioned99,loo . 
The pathophysiology in male osteoporosis is only minimally explored. However, causes of 
secondary osteoporosis have been shown to be present in 30 - 60 % of men with vertebral 
fractures lOl ,102. Glucocorticosteroid use is one of the most prominent causes of osteoporosis 
in men, accounting for up to 20 % of the men evaluatedIOl .IO). Also alcohol abuse (about 10 
%) and hypogonadism (about 8 %) are frequently found in male patients with osteoporosis lOl -
103 
For the treatment of male osteoporosis it is important to treat any underlying cause. The 
treatment of glucocorticosteroid-induced osteoporosis has been discussed in the previous 
chapter. In hypogonadism, androgen replacement has been shown to increase bone mass1t}l,105. 
Primary or idiopathic osteoporosis is a diagnosis by exclusion, which results after causes of 
secondary osteoporosis have been excluded. With detailed biochemical and 
histomorphometric analyses no consistent features of primary osteoporosis have been 
found"·IO). So far, no appropriate treatment advices are available. Some beneficial effects of 
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pamidronate in a heterogenous patients group have been found 106 , Also with etidronate 
positive results have been obtained, with an increase in spinal BMD of 9 % after one year 
of treatment lO7 , Although specific data are scarce, there is no reason, why bisphosphonates 
(and other antiresorptive agents) would not be effective in men as they are in wornenlO8 , In 
men with idiopathic osteoporosis low levels of IGF-I have been reported109 , and it has been 
shown that administration of growth honnone in elderly men resulted in an increase of 
lumbar bone mineral densityllO, Whether this is a relevant treatment potential has to be sorted 
out further. 
In general, the various treatment options, which are available for women, could be 
transferred to men as well, with the exception of HRT, 
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SCOPE OF THE THESIS 

Scope of the thesis 
SCOPE OF THE THESIS 
The aim of this thesis was to obtain insight in longitudinal bone mass measurements and bone 
turnover parameters in postmenopausal osteoporosis and growth hormone deficient patients. 
treated with a combination of medications. These combinations of medication consisted of 
a known inhibitor of bone resorption, which was combined in randomized studies with a 
potential activator of bone formation. The reason for this was to observe, whether it was 
possible not only to diminish bone resorption but on the other hand also increase bone 
formation, i.e. increase of activation frequency and thereby reach a neUo positive result. 
Another part of the thesis consists of normative data of DXA measurement in the lumbar 
spine as well as in the proximal femur in normal caucasian Dutch women. 
In the chapters 1-4 a general overview of the current methods with respect to bone mass 
measurements, bone turnover parameters and treatment options, which are avialable at 
present, has been given. 
In chapter 6 and 7 the data of bone mass measurements and turnover parameters are 
presented, obtained in females with established postmenopausal osteoporosis. These women 
were treated for 3 years with a combination of honnone-replacement therapy with or without 
the anabolic steroid nandrolone-decanoate. Chapter 6 describes the effects after two years 
of treatment. Chapler 7 describes the effects in the same groups in terms of bone mass and 
turnover after the treatment has been stopped for a period of one year. 
Chapler 8 describes the effect on the same parameters in females with postmenopausal 
osteoporosis, all treated with the bisphosphonate pamidronate, whereas half of these women 
were (double-blind) treated with recombinant human growth hornlOne (rhGH). 
Chapter 9 describes the same combination of medications, but now applied to growth 
honnone deficient patients. In this group of patients the pamidronate was initially given two 
weeks before adding rhGH to all patients. 
Finally in chapter 10 cross-sectional nomlative data of bone mass measurements for the 
Dutch female population are presented, which can be used in further studies as a represen-
tative normative data set. 
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CAN NANDROLONE ADD TO THE EFFECT OF HORMONAL 
REPLACEMENT THERAPY IN POSTMENOPAUSAL 
OSTEOPOROSIS? 
J.C. Birkenhiiger, R.J. Erdtsieck, J. Zeelenberg, C.van Kuijk', L.C.P. van Veen', D.H. 
Birkenhager- Frenkel', G.P.M. Luiken', P.P.M. Kooy', EJ. Gerritsma', P. Mulder' and 
H.A.P. Pols. 
Departments of Medicine (III) and Clinical Endocrinology, Radiodiagnostics', Pathology', 
Nuclear Medicine', Otorhinolaryngology' and Biostatistics'. University Hospital 
"Dijkzigt", Erasmus University, Rotterdam, The Netherlands. 
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HRT + ND I 
SUMMARY 
Thirty six women with postmenopausal osteoporosis (31 of them with at least one noo-
traumatic vertebral compression fracture) were matched pair-wise as to age, years since 
menopause and body mass index and randomized to receive either cyclical estrogen-
progestagen replacement treatment (group I) or the same treatment plus nandrolone decanoate 
(group 2). During the first year of treatment in both groups the forearm BMC (SPA) rose 
proximally and distally 2-3 %. Over 2 years the increments of forearm BMC in both groups 
were up to 4.5%. Lumbar BMD (DPA) rose in both groups nearly 10% over the first year 
and 12 % over 2 years. The cancellous bone density of L3 (QCT) showed in 6 months an 
increase of 21 % in group I and 29% in group 2 to subsequently stay at that level. All these 
changes from the basal levels were highly significant but there were no significant differences 
between the 2 groups. These 2 conclusions were also drawn with regard to the induced fall 
of serum alkaline phosphatase (-23%), osteocalcin (-35% to 44%) and procollagen I (-15% 
to 22%) and of the fasting urinary hydroxyproline (-33% to 36%). No significant increase 
in the number of new deformed vertebrae occurred in 2 years. 
INTRODUCTION 
With many prospective studies it has amply been demonstrated that estrogen deprivation 
causes an increase of the bone resorption rate and that conversely substitution with estrogens 
may largely or completely inhibit bone resorption l .'. Also, fracture incidence in 
postmenopausal women appears to be lowered by estrogen use7-!!, but prospective controlled 
studies of the efficacy of estrogens in patients with established postmenopausal osteoporosis 
are scarce12, Most of the above mentioned prospective trials have been carried out in nonnal 
postmenopausal women, albeit in some studies after bilateral oophorectomy. 
Characteristically, with this treatment, as with other anti resorptive therapeutic modalities, a 
modest initial gain in bone mineral density may be observed, limited to the first 1-2 years 
of treatment. In the forearm this potential initial gain in bone density will -depending on the 
time elapsed since the menopause- amount to 3 % at mosr~'s. This phenomenon is generally 
ascribed to the coupling of bone formation to bone resorption (or: dependence of osteoblastic 
on osteoclastic activity) in the basic multicellular units (BMU)Il. A transient increase of bone 
(mineral) mass after sudden inhibition of bone resorption is then explained by the far longer 
life-time of the osteoblasts as compared to that of osteoclasts. 
The possible antiresorptive activity of androgens (anabolic steroids) is less well documented 
than that of estrogens with or without progestagens, although histomorphometric evidence 
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of it has been obtainedl4 , Treatment of women suffering from postmenopausal osteoporosis 
with stanozolol for 2.5 years induced a rise of total body Ca (neutron-activation), but no 
change in foreano bone utineral content (BMC; by single photon absorptiometry, SPA) and 
no consistent effect on the urinary hydroxyproline excretion's. More recent studies of the 
effect of the anabolic steroid nandrolone decanoate in postmenopausal osteoporosis include 
two open non-randomized comparative trials of around 6 and 12 months, respectively, in 
which significant increases of foreano BMC and lumbar vertebral bone mineral density 
(BMD; by quantitative CT-densitometry, QCT) were noted",I7, In two double blind-studies, 
one comparative and placebo-controlled lasting 2 years and the other placebo-controlled 
during I year, rises of 4 and 3 %, respectively, of the foreano BMC have been observed over 
one year"''', No increase of the lumbar vertebral BMD (by dual photon absorptiometry, 
DPA) was found", while the absolute urinary hydroxyproline excretion appeared to be 
reduced and serum alkaline phosphatase did not change l9 .There are also other indications that 
anabolics such as nandrolone may enhance the activity of osteoblasts. such as raising the 
serum osteocalcin and (temporarily) procollagen type I levels21.22, Although in osteoblasts 
estrogen as well as androgen receptors have been found23,2~, the mechanism of action of both 
types of steroids on bone metabolism, such as the established inhibition of bone resorption 
by estrogens, has not yet been clarified, 
To investigate the posibility that anabolic steroids, such as nandrolone decanoate, stimulate 
bone fOffilation rather than inhibit bone resorption (or stimulate bone fonoation in addition 
to inhibiting bone resorption) and thus break through Ihe above mentioned coupling of bone 
fonnation to bone resorption we compared in women with postmenopausal, osteoporosis the 
effects of treatment with a combination of honoonal replacement therapy (HRT) and 
nandrolone decanoate with those of treatment by HRT alone, In other words the possible 
effects of nandrolone decanoate were studied under conditions, where bone resorption was 
already depressed by cyclical treatment with a classical combination of estrogen and 
progestagen. In this comparative randomized single blind trial of two years duration we used 
various types of bone mass measurement as well as biochemical parameters of bone 
metabolism. 
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METHODS AND MATERIALS 
A. Patients and It·eatment. 
Women, aged 50·70 years, with postmenopausal osteoporosis (at least one non·traumatic 
vertebral compression fracture, wedge Of crush) or osteopenia were matched pair-wise with 
regard to age (difference < 5 years), years since menopause (YSM, difference < 5 years) 
and body mass index (BMI): weight (kg)/height(m') (difference < 3.0). Osteopenia (5 
patients) was defined as a lumbar BMD value (by DPA) of > 2 SD below the normal mean 
of age·matched controls (25). After informed consent had been obtained the patients were 
randomized pair·wise to receive either hormonal replacement therapy (HRT) or HRT plus 
nandrolone decanoate (ND, Deca·Durabolin (R), Organon International BY, Oss, The 
Netherlands). 
HRT was given as estradiol valerate (Progynova (R), Schering·Nederiand BY, Weesp, The 
Netherlands) 2 mg orally daily on day I through 25 each month and medroxyprogesterone 
acetate (Provera (R), Upjohn·Nederland, Ede, The Netherlands) 10 mg orally daily on day 
16 through 25 each month. ND was administered intramuscularly in a dosage of 50 mg once 
every 4 weeks. When needed according to the dietary history calcium suppletion up to a total 
intake of at least 1000 mg was given in the form of Ca Sandoz effervescent tablets (n = 28). 
Signed infomled consent was obtained as well as permission by the Universital Hospital 
Medical Ethical Committee. 
Treatment was single blinded, i.e. the biochemical data, the radiographs (vertebral deformity) 
and the bone densitometric data were all coded. 
Initially 42 patients were randomized to enter the study. Seven of these patients wanted to 
terminate their participation in the trial after 6 to 21 months (only one of them being 
replaced), so that for evaluation after 2 years treatment the data of 36 patients are available. 
The characteristics of both treatment groups of patients have been listed in Table I. Five of 
the 7 patients who stopped treatment did so because of voice problems, 2 because of the 
extent of uterine bleeding. In all patients the diagnosis osteoporosis (osteopenia) was 
confimled by biochemistry and iliac crest biopsy. 
B. Bone mineral mass measurements. 
I. SPA of the right forearm was performed at the (ultra)distal and proximal site with 
intervals of 3 months according to Nilas et al. 26 with a Nuclear Data ll00a scanner. The (fat· 
corrected) results are expressed as bone mineral content (BMC, arbitrary units (U)/cm) and 
bone mineral density (BMD, U/cm'). In our hands the coefficient of variation (C.Y.) for 
BMD in normal individuals is 1.9 at the distal site and 1.0% at the proximal site. During the 
first 18 months of the study a calibration·phantom was scanned daily. A slight drift of ·1.8% 
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was observed. Subsequently a new software version including a master calibration was 
installed. This calibration was run weekly. No drift was seen any more: at yearly intervals 
the BMC of the phantom amounted to 37.6,37.5 and 37.6 Ulcm, respectively. 
2. DPA of the 2nd through 4th lumbar vertebrae was done at 3 months intervals according 
to Krolner and Nielsen" with a NOVO BMC-Lab 22a scanner. Results are expressed as 
BMC (g hydroxyapatite = HA) and BMD (g HA/cm'). For BMD in osteoporotic women a 
C. V. of 2.3% was found. During the study three \S3Gd-sources have been used. There were 
no software changes. Immediately before and after a source change a calibration-phantom 
(supplied by the manufacturer) consisting of 3 cylindrical chambers with diameters of I, 3 
and 5 cm and containing a mineral equivalent solution (402 mg K,HP04/ml, equivalent to 
398 mg HAlml) was measured. Daily quality control was perfonned by scanning an 
aluminum tube supplied by the manufacturer. No drift of the BMC value of the aluminum 
tube was observed. With the three sources the BMC value of the tube was 32.6 ± 0.2 (SD), 
32.5 ± 0.2 and 32.7 ± 0.2 g HA equivalent, respectively. 
3. OCT of the trabecular (cancellous) compartment of the 2nd and 3rd lumbar vertebrae was 
carried out at intervals of 6 months with the method we previously described as QCT"'b'" 
Scans were made at 120 kVP. A simultaneous calibration device was used- containing 
different concentrations of K2HP04 in water as bone mimicking material. The CT -system was 
calibrated before each session according to the recommendations of the manufacturer. The 
results are expressed as mg K,HP04 equivalentlml. In osteoporotics the C. V. for the 
cancellous bone compartment amounted to 2.7%28. Fractured vertebrae were not measured. 
C. Radiological examination. 
Standardized lateral view radiology of the thoracic and lumbar vertebral column (5th thoracic 
through 4th lumbar vertebrae) was perfOlmed yearly. The radiology of the lumbar vertebral 
column was carried out at long distance (2 m). Pre-existing and new vertebral fractures 
(deformities) were evaluated using as definitions: a) loss of anterior andlor mid-height of ~ 
20% of the posterior height of the vertebral body and b) loss of posterior height of ~ 20% 
of the posterior height of both or one of the adjacent vertebral bodies. Heights were 
measured using a digital ruler. The coefficient of variation of the indices was < 3 %. 
D. Biochemistry. 
Every 3 months were detennined: 
I. Serum Ca, P, alkaline phosphatase, creatinine and albumin with standard methods. 
2. Serum osteocalcin and procollagen type I with RIA (INC, Stillwater, USA and 
Fomlos Diagnostica, Oulunsalo, Finland, respectively) and 
3. Fasting (2 hr) urinary hydroxyproline by Hypronosticon (Organon Technika, Oss, the 
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Netherlands}. The data obtained were corrected for the creatinine clearance (glo-
merular filtrate, OF) and expressed as nmol/ 100 ml OF. 
At zero time and after 3 months: 
4. 176-Estradiol by RIA (Diagnostic Products Corporation, Los Angeles, USA). 
Every 6 months: 
5. Serum total and HDL-cholesterol with standard methods. 
All blood samples were taken in the non-fasting state. 
E. Phoniatric investigations. 
The patients were examined by the phoniatrician and the speech-pathologist of the Division 
of Phoniatrics of the Department of Otorhinolaryngology. These examinations were 
performed before and aner one year of medication and consisted of a standard voice 
anamnesis, a logopaedic voice evaluation, observation of the vocal cord aspect and 
determination of the voice field, the maximum phonation time, voice breaks and pitch 
perturbation. 
F. Statistics. 
Within each of both treatment groups changes (either absolute or relative) over time have 
been tested by means of the Wilcoxon signed ranks test (two-sided). Between the two 
treatment groups absolute values and percent changes from baseline have been compared and 
tested by means of the Mann-Whitney U-test (two-sided). 
RESULTS 
1. Forearm densitometry (SPA), 
At both sites in the forearm the initial (fat-corrected) BMC values by SPA of the HRT- and 
the HRT + ND-group (group 1 and 2, respectively) were practically identical (Table 6.1). 
The course of the proximal and distal forearm BMC during treatment is presented in Fig. 6.1 
A and B. In group 1 the BMC rose proximally 2.2% over the first year and 2.8% over 2 
years (P < .02 and = .005, respectively). In group 2 the corresponding numbers were +3.2 
and +4.5% (P = .001 and < .001, respectively). At the distal site the rise of the BMC 
consisted in group 1 of 3.1 % over the first year and 4.4% over 2 years (n.s. and P = .02, 
respectively) and in group 2 of2.3 and 4.5% (n.s. and P = .002, respectively). At both sites 
the BMC (and BMD; data not shown) increments observed after 1 and 2 years of treatment 
were not significantly different in both treatment groups. 
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Table 6.1 Pretreatmellt patients characteristics 
HRT (1) 
n 18 
n with vertebral fractures 15 
Age (yrs. ± S.D.) 60.7 ± 3.9 
YSM (yrs. ± S.D.) 13.7 ± 6.2 
BMI (kg/m'. ± S.D.) 24.8 ± 2.9 
Bone densitometfl': 
BMC forearm (SPA) 
prox. (U/em) 32.4 ± 1.2 
distal (U/em) 31.6 ± 1.2 
L2·L4 (DPA): 
BMC (gHA) 26.5 ± 1.4 
BMD (gHNcm2) 0.62 ± 0.02 
B~ID L3 (QCT) 
(mg K2HPO/ml) 44.3 ± 6.1 
Biochemistry: 
Serum: 
Alkaline phosphatase (U/I) 68.2 ± 6.8 
Osteocalcin 4.0 ± 0.4 
Procollagen 115.6 ± 10.6 
Urinary (fasting 2h): 
Hydroxyproline 15.2 ± 4.4 
(nmolll00 ml GF) 
YSM: years since menopause 
HRT: hormonal replacement therapy (estrogen + progeslagen) 
NO: nandrolone-decanoate 
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18 
16 
62.6 ± 4.2 n.s. 
14.2 ± 7.7 n.S. 
25.5 ± 4.9 n.s. 
32.1 ± 1.5 n.s. 
31.0 ± 1.5 0.5. 
28.8 ± 1.6 n.s. 
0.64 ± 0.03 n.s. 
42.1 ± 4.2 n.s. 
64.8 ± 4.9 n.s. 
4.1 ± 0.5 n.s. 
111.9 ± 10.3 n.s. 
16.8 ± 7.0 0.5. 
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Figure 6.1 Course of the BMC (by SPA) of the foreann (U/C/n). Group I: cyclical 
treatment with estrogen and progestogen; group 2: cyclical treatmelll with 
estrogen and progestogen, combined with nandrololle (both groups n = 18). 
Means ± S.E.M. A: Proximal site, B: Distal site. Statistical analysis l-VGS 
pet/onlled at 12 and 24 mOlllhs. 
2. Lumbar spine densitometry. 
DPA. 
The initial BMC and BMD values of the 2nd through 4th lumbar vertebrae were not different 
in the 2 groups (Table 6.1). 
The erfect or treatment on lumbar BMC is depicted in Fig. 6.2. In group I the BMC 
increased over the first year by 9.9 and over 2 years by 12.5% (P < .001 for both), while 
in treatment group 2 the respective increments were 9.2 and 12.2% (P = .001 and < .001, 
91 
CHAPTER 6 
respectively). The course of the BMC (and of the BMD; data not shown) was in both 
treatment groups not significantly different. 
OCT. 
The basal BMD values of L, (n = 16 in both treatment groups, Fig. 6.3) were not signifi-
cantly different between in group 1 and 2. It rose in 6 months by 21.0 and 29.0% (P = .002 
and .001), respectively, to stay at about that level for the duration of treatment. Again, there 
was no significant difference between the extent of the increase of the QCT of L, (and of L,; 
data not shown) in both treatment groups. 
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Figure 6.2 Course of the BMC (by DPA) of the 2nd through 4th lumbar venebral body (g 
hydro.\yapatite!cm'). See also the legend to Fig. 6.1. 
3. Vertebral fraetm'es (deformities). 
Using the standardized radiographs of the 15 patients of group 1 and 16 patients of group 2, 
who initially had vertebral compression fractures, the average number of deformed vertebral 
bodies (for definition see Methods, section C) per patient was before treatment 3.53 in 
group 1 and 2.81 in group 2. After 2 years treatment the corresponding numbers were 3.73 
and 3.13 (n.s. within both groups). None of the 5 patients initially without vertebral fractures 
showed evidence of subsequent compression. 
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Figure 6.3 COllrse of the callcel/olls BMD (by QCT) of the 3rd lumbar venebral body Img 
K,HPO/ml). See also the legelld to Fig. 6.1. Grollp 1: II = 14. grollp 2: II 
= 15. Statistical 0110 lysis was pelfonlled at 6, 12 alld 24 months. 
4. Biochemical investigations. 
In both treatment groups the serum Ca level (group 1 2.39 ± 0.02 (S.E.M.) and in group 
22.36 ± 0.02 mM) did not change significantly. Serum P, however, fell in both groups: in 
group 1 from 1.20 ± 0.03 to 1.06 ± 0.03 mM as measured after 6 months and in group 
2from 1.17 ± 0.04 to 0.95 ± 0.03 mM after 3 months (P < .001 in both instances). In 
group 1 the P level was after 3, 12, 18 and 24 months significantly higher than in group 2. 
In group 1 serum creatinine (68.0 ± 2.7 I,M) did not change over the study period, whereas 
in group 2 it rose from 72.2 ± 2.1 to 80.3 ± 1.9 after 3 and to 85.5 ± 2.5 I'M after 12 
months (P ,,; .001) to subsequently stay at that level. In the two groups of patients the initial 
average values of serum alkaline phosphatase, osteocalcin and procollagen I and the fasting 
urinary hydroxyproline were not significantly different (Table 6.1). In both groups an 
identical decrease (of 23 %) of the serum alkaline phosphatase was seen, that was complete 
after 6 months of treatment (P ,; .002, Fig. 6.4A). Over the same period serum osteocalcin 
fell by 28 % in group 1 and 27 % in group 2, while the maximal decreases were 35 and 44 % 
after 12-24 months (Fig. 6.4B; P < .01). Serum procollagen type I decreased by 22 and 
93 
A ..... group 1 •• I group 2 
80 
60 ~* ** * ~ 1 -r-- I t-----'! 
** ** ** 40 
J 
0 6 12 18 24 
B 
"'-
4 ~ '" ** ** e 
24 '" ... 1 ... _ ......... ; ........... '[ 
.2 
E * ** 2 ** 
0 
0 6 12 18 24 
C 
120 
* 
100 ** 
3 
80 ** 
-----:.;-~--,-".,.-~-t-
* 
** 
J 
0 6 12 18 24 
Time (months) 
Figure 6.4 Course oj semlll alkalille phosphatase (A). osteocalcill (B) alld procollagell I 
(C) during cyclical treatlllellt \Vith estrogen alld progestagell (group 1) and 
cyclical treatlllellIwith estrogell and progestagell. cOlllbined with lIandrololle 
(group 2). All groups n ~ 18. except jor the groups oj C: n ~ 17. Means ± 
S.E.M. Statistical analysis lVas peljorllled at 6. 12 and 24 1II01llhs. 
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15% in group 1 and 2, respectively, after 6 months treatment (Fig. 6.4C; P < .00] and .05, 
respectively). Of the 2 hour fasting urinary hydroxyproline a similar fall was observed in 
both groups, that was maximal at 12 months: minus 36% in group 1 and minus 33% in group 
2 (Fig. 6.5; P < .01). 
Before treatment the average serum estradiol level was in group 1 and 2 33.6 ± 4.6 
(S.E.M.) pM and 34.1 ± 5.9 pM, respectively. After 3 months of treatment with 2 mg 
estradiol valerate the estradiol concentration had risen to 264 ± 37.5 pM and 250 ± 60.6 
pM, respectively. 
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Figure 6.5 Course oJ2hJasting urinary hydrm),proline, correctedJor glomentlar filtration 
dllling cyclical treatment lVith estrogen and progestagen (group 1) and cyclical 
treatment with estrogen alld progestagen, combined with nandrololle (group 
2). Both groups II = 18. Means ± S.E.M. Statistical analysis was pet/onned 
at 6, 12 alld 24 months. 
5. Adverse effects. 
A. Phoniatric evaluation. 
After one year of medication a considerably higher percentage of patients of group 2 as 
compared to group 1 complained of change of voice timbre, voice unsteadiness, voice 
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lowering and loss of high frequencies (Table 6.2). Logopedic evaluation revealed a 
significantly higher percentage of patienls in group 2 than in group 1 with an increase of 
voice creakiness and voice instability (Table 6.2). Likewise, with voice field measurements 
a significantly lower mean frequency during speech and lower highest frequency was 
observed in group 2. \Vith regard to the vocal cord aspect, maximum phonation time, voice 
breaks and pitch perturbation no significant differences between the 2 groups were found. 
The results of the phoniatric studies will be reported more extensively elsewhere. 
B. Serum total and HDL-cholesterol. 
Because it was not possible to obtain fasting blood samples on follow-up, plasma triglyceride 
levels could not be taken into account. In group 1 serum total cholesterol showed a decrease 
from 6.49 ± 1.39 (S.D.) to 5.91 ± 1.06 mM (P < .01) after 6 months. In group 2 no 
change was seen: 6.42 ± 1.31 and 6.35 ± 1.69 mM. 
In contrast, HDL-cholesterol was unchanged after 6 months treatment with oestrogen-
progestagen·cycles (1.45 ± 0.49 and 1.42 ± 0.43 mM), bUI fell in the patients who were 
additionally treated with nandrolone decanoate: from 1.38 ± 0.29 to 1.22 ± 0.18 mM (P 
< .01). 
C. Other. 
Liver enzymes did not change in the 2 groups. There were also no complaints or signs of 
increased hair growth, facial or elsewhere. 
Table 6.2 Phoniatric emlaation after 1 year treatment 
HRT ([) HRT + ND (2) P-mlue 
n 17 22 
voice timbre change % 6 64 < .01 
voice unsteadiness % a 52 < .01 
voice lowering % 12 86 < .01 
loss of high 
frequencies % 18 62 < .01 
increase voice 
creakiness % a 55 < .01 
voice instability % a 55 < .01 
mean frequency Hz 222 195 < .01 
highest frequency Hz 731 505 < .01 
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DISCUSSION 
In this study HRT induced an impressiYe increase in both trabecular and cortical bone 
mineral mass. This increase was not enhanced by the addition of nandrolone decanoate to the 
treatment. Most of the gain in bone mineral mass during HRT was seen during the first year. 
The increase in bone mineral mass and density we found during two years of estrogen-
progestagen-treatment at the forearm and at the lumbar yertebrae (by DPA; up to 12 %) is 
comparable to the recently reported effect on bone mass of continuous estrogen-progeslagen-
treatment of proven postmenopausal osteoporosis12. At these sites and with these methods this 
rise appears to be larger than that regularly seen in Donnal early postmenopausal women 
treated with estrogen or a combination of estrogen and progestagenJ-5 . We did not include an 
untreated control group. The rise in lumbar BMC we observed could be compared to a loss 
of lumbar BMC of about 4% oyer 2 years in untreated established postmenopausal 
osteoporosis29• The increment of the lumbar bone mineral mass seen in both our treatment 
groups is also larger than that reported by Storm et al. to occur over 1-2 years in 
osteoporotic women treated with the antiresorptively active bisphosphonate etidronate29 • In 
contrast to HRT etidronate did not induce an increase in foreann BMC. In this respect it may 
be releyant that - in contrast to for instance etidronate" and PTH (1-34) or (1_38)30.)( - HRT 
induces an increase of appendicular as well as axial bone mass. 
Preliminary histomorphometric results obtained in these patients after 2 years treatment have 
been reported". In both groups cortical thickness rose significantly, while trabecular bone 
volume did not change. There was no significant difference between the course in both 
groups. These results do not contradict those reported here, as it has been shown that the 
correlation between the histomorphometrically estimated trabecular bone volume in the iliac 
crest and the results of bone mineral mass measurements elsewhere is not high33. 
The observation of a faster and more extensiye rise of the lumbar BMD measured by QCT 
as compared to that measured by DPA might be explained by the fact that with QCT the 
trabecular (cancellous) compartment of the yertebral body is selectiYely measured. Secondly, 
the results of single energy QCT may be greatly influenced by the bone marrow fat 
contentJUS in that sense that a reduction in the proportion of fat marrow could show up as 
an increase in BMD. Conceivably the honnonal intervention may have led to such a 
reduction. Howeyer, one would then haye expected a significantly larger (apparent) increase 
of the QCT yalues in the patients additionally treated with nandrolone. Furthermore, the 
increases of the trabecular BMD of 21 % and 29% in the HRT and the HRT + ND group, 
respectiYely, are too high to be largely ascribed to marrow fat loss. 
The fall in biochemical parameters of bone resorption (fasting urinary hydroxyproline) and 
of osteoblastic actiyity (serum alkaline phosphatase, osteocalcin and procollagen type I) was 
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also comparable in both treatment groups. As expected, the decrease of urinary 
hydroxyproline was faster and tended to be larger than that of the other parameters. Geusens 
and Dequekerl9, treating osteoporotic patients with nandrolone only. saw a considerable and 
persisting lowering of the urinary excretion of hydroxyproline. 
The fact that an anabolic agent like nandrolone over 2 years does not add to the effect on 
bone mass of an estrogen-progestagen cyclic substitution scheme that as to dose level is 
considered to be sufficiently high to prevent bone loss" and that led to serum estradiol values 
within the normal preovulatory range, indicates that the anabolic agent acts mainly by 
inhibiting bone resorption and that bone resorption is already maximally inhibited by the 
estrogen-progestagen combination at the dose level used. An alternative explanation would 
be an interaction between nandrolone and estradiol, for example at the receptor level. \Ve 
have also to consider the possible anabolic properties of medroxyprogesterone, One cannot, 
however, expect a major effect of the dosage used on bone mineral mass, especially in the 
spine37 , Based on the 90% confidence limits of our data an additional effect of nandrolone 
of up to 3.5% for lumbar BMC or up to 2.5% for lumbar BMD cannot be excluded (Type 
II error). For the foreanll BMC this would amount to zero proximally and 3% distally. With 
nandrolone monotherapy other investigators found an increase of forearm BMC of 4-5 % over 
1-2 years l8,19, 
In established osteoporosis a vertebral fracture incidence of 35-54 per 100 patient-years has 
been reported". In 31 patients about 25 new vertebral deformities would have been expected 
in 2 years. In both groups the average number of deformed vertebrae per patient observed 
before and after 2 years treatment did not show a significant increase. Further compression 
of already deformed vertebrae has not been taken into account, but given the limited number 
of patients studied and the relatively short follow-up we do not want to attach too much 
importance to these fracture data in contrast to the results of the bone mass measurements. 
Adverse effects mainly concerned voice changes that occurred in the great majority of the 
nandrolone treated women and that apparently were not prevented by the simultaneous 
treatment with estrogen. The possible reversibility of voice changes is still under investi-
gation. With regard to the lipoprotein profile nandrolone neutralized the favorable effect of 
the estrogen-progestagen cyclic treatment on total cholesterol, while a slight reduction in 
HDL-cholesterol was induced by this steroid. It is clear that these adverse effects need 
consideration, whether nandrolone is given as mooo- or as adjuvant therapy. 
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HRT + NDII 
SUMMARY 
Thirty three women with postmenopausal osteoporosis wefe matched pair-wise as to age, 
years since menopause and body mass index and randomized to receive either cyclical 
estrogen-progestagen replacement treatment (group 1) or the same treatment plus nandrolone 
decanoate (ND) (group 2). Both groups were treated during 3 years and subsequently 
followed for another year off treatment. 
One year after cessation of the treatment the distal foreann bone mineral content was in 
group 2 significantly higher than in group 1. Bone mass measurements in the axial skeleton 
already showed a significant difference in favour of group 2 after 3 years treatment, which 
persisted during the year off treatment. The decline in lumbar bone mineral mass and density 
in the one year off treatment was similar in both groups. Correction for body mass did not 
change these results. Done turnover parameters did not show significant differences between 
the two groups after cessation of treatment. A higher muscle mass, induced by ND, could 
partly explain the differences between the groups since even one year after treatment was 
stopped an increased serum creatinine level was still observed in group 2. 
INTRODUCTION 
There are many prospective studies which clearly demonstrate that estrogen deprivation 
causes an increased bone loss, which can be prevented by estrogenst-s. In addition 
epidemiological studies indicate that hormone replacement therapy (HRT) reduces the 
incidence of osteoporotic fractures6-8. 
Also in patients with established osteoporosis beneficial effects of HRT have been reported. 
Previously we and others'-II showed that in osteoporotic women treatment with HRT for 1-2 
years resulted in a considerable increase in both appendicular and axial bone mineral mass. 
Furthermore, we observed that combined treatment of HRT plus nandrolone decanoate (ND) 
did not result in a further rise of bone mass, as measured after 2 years. Other studies have 
demonstrated that treatment with anabolic steroids only can increase bone mass in women 
with established osteoporosislZ+15 . 
To obtain more insight in the longterm effects of HRT versus HRT plus ND we extended our 
previous observations (9) up to 3 years. This study intended to investigate the possible 
potency of anabolic steroids to stimulate bone formation rather than inhibit bone 
resorption (or stimulate bone formation in addition to inhibiting bone resorption) and thus 
break through the coupling of bone formation to bone resorption. 
Because data on the course of bone mass measurements and of bone turnover parameters 
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after cessation of these treatment modalities are currently not available we also followed these 
parameters during the first year off treatment. 
METHODS AND MATERIALS 
A. Patients and treatment. 
Women, aged 50-70 years, with postmenopausal osteoporosis (at least one non-traumatic 
vertebral compression fracture, wedge or crush) or osteopenia were matched pair-wise with 
regard to age (difference,;; 5 years), years since menopause (YSM, difference,;; 5 years) 
and body mass index (BMI): weight (kg)/height (m2) (difference ,;; 3.0). Osteopenia (5 
patients) was defined as a lumbar BMD value (by DPA) of ;;, 2 SD below the normal mean 
of age-matched controls. The patients were randomized pair-wise after informed consent had 
been obtained to receive either hormonal replacement therapy (HRT) or HRT plus 
nandrolone-decanoate (ND, Deca-DurabolinR, Organon International BV, Oss, The 
Netherlands). 
HRT was given as estradiol valerate (Progynova', Schering-Nederland BV, Weesp, The 
Netherlands) 2 mg orally, day 1 - 25 of each monUI and medroxyprogesterone acetate 
(Provera', Upjohn-Nederland, Ede, The Netherlands) 10 mg orally, day 16 - 25 of each 
month. ND was administered intramuscularly in a dosage of 50 mg once every 4 weeks. 
When needed according to the dietary history calcium suppletion up to a total of at least 1000 
mg in the foml of a Ca-Sandoz' effervescent tablet containing 0.5 g of elementary calcium 
was given (n=28). Compliance was measured by means of tablet counting. Treatment was 
single blinded, i.e. the biochemical data and the bone densitometric data were all coded. 
Initially 42 patients were randomized to enter the study. 
Nine of these patients wanted to terminate their participation in the trial after 6 to 33 months 
(only one of them replaced), so that for evaluation after 3 years treatment the data of 34 
patients are available. Five of the 9 patients who stopped treatment did so because of voice 
problems (all five received HRT + ND), 2 because of extent of uterine bleeding (HRT), one 
moved elsewhere (HRT) and one died of myocardial infarction (HRT). In the fourth year one 
patient started again with therapy because of depression after stopping HRT. The remaining 
33 patients (group 1; n=16, group 2; n=17) could be foIlowed for one year after the 
treatment was stopped. The initial average age and YSM were 60.6 ± 4.1 (S.D.) and 14.0 
+ 6.4 years, respectively, in the HRT- and 61.9 ± 4.4 and 14.1 ± 6.3 years, respectively 
in the HRT + ND group. 
In all patients the diagnosis of primary osteoporosis was confirmed by biochemistry and iliac 
crest biopsy. 
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B. Bone mineral mass measurements. 
1. SPA of the right foreann was perfonned at the (ultra)distal and proximal sites with 
intervals of 3 months according to Nilas et a!. 16 with a Nuclear Data ll00a scanner. The (fat-
corrected) results are expressed as bone mineral content (BMC, arbitrary units (U)/cm). The 
coefficient of variation in nonnal subjects in our hands is 1.9 % for the distal site and 1.0 
% for the proximal site17• 
2. DPA of the 2nd through 4th lumbar vertebrae was done every 3 months according to 
Krolner and NielsenIs with a NOVO BMC-Lab 22a scanner. Results are expressed as BMC 
in g hydroxyapatite (HA). The coefficient of variation in osteoporotic women in our 
laboratory is 2.3 %17. 
3. Single energy OCT of the trabecular (cancellous) compartment of the 2nd and 3rd lumbar 
vertebrae was carried out at intervals of 6 months with the method we previously described 
as QCTtrabl7. Scans were made at 120 kVP. The results are expressed as bone mineral 
density (BMD, mg ~HP04 equivalent/ml). The coefficient of variation in twenty 
osteoporotic women in OUf laboratory is 2.7 %17. Fractured vertebrae were not measured. 
C. Radiogrammetry of the thoracic and lumbar vertebrae. 
New fractures were defined as a reduction of 15 % or more of the anterior or mid vertebral 
height as compared to the posterior vertebral height. 
D. Biochemistry. 
Every 3 months the following parameters were detennined: 
1. Serum Ca, P, alkaline phosphatase, creatinine, albumin and haemoglobin with 
standard methods. 
2. Serum osteocalcin and procollagen type I with RIA (INC, Stillwater, USA and 
Fonnos Diagnostica, Oulunsalo, Finland, respectively) and 
3. Fasting (2 hr) urinary hydroxyproline by Hypronosticon (Organon Technika, Oss, The 
Netherlands) and Ca by a standard method. The hydroxyproline data obtained were 
expressed as nmolllOOmi glomerular filtrate (GF). 
4. Every six months serum total and HDL-cholesterol were detennined by standard 
methods in the non-fasting state. 
E. Statistics. 
Within each of both treatment groups changes (either absolute or relative) over time have 
been tested by means of Wilcoxon signed ranks test (two-sided). Between the two treatment 
groups absolute values and percent changes from baseline have been compared and tested by 
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means of the Mann-Whitney V-test (two sided). 
RESULTS 
Bone mass measurements. 
The changes with time within the treatment groups on and off treatment are shown in Fig. 
7.1 A and B for the forearm (SPA) and 7.2 and 7.3 for lumbar spine (DPA and QCT, 
respectively). The differences within the two groups after 36 months vs 24 months were only 
significant (P < .05) for the QCT-measurement in group 1. The statistical analysis of the 
differences between the two groups at the time points 1,2,3 and 4 years (QCT, because of 
technical reasons at 3 1/2 instead of 4 years) are given in Table 7.1. 
Correction of the bone mass measurements for body mass index (BMI) did not change these 
results. 
Table 7.1 Statistical differences between treatment groups 
2 3 3 1/2 4 years 
SPA prox N.S. N.S N.S. N.S. 
SPA dist N.S. N.S. N.S. .05 
DPA N.S. N.S. .05 <.05 
QCT N.S. N.S. <.05 .05 
Creatinine <.001 <.001 <.001 <.01 
Hemoglobin <.001 <.001 <.001 N.S. 
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Biochemical investigations. 
Serum Ca was initially not different between both groups and in neitiler group a significance 
change in serum Ca was observed. The changes over time within the treatment groups of 
serum alkaline phosphatase, osteocalcin, procollagen type I and urinary hydroxyproline are 
depicted in Fig. 7.4 and 7.5. There were no statistical differences at the various time points 
between both groups. Serum creatinine was unchanged in group I during the total study, 
while in group 2 it showed an increase from 71.7 + 2.2 to 80.0 ± 2.1 umolll after 3 months 
and 88.1 + 2.6 umolll after 3 years of treatment and a decline to 80.2 ± 2.3 umolll one 
year after termination of the treatment (P t=3yrs vs t=O < .01, P t=4yrs vs t=3yrs < .05; 
Fig. 7.6). 
In group 1 the hemoglobin level (8.3 +(S.E.M.) 0.2 mmolll) also did not change during 
treatment, whereas in group 2 a rise was seen that amounted to 16 % after 3 years (p < .001) 
with a rapid decline until one year after the end of the treatment (P vs t=O NS, P vs t=3yrs 
< .001; Fig. 7.7). 
Both for hemoglobin and serum creatinine the values in group 2 were significantly higher 
than in group 1 from 3 months onwards. At 4 years this was the case with regard to 
creatinine only (Table 7.1). 
Vertebral fractures. 
Over the third year of observation 1 new vertebral fracture has been observed only in group 
I, while after the end of treatment in both groups 2 new fractures have been found (NS). In 
the terms we previously reported before and after 2 years treatment', this would for group 
1 amount to 3.73 fractures per patient after 2 years and 3.91 after 4 years and for group 2 
3.13 and 3.25 respectively. 
Compliance. 
No differences between the two groups were observed by means of tablet counting. The 
nandrolone decanoate administration was perfoolled by the general practitioner. The patients 
attended to all scheduled hospital visits within one week. The patients also reported monthly 
withdrawal bleedings, except for five women who had undergone a hysterectomy. 
The administration of nandrolone decanoate did not influence the serum estradiol levels: after 
3 months of treatment estradiol had risen from 33.6 + 4.6 (S.E.M.) to 264 + 37.5 pM in 
group 1 and from 34.1 ± 5.9 to 250 + 60.6 pM in group 2. 
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Adverse effeets. 
Phoniatric evaluation. As reported previously' a considerably higher percentage of the 
patients in group 2 as compared to group I had subjective and objective voice changes: For 
example. voice timbre changes. loss of high frequency and voice instability were found in 
around 60 % of the patients in group 2 and in 0-18 % of group I. Elsewhere these changes 
are reported extensively19. The reversibility of the voice changes is still under investigation. 
No complaints or signs of increased hair growth, facial or elsewhere were mentioned. We 
saw no effects on the plasma level of liver enzymes. 
Serum total and HDL-cholesterol. In group 1 serum total cholesterol fell from 6.39 ± 1.31 
(S.E.M.) to 5.86 ± 1.14 ruM (P < .OJ), 6.07 ± 1.06 and 6.24 + 1.29 ruM after 6 months, 
I and 3 years respectively. No change of total cholesterol was seen in group 2: initial value 
6.86 ± 1.34 and 6.88 ± 1.72, 6.68 + 1.06 and 6.36 ± 0.70 mM after 6 months, I and 3 
years respectively. 
HDL-cholesterol on the other hand did not show a consistent fall either in group 1: 1.61 ± 
0.55 initially and 1.47 + 0.48, 1.63 ± 0.65 and 1.25 + 0.33 ruM (P < .OJ) after 6 
months, 1 and 3 years or in group 2: 1.37 + 0.26 initially and 1.21 + 0.18, 1.21 + 0.16 
and 1.06 ± 0.24 ruM (P < .01) after 6 months, I and 3 years. 
One year after tenninating treatment total cholesterol amounted to 6.37 + 1.10 ruM in group 
1 and 6.60 + 1.01 ruM in group 2. HDL-cholesterol again did not show a significant 
change. 
lL 
CD 
E 
0 
0 
'0 
E 
c 
Figure 7.5 
## 
20 n.s. 
10 
### 
*** 
group 1 
- - • group 2 
0 
0 6 12 18 24 30 36 42 48 
Time (months) 
Course ojjasling 2h urinary hydroxyproline in bOlh Irealmem groups. 
See also Ihe legend 10 Fig. 7.1. 
111 
CHAPTER 7 
S 
0 
E 
0 
~ 
E 
Figure 7.6 
S 
0 
E 
E 
Figure 7.7 
90 
80 
70 " ~T I ~r-'-_"Il-"""l:--:lr n.s. 1" I n.s. ""l n.s. 
60 
f __ group 1 __ • group 2 
o ~l -,-----,-----;-~~ 
o 6 12 18 24 30 36 42 48 
Time (months) 
Course of senml creatinine. Means + S.E.M. See also the legend to 
Fig. 7.1. 
*** 
10 *** ~ ### ,;r--J; ...... ;r; __ ~ .... ...... 
,;; .... 
'" 
n.s. 
9 
.. ' - - .;r 
, 1 I 1 1 1 1 
8 I I n.s. n.s. n.s. 
7 
J group 1 __ • group 2 
0 6 12 18 24 30 36 42 48 
Time (months) 
COllrse of the hemoglobin level. See also the legend to Fig. 7.1. 
112 
HRT + ND II 
DISCUSSION 
We previously described the effect of 2 years treatment of patients with postmenopausal 
osteoporosis with estrogen and progestagen (HRT) on bone mineral mass and biochemical 
parameters. No additional effect of nandrolone decanoate on bone mineral mass in the 
forearm and the lumbar vertebrae was observed9 . The same groups were treated for another 
year in the same way. As compared to the initial values after 2 years treatment a gain of 
bone mineral mass at the foreann of up to 4.5 % and in the lumbar vertebrae (by DPA) of 
up to 12.5 % was observed, while QCT measurements showed a gain of the BMD up to 29 
%. Our SPA and DPA values are comparable (not identical) with the effect of cyclical and 
continuous estrogen-progestagen treatment of proven postmenopausal osteoporosis10. II . 
As could be expected there was no further increment in the HRT -group during the third year 
of treatment. However, in the HRT + ND group a further increase for lumbar BMC (DPA) 
of 3.5 % was found resulting in a significant difference between both groups at the end of 
the third year of treatment (Table 7.1). Lumbar BMD (QCT) appeared to fall during the third 
year in group 1 only, also resulting in a significant difference between the groups after 3 
years. 
The favourable effect of additional treatment with ND on bone mass, as found after 3 years, 
is still present 1 year after cessation of treatment. Geusens et al. reported a maintenance of 
bone mineral mass in cortical bone after withdrawal of nandrolone decanoate in osteoporotic 
women20• In our study the rate of bone loss in the axial skeleton appears to be comparable 
in both groups. In other words, the beneficial effect of HRT + ND in the third year of 
treatment is not followed by a higher loss during the period off treatment. Although we did 
not observe significant differences between the biochemical parameters in both groups, the 
time course of especially serum alkaline phosphatase and urinary hydroxyproline showed in 
the HRT group a tendency towards a higher turnover during the third year. This might 
implicate that during this period the anti-resorptive action of HRT alone is less effective than 
in the HRT + ND group. This possibility is also compatible with the observation that the 
differences in bone mass measurements between both groups are primarily found at sites with 
a relatively high amount of cancellous bone. At the foreann bone loss was only observed at 
the distal site in the HRT group. 
We also looked at the possibility whether the favourable effect of additional treatment with 
ND could be induced by indirect effects. A possible role for changes ill body mass index 
seems unlikely. since correction of the bone mass measurements for BMI did not change our 
results. However, this does not exclude a possible influence of changes in muscle mass. It 
is well-known that anabolic steroids induce an increase in muscle mass 21.22, while it is also 
known that there exists a positive correlation between muscle strength and bone mass23. The 
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highly significant increase in serum creatinine in the HRT + ND group, compared to the 
HRT group, clearly indicates an increase in muscle mass. Therefore, the observed differences 
in the course of bone mass in the two groups could at least partly be explained by this effect 
of ND on muscle mass, although muscle strength was not measured in this study. Also we 
cannot rule out the possible effect of increased muscle mass on the activity level and thereby 
on the feeling of well being in the group treated with ND. 
Finally we have to take into account that especially the lumbar QCT measurements could be 
influenced by changes in the bone marrow. In this respect the observed rise of hemoglobin 
in the HRt + ND group might indicate an increase in the amount of red marrow. Since 
single energy QCT, as used in our study, will show an apparent increase of BMD when the 
amount of red marrow increases2-1, the QCT measurements have to be interpreted with some 
caution. However, if one compares the course of lumbar bone mass as obtained with DPA 
this phenomenon can not explain the differences in axial bone mass between the groups at 
the end of the third year of treatment. 
There were no differences in compliance between the two treatment groups. \Ve observed 
no influence of the ND on the estradiol levels. Furthermore, the estradiol dosage used is 
generally considered adequate, which was confirmed by the estradiol levels measured. 
Taken together our study shows that treatment with HRT in women with postmenopausal 
osteoporosis will initially result in a considerable increase of both axial and appendicular 
bone mass. That the beneficial effects of additional treatment with ND is not apparent before 
the third year of treatment might indirectly indicate that during longteml treatment with HRT 
of patients with postmenopausal osteoporosis some escape will occur from the antiresorptive 
activity of HRT. Up to now such a partial escape has not been reported in long-term HRT'·J, 
but this may be due to the fact that most long-tenn data have been obtained in normal 
postmenopausal women and not in patients with postmenopausal osteoporosis. 
Acknowledgements. 
We thank Dr. P .T.A.M. Lips (Amsterdam) for referral of several patients and his assistance 
in the follow-up of these patients. 
The support by Organon Nederland B. V., ass, The Netherlands is gratefully acknowledged. 
114 
HRT + ND II 
Referellces 
1. Recker RR. Saville PO, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in 
postmenopausal women, Ann Int Med 1977;87:649-655. 
2. Nachtigal! LE, Nachtigall RH. Nachtigall RD. Beckman EM. Estrogen replacement therapyI: A 10-
year prospective study in relationship to osteoporosis. J Obstet & GynecoI1979;93:277-281. 
3. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophoreclomised 
women. Lancet 1980;ii:1151-1154. 
4. Christiansen C, Christensen MS, TransboI l. Bone mass in postmenopausal women after withdrawal 
of oestrogenJprogestagen replacement therapy. Lancet 19& I ;i:459-461. 
5. Quigley MET, Martin PL, Bumier AM, Brooks P. Estrogen therapy arrests bone loss in elderly 
women. Am J Obstet Gynecol1987;156:t516·1523. 
6. Hutchinson TA, Polansky SM, Feinstein AR. Postmenopausal oestrogen protects against fractures of 
hip and distal radius. A case control study. Lancet 1979;i:705-709. 
7. Weiss NS. Vre CL, Ballard JH. Williams AR, Dating JR. Decreased risk of fractures of the hip and 
lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-1198. 
B. Ettinger B, Genant HK, Cann CEo Long-term estrogen replacement therapy prevents bone loss and 
fractures. Ann Int Med 1985;lO2:319-324. 
9. Birkenhager JC, Erdtsieck RJ, Zeelenberg J, van Kuijk C, van Veen LCP, Birkenhager-Frenkel DH, 
Luiken GPM, Kooy PPM, Gerritsma EJ, Mulder P, Pols HAP. Can nandrolone add to the effect of 
honnonal replacement therapy in postmenopausal osteoporosis? Done and Mineral 1992;IB:251-265. 
lO. Christiansen C, Riis Bl. l71l-estradiol and continuous norethisterone: A unique treatment for 
established osteoporosis in elderly women. J Clin Endocr Metab 1990;71:836-871. 
11. Lufkin GE, Walmer HW, O'Fallon WM, Hodgson SF. Kotowicz MA, Lane AW, Judd HL, Caplan 
RH, Riggs BL. Treatment of postmenopausal osteoporosis with transdennal estrogen. Ann Int Med 
1990;1l7:1-9. 
12. Riggs BL, Jowsey J, Goldsmith RS, Kelly PI, Hoffman DL, ArnaUd CD. Short- and long-term effects 
of estrogen and synthetic anabotic honnone in postmenopausal osteoporosis. J Clin Invest 
1972;51: 1659-1662. 
13. Need AG. Horowitz M, Bridges A, Rad ADipD, Morris GA, Nordin DEC. Effects of nandrolone 
decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Arch 
Int Med 1989;149:57-60. 
14. Dequeker J, Geusens P. Anabolic steroids and osteoporosis. Acta EndocrinoI 1985;suppI271:452. 
15. Hassager C. Riis Bl, Podenphant 1, Christiansen C. Nandrolone decanoate treatment of post-
menopausal osteoporosis for 2 years and effects of withdrawal. Maturitas 1989;11:305-317.15. 
16. Nilas L, Borg J, Gotfredsen A, Christiansen C. Comparison of single- and dual absorpliometry in 
postmenopausal bone mineral loss. J Nuel Med 1985;26:1257-1262. 
17. van Berkwn FNR, Birkenhager JC, van Veen LCP, Zeelenberg J, Birkenhager-Frenkel DH. 
Trouerbach WTh, Stijnen T. Pols HAP. Non-invasive axial and peripheral assessment of bone mineral 
content: A comparison between osteoporotic women and nonnal subjects. J Bone Min Res 1989;4:679-
685. 
lB. KreIner B, Nielsen P. Measurement of bone mineral content (BMC) of the lumbar spine I. Theory and 
application ofa new two-dimensional dual-photon attenuation method. ScandJ Lab Invest 1980;40:653-
663. 
19. Gerritsma EJ. Brocaar MP, Hakkesteegt MM, Birkenhager JC. Virilisation of the voice in 
postmenopausal women due 10 the anabolic steroid nandrolone decanoale (Deca-Durabolin). Clin. 
Otolaryng. and all. SC. (Accepted for publication.) 
20. Geusens P, Dequeker J. Verstraeten A, Nijs J. Van Holsbeeck M. Bone mineral content, cortical 
thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone 
decanoate. I-alpha hydroxyvitamin D), or intenniuent calcium infusions. Maturitas 1986;8:281-289. 
21. LaBree M. A review of anabolic steroids J Sports Med Phys Finnes 1991;31:618-26. 
22. Rogol AD, Yesalis 1IJ CEo Anabolic-androgenic steroids and Athletes: What are the issues? J Clin 
Endocr Metab 1992;74:465-69. 
115 
CHAPTER 7 
23. Pocock N.Eisman J, Gwinn T, Sambrook P, Kelly P, Freund J, Yeates M. Muscle strength, physical 
Finness, and weight but not age predict femoral neck bone mass. J Bone Min Res 1989;4:441-448. 
24. Kuijk van C, Grashuis JL, Siceobeek JCM, SeMite HE, Trouerbach WTh. Evaluation of 
postprocessing dual-energy methods in quantitative computed tomography. Part 2: Practical aspects. 
Invest Radiol 1990;25:882-889. 
116 
CHAPTER 8 
TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH A 
COMBINATION OF GROWTH HORMONE AND PAMIDRONATE. 
A PLACEBO-CONTROLLED TRIAL. 
R.J. Erdtsieck, H.A.P. Pols, N.K.Valk, B.M. van Ouwerkerk', S.W.J. Lamberts, P. 
Mulder' and J.C. Birkenhager. 
Department of Internal Medicine JII and Clinical Endocrinology, University Hospital 
"Dijkzigtn , Erasmus University, Rotterdam, lDepartment of Internal Medicine, 
"Merwede" Hospital, Dordrecht and 'Department of Epidenniology & Biostatistics, 
Erasmus University, Rotterdam, The Netherlands. 
Clinical Endocrinology 1995;43:557-565 

GH and pamidronate in osteoporosis 
SUMMARY 
Objective. 
It is known that growth honnone (GH) can induce accelerated bone turnover in GH deficient 
people as well as healthy elderly people. In this study we examined the effect of recombinant 
human GH (rhGH) on bone mineral mass and bone turnover in the presence of the bone 
resorption inhibiting agent, pamidronate. Also effects on body composition were studied. 
Methods. 
21 postmenopausal osteoporotic women were treated with the bisphosphonate pamidronate 
during twelve months. During the initial 6 months rhGH was administered (0.0675 IV/kg, 
3 times/week) in a placebo-controlled fashion (IO vs II patients). 
Measurements. 
Bone mineral content (BMC) of the lumbar spine and femoral neck was measured with dual 
energy X-ray absorptiometry and BMC of the distal and proximal forearnl with single photon 
absorptiometry. Body composition was measured with bioelectrical impedance and total body 
dual energy X-ray absorptiometry. Furthennore serum IOF-I and biochemical indices of bone 
turnover were measured. 
Results. 
The group treated with rhGH showed a two- to three-fold increase in serum IGF-I levels. No 
effects on bone mineral mass were observed in the group treated with rhGH, after the initial 
6 months of treatment with rhGH nor after the total period of 12 months. In women treated 
with pamidronate, however. a consistent increase of about 5 % at the lumbar spine and 
somewhat lower in the distal forearm was reached from 6 months onwards. In both groups 
no change in BMC at the femoral neck and foreann was observed. 
Compared to baseline the biochemical measurements of bone turnover showed a decrease of 
about 50 % in the pamidronate-treated group, whereas in the group additionally treated with 
rhGH this effect was blunted. 
The body composition measurements showed clear effects of rhGH administration, i.e. a 
decrease of fat mass of about 5 % and an increase of lean body mass of about 3 %. 
However, these effects disappeared after the treatment with rhGH was stopped; fat mass as 
well as lean body mass returned to initial values. 
Conclusions. 
The present study suggests that treatment with rhGH blunted both the pamidronate-induced 
accumulation of bone mineral mass and the reduction of biochemical markers of bone 
turnover. Furthennore the positive effect of rhGH on body composition disappears 
completely after cessation of treatment with rhGH. 
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INTRODUCTION 
Several approaches for the medical treatment of postmenopausal osteoporosis are available 
at present. Among these are estrogens, bisphosphonates, anabolic steroids, calcitonin, 
fluoride and vitamin D preparations'-7. Most of these treatment schemes are effective by 
diminishing bone resorption, whereas only fluoride is able to increase osteoblastic activity8.9. 
Recently Heaney argued that much of the apparent gain in bone mass produced by several 
agents currently employed to treat osteoporosis can be explained by the so called "bone-
remodelling transient"lO. In other words the gain of bone induced by an inhibitor of bone 
resorption will only be transient because the associated rate of change in bone mass persists 
for only one remodelling period. A more fundamental change in bone mineral mass can only 
be obtained if a given drug can induce a change in the balance between formation and 
resorption at each individual remodelling locus. 
Recent evidence suggests a role for growth hormone (GH) as an osteotrophic factor. It is 
known that GH is responsible for longitudinal bone growth through a direct stimulation of 
chondrocytes and osteoblastsll. 12 • In adults GH also activates bone remodelling lJ,i4, and 
probably diminishes bone loss as compared to controls14 • Furthennore, several studies 
indicate that in GH deficient (GHD) adults treatment with recombinant human GH (rhGH) 
results in an increase of bone turnover parameters and after long-term treatment even a rise 
of bone mineral mass has been observed IS-18 • In addition studies of patients with endogenous 
high levels of GH (acromegaly) have shown a stimulated bone turnover and an increased 
bone mineral mass t9,20, 
Normal aging and GHD show some striking common features. Both GHD as well as nom1al 
aging are associated with decreases in protein synthesis, decreases in percentages of lean 
body and bone mass as well as with increases in percentage body fatl l -26 _ It is possible that 
reduced GH and IGF-I secretion may account, at least in part, for one or more of the above 
effects of aging"'" and that elderly individuals might benefit from treatment with rhGH. In 
several studies administration of rhGH for periods varying from a few weeks to twelve 
months, resulted in improvement of nitrogen balance, an increase in lean body mass, and a 
decrease in percentage body fat 14,29-31, 
Very little is known about the effects of rhGH in the treatment of postmenopausal osteoporo-
sis, In a small study in which GH was administered in sequence with calcitonin in women 
with postmenopausal osteoporosis a small favourable effect was observed3l_ In the present 
placebo·controlled study we tested whether rhGH might have an additional anabolic effect 
on bone formation in postmenopausal osteoporotic women treated with the bone resorption 
inhibitor pamidronate. Furthermore, the effects of rhGH on body composition were 
evaluated. 
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MATERIALS AND METHODS 
Patients and treatment. 
After review and approval of the protocol by the Ethical Committee of our institution. written 
infonned consent was obtained from the patients. All 23 patients were caucasian 
postmenopausal osteoporotic women with at least one non-traumatic vertebral fracture (not 
the lumbar vertebrae 2 - 4). The presence of vertebral fractures was assessed by clinical 
reading. The basal number of vertebral fractures did not differ between both groups. Patients 
with any disorder known to affect bone mass were excluded from this study. as were women 
with a history of malignancy, as well as patients with a known history of diabetes mellitus 
or hypertension. All patients were treated with pamidronate. The patients were randomly 
assigned to receive either rhOR or placebo. 
All patients received during 12 months pamidronate as an enteric-coated tablet, 150 mg per 
day, orally on an empty stomach. During the initial six months rhOR or placebo was self 
administered by means of subcutaneous injection of 0.0625 IVlkg with a maximum of 4 IV, 
3 times per week (monday, wednesday, friday). In a pilot-study this dose resulted in high 
nom1al IOF-I levels. Treatment was double blinded with regard to rhOR or placebo. rhOR 
(Rumatrope) and placebo was supplied by Eli Lilly Co. Indianapolis, IN., USA. Placebo 
vials were indistinguishable from rhOR vials. 
In patients with a calcium intake below 1000 mg (according to dietary history), a Ca-Sandoz 
effervescent tablet containing 0.5 g elemental calcium was given. This applied to 5 patients 
in the OR-group and 6 patients in the placebo group. Compliance was measured by means 
of tablet and vial counting. 
Bone mineral mass measurements. 
Single photon absorptiometry (SPA) of the right forearm was performed at the distal and 
proximal sites with an interval of3 months using a Nuclear Data 1100a scanner". The (fat-
corrected) results are expressed as bone mineral content (BMC; arbitrary units, U/cm). The 
coefficient of variation in our hands is 1.9 % for the distal site and 1.0 % for the proximal 
site. 
Dual energy X-ray absorptiometry (DXA; Lunar DPX-L, Lunar Radiation, Madison, WI, 
USA) was perfom1ed at the lumbar vertebrae 2-4 (L2-4) and in the left proximal femur: the 
femoral neck, Ward's triangle and trochanteric region according to the instructions of the 
manufacturer". BMC is expressed as grams of bone mineral (g/cm). For osteoporotic women 
the coefficient of variation is 1.5% for the lumbar spine and 1.8, 2.4 and 2.8% in the 
femoral neck, Ward's triangle and trochanteric region, respectively. 
Quality assurance, including calibration with the standard of the machines (SPA and DXA), 
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was perfonned routinely every working day. No drift was observed during the whole study 
period. 
Body composition. 
Body composition was measured after an overnight fast by the bioelectrical impedance 
method (BIA) with a body composition analyzer (RJL-systems B1A-lOl Detroit, MI, USA) 
as described previously,,·l6. Through regression equation, fat free mass (FFM) was 
calculated. Fat mass was calculated by subtracting FFM from body weight (Lukaski el al., 
1986). 
Body composition was also measured by using the DPX-L densitometer. The instrument 
measures fat mass, lean mass and bone mineral content. The method is well validated". 
Biochemistry. 
At baseline and after I, 3, 6, 9, and 12 months the following fasting serum parameters were 
determined: 
• 
• 
Calcium, phosphate, alkaline phosphatase, creatinine, albumin, glucose and glycosyla-
ted hemoglobin (HbA,C) with standard methods. 
Insulin-like growth factor-I (IGF-I), osteocalcin and procollagen type 1 (PICP) with 
radioimmuno-assay (RIA) (Medgenix Diagnostics, Brussels, Belgium; Incstar 
Corporation, Stillwater, USA and Orion Diagnostica, Espoo, Finland respectively). 
At baseline and after 3, 6, 9 and 12 months the following urinary parameters were determi-
ned: 
* Fasting (2h) hydroxyproline by Hypronosticon (Organon Technika, Oss, The Nether-
lands) and excretion of free deoxypyridinoline by enzyme linked immuno sorbent 
assay (Pyrilinks D, Metra biosystems, Palo Alto, USA). 
All samples were collected after an overnight fast on the day after administration of rhGH 
or placebo. 
Statistics. 
Values are expressed as means ± SEM. At baseline differences between groups were tested 
by Student's t-test for unpaired data, with a P value of < .05 for significance. 
Statistics within and between treatment groups were perfornled by means of repeated 
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Table 8.1 Clinical and biochemic/wi characteristics of the patients 
characteristic rhGH (n~ 10) placebo (n~ll) 
mean range mean range P 
Age (yr) 63.5 57-74 62.8 55-72 NS 
YSM (yr) 20.2 7-30 14.4 5-27 NS 
BMI (kg/m,) 25.0 19.6-27.4 25.6 19.0-32.5 NS 
Height (cm) 162.5 149-179 160.5 153-178 NS 
Weight (kg) 65.3 56.0-77.5 66.7 45.0-89.1 NS 
BMC,,,," (gHa) 32.7 23.4-39.7 31.8 21.2-44.6 NS 
BMCll", MOl; (gHa) 3.5 3.1-4.4 3.6 1.9-6.0 NS 
BMC,u' (gHa) 1.6 1.2-2.4 1.7 1.0-3.5 NS 
BMCacch (gHa) 8.2 4.6-14.3 7.3 3.2-11.6 NS 
BMC SPA,JL\\(Ulcm) 29.4 22.2-38.2 27.8 14.0-40.3 ~.05 
BMC SPApro,(U/cm) 30.8 19.5-38.4 30.3 16.3-42.9 NS 
BIA fat (%) 39.6 33.3-47.3 37.7 28.1-55.2 NS 
DXA fat (%) 32.1 21.5-38.4 35.1 26.1-46.9 NS 
Calcium (mmolll) 2.28 2.10-2.40 2.29 2.15-2.44 NS 
Phosphorus (mmolll) 1.13 0.99-1.27 1.19 0.81-1.41 NS 
Creatinine (Ilmolll) 67 48-91 78 49-113 NS 
APase (UlI) 57.2 44-82 79.5 37-124 <.05 
IGF-! (nmolll) 20.0 9.6-33.0 24.2 13.2-48.0 NS 
Osteocalcin (pgll) 3.0 1.0- 6.5 4.7 0.6- 8.5 NS 
Procollagen I (pgll) !04.2 44-286 108.1 74·178 NS 
24 hr urinary: 
Calcium 0.61 0.15-1.09 0.46 0.20·0.89 NS 
(mmollmmol creal) 
2 hr fasting urinary: 
OH+proline 
(mmollmo! creat) 20.8 9.6-39.4 23.5 10.2-60.0 NS 
free deoxypyridinoline 80.3 36.7-171.0 51.3 14.6-88.1 NS 
(nmollmol creat) 
NS: no significance between groups 
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measures analysis of variance (nnANOV A). The dependent variable is assumed to have a 
linear trend relationship with time; in the model the slope is different between the two 
treatment groups. In the GH group file model includes additional effects after stopping rhGH 
in month 9 and 12. 
If the nnANOV A resulted in a significant main effect between treatment groups, we 
performed a Student's t-test posthoc analysis for paired data within groups and for unpaired 
data between groups, with a P value of < .05 for significance. 
RESULTS 
Side effects, baseline values. 
Initially 23 patients entered the study. 12 patients were treated with pamidronate only 
(placebo-group). One of these patients decided to stop at 4 months, because of gastric 
complaints, related to the use of the bisphosphonate. The II patients of the other group were 
treated with APD and rhGH (rhGH-group). In this group one patient was taken out at 3 
months because of cardiac complaints related to fluid retention (minor cardiac failure, which 
was treated with diuretics). The remaining 21 patients (placebo-group; n~lI, rhGH-group; 
n~ 10) completed the 12 months study period and were eligible for evaluation. Except for 
I patient complaining temporarily of gastric complaints no side effects were observed in these 
patients. rhGH injections were tolerated well, no dose adjustments were necessary. 
The baseline values are presented in Table 8.1. No significant differences as to age, or years 
since menopause (YSM) were found between both groups. Also anthropometric data were 
comparab1e. The initial bone mass measurements showed no significant differences except 
for the distal forearm BMC, measured with SPA (Table 8.1). Body composition did not show 
any differences at baseline when calculated with BIA or measured with DXA. The baseline 
biochemical measurements showed a higher serum alkaline phosphatase (P < .05) in the 
placebo-treated group, otherwise there were no differences (Table 8.1). 
Longitudinal bone mass measurements. 
The time course of the different bone mineral mass measurements are shown in Fig. 8.1 A-
D. For the lumbar spine a rapid increase in the placebo-group was observed after three 
months for the lumbar spine as well as the distal forearm, with a much slower increase 
during the subsequent nine months. For the rhGH-group no significant cbanges were 
observed during (0-6 months) and after cessation (6-12 months) of treatment. In the femoral 
neck (as well as the Ward's triangle and trochanteric region) no significant changes during 
the whole treatment period (12 months) for either group were observed. 
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For the foreann a similar pattern as in the lumbar spine was found, however no significance 
wasreached between both groups. The proximal forearnl showed no clear changes in either 
group. 
Body composition. 
Baseline measurements for body composition showed a correlation between fat mass 
assessment by BrA and DXA (r = 0.74, P < .001). Also the changes in time measured by 
the two methods were well correlated (r = 0.85, P < .001). 
In the placebo-group no changes in body composition were observed during the year of 
treatment. In the rhGH-group, irrespective of the method used, a significant decline of the 
percentage fat of about 5-7 % compared to initial values occurred. After the treatment with 
rhGH was withdrawn an increment of fat mass occurred, reaching pretreatment levels within 
3 months, when measured by BrA (Fig. 8.2A). Total body DXA measurements were not 
perfonned at 9 months (Fig. 8.2B). When lean body mass was analysed by DXA, again no 
changes in the placebo-group were found whereas a significant increase in lean mass of about 
2.5 % after 3 months was found in the rhGH-group (Fig. 8.2e). Again, these changes 
disappeared after treatment with rhGH was stopped at six months and returned to 
pretreatment values. 
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Biochemical parameters. 
Baseline serum lGF-I levels did not differ between the groups. They also did not differ from 
the values found in a control population of women (n = 115), aged 55 years and over (18.1 
± 3.2 nmol/I vs 22.1 ± 6.4 nmol/I (in our patients». Serum IGF-I increased rapidly after 
I month in the rhGH-group and stabilized during rhGH-treatment. After cessation of rhGH-
treatment a rapid return to pretreatment values was observed (Fig. 8.3). 
Serum Ca, P and creatinine did not change during the treatment period between or within 
groups. During the treatment period no changes in glucose metabolism (glucose, glycosylated 
Hb) were observed in both groups. 
The relative changes of serum alkaline phosphatase, osteocalcin, procollagen type lover tinle 
within and between both treatment groups are depicted in Fig. 8.4 A-C. In the placebo-group 
as well as in the rhGH-group a significant increase in alkaline phosphatase was found after 
I monUl. From 6 months onwards in the placebo-group and from 9 months onwards in the 
GH-group a significant decline of serum alkaline phosphatase was found. For osteocalcin a 
rapid decrease in the placebo-group was observed, whereas in the rhGH-group a non-
significant increase was observed. From 3 months onwards a significant difference between 
both treatment groups existed. Procollagen type I showed a small increase after I month in 
the rhGH-group, followed by a non-significant decline (compared to initial values). In the 
placebo-group an instant decline was observed from initiation of treatment onwards. 
In the placebo-group, urinary OH-proline (corrected for urinary creatinine) showed a rapid 
although not significant decline, whereas in the rhGH-group no changes at all were observed 
(Fig 8.4D). Also urinary free deoxypyridinoline, which is a more specific marker of bone 
resorption, showed only in the placebo-group a temporarily significant decline. 
DISCUSSION 
In this study postmenopausal osteoporotic women were treated for a period of one year with 
pamidronate. In a placebo-controlled manner, half of the women received also rhGH during 
the initial six months. No additional effect of rhGH treatment was found on bone mineral 
mass. On the contrary, the beneficial effect of pamidronate on bone mass was blunted by the 
additon of rhGH. 
In the placebo-group, treated with pamidronate only an increase of bone mineral mass at sites 
representing cancellous bone (lumbar spine and distal foreann) was observed, whereas no 
significant changes were observed at sites merely containing cortical bone (femoral neck and 
proximal fore amI) . A similar gain of bone mineral mass, explained by the so-called 
"transient"JO, has been reported by other investigators using bisphosphonates·4.38. In the rhGH-
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group a rapid and consistent increase of circulating IGF-I levels was observed, indicating that 
the dose of rhGH used (0.0625 lU/kg, 3 times/wk) was sufficient to reach a level which is 
supra physiological for this age group. After withdrawal of rhGH administration, IGF-I values 
returned to baseline values. Other investigators recently showed that in postmenopausal 
women a comparable dosage of rhGH as used in our study induces a prompt and sustained 
increase in bone remodelling14 , However, in our osteoporotic women the simultaneous 
addition of pamidronate appears to attenuate this rhGH-induced increase in bone turnover. 
Therefore, the absence of a clear change in the activation of bone remodelling units, as 
reflected by the markers of bone turnover, might explain that in the rhGH-group no change 
of bone mineral mass was observed. It became only apparent after the study that tile baseline 
bone turnover rate appeared somewhat lower in the rhGH treated patients. However, this 
does not detract from our main conclusion that combined treatment of rhGH and 
pamidronate, for a relatively short period of six months, does not result in a positive effect 
on bone mineral mass. 
The present combination of therapeutic modalities in the treatment of postmenopausal 
osteoporosis was based on the assumption that it might be possible to activate bone fonnation 
by rhGH in the presence of an anti-resorptive therapy (pamidronate). However, this turned 
out not to occur. Several possible explanations can be given. First, we have to take into 
account that the postmenopausal women we have treated are not growth homlone deficient 
and may therefore be less sensitive to supraphysiological dosages of growth hormone. 
However, several studies have indicated that both short_30 and long-tennl4 treatment with 
comparable dosages rhGH resulted in an increased bone turnover. Compared to controls, in 
which a bone loss of 2-3 % was observed, the rhGH treated group did not show a change 
in bone mass measurement14 • In the present study we also observed in the rhGH treated 
patients at least initially a trend towards an increase of all bone formation markers, which 
was not accompanied by an increase of bone resorption. However, this apparent shift of tile 
balance towards formation did not result in a clear rise of bone mass. 
Secondly, the treatment period might have been too short to observe an osteotropic effect of 
rhGH. In GHD patients only long-term treatment with rhGH beyond six months resulted in 
a sustained increase of bone mineral mass18 • 
Thirdly, the present scheme of continuous rhGH and pamidronate treatment might have 
inhibited potential beneficial effects of rhGH on osteoblastic function. Whether it may be 
necessary to administer rhGH cyclically in tandem with pamidronate remains to be seen. No 
extensive data with respect to cyclical treatment are currently available. Only one study 32 
using GH in sequence with the bone resorption inhibitor calcitonin did not support the idea 
that such an approach indeed results in a more favourable response than could be expected 
from treatment with an inhibitor of bone resorption alone. 
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Fourthly, we can not exclude the possibility that the rhGH-induced increase of bone turnover 
may have made the bone tissue less sensitive to the bisphosphonate. 
Finally, one can argue that the number of patients in this study is too small. However, based 
on the present results it is highly unlikely that inclusion of more patients will change the 
results towards a more favourable effect of combined treatment versus treatment with 
pamidronate alone. 
rhGH treatment affects body composition with a decrease of fat mass and increase of lean 
body mass"·,,·40. Body composition in this group of elderly patients also changed accordingly 
during rhGH treatment with a decrease of fat mass and a rise of lean body mass. The 
changes observed were comparable to those obtained in GHD adult individuals during rhGH 
replacement therapy40·4I. One might speculate, that increased lean body mass might (and 
thereby muscle mass) benefit strength and possibly coordination, which may eventually lead 
to a reduction in fall and fracture rate.f2. 
Still, the methodology used in this study to measure body composition merits some further 
comments. The validation of the B1A method has not been carried out for different patient 
groups. The hydration status significantly influences the outcome, in tile sense that a slight 
dehydration, as might be the case in the elderly, overestimates the percentage body fat"'" 
The DXA method is better validated and measures fat directly". The DXA technique does 
not distinguish between intra- and extracellular water. The increase in fat free mass as 
observed in our patients during GH treatment indicates an accumulation of body water. The 
decrease in fat mass, as measured by DXA, however, might be a true phenomenon. As the 
changes in body composition, measured by B1A and DXA are closely in parallel, these 
changes might therefore have clinical significance. 
Taken together OUf results clearly show that simultaneously started combined treatment with 
rhGH and pamidronate during six months offers no new approach in the treattnent of 
postmenopausal osteoporosis. Even if long-term treatment Witll rhGH results in a favourable 
shift of the balance between bone resorption and formation, then it is still questionable 
whether such an effect justifies long-term treatment given the side-effects of GH-treatment 
and its high costs. Nevertheless, further studies are needed to elucidate whether in selected 
cases with a low bone turnover administration of rhGH in sequence with an inhibitor of bone 
resorption is a useful option. 
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SUMMARY 
Objective. 
A potential drawback of GH replacement therapy in GH deficient (GHD) patients is the 
initial decrease in bone mass. The present study investigates the effects of the addition of 
pamidronate to GH replacement therapy in adult GHD subjects, on serum levels of 
parathyroid honmone (PTH) and 1,2S-dihydroxyvitarnin D, (1,2S-(OH),D,), renal phosphate 
handling, bone turnover and bone mineral content (BMC). 
Design. 
Six GHD adult patients were studied for two periods of six months with a wash out period 
of three years. In the first period they were treated with conventional replacement therapy 
and GH. In the second study period GH treatment was identical, while after two weeks ISO 
mg pamidronate per day was added. 
Results. 
In the first study period (GH only) there was a significant increase of phosphate reabsorption, 
WitllOut a change in serum PTH and 1,2S-(OH),D, levels. This suggests a specific effect of 
GH or IGF-I on renal phosphate handling. This, indeed was supported by the close 
correlation between serum IGF-I levels and TmPIGFR (r=0.7S, P < .0001). When GH was 
administered together with pamidronate, this correlation was less, but remained significant 
(r=0.44, P < .001). 
The increase in bone turnover and decrease in BMC, as initially observed during GH 
replacement therapy alone, were attenuated by simultaneous pamidronate administration. The 
percentual decline of lumbar spine BMC (measured with dual-photon absorptiometry) at six 
months was -3.1 ± I.S% during GH replacement therapy alone, versus +3.8 ± 2.0% 
during the administration of the combination of GH and parnidronate (measured with dual-
energy x-ray absorptiometry). At the distal and proximal foreanm the changes amounted -O.S 
± 3.4% versus +4.S ± 1.8% and -I ± 1.2% versus +1.2 ± 1.1% respectively. 
Conclusions. 
This study shows that the addition of a bisphosphonate to GH replacement therapy in GHD 
adults counteracts the GH (or IGF-I) induced increase in renal phosphate reabsorption. 
Furthennore, it reduces GH-induced bone turnover and prevents the initial decrease in bone 
mineral content as seen during GH treatment alone, resulting in a beneficial effect on bone 
mineral mass. Pamidronate might therefore be an important adjunct to GH replacement 
therapy in adults with GHD and severe osteopenia during the early phase of GH-induced 
stimulation of bone turnover. 
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INTRODUCTION 
Several studies indicate that GH increases renal phosphate reabsorption and stimulates the 
renal production of the active vitamin D metabolite 1,25-dihydroxyvitamin D (1,25-
(OH),D,'-'. In other words at the level of renal phosphate handling GH appears to act as a 
parathyroid hormone (PTH) antagonist, while at the level of the renal la-hydroxylase an 
opposite more PTH-like action appears to take place'. This apparent dichotomy in the 
interaction between GH and PTH prompted us to compare two periods of GH replacement 
therapy in the same GH deficient (GHD) individuals; one period with GH treatment alone 
and a second period whereby GH treatment was combined with the bisphosphonate 
pamidronate, It is known from other studies that pamidronate treatment results in an increase 
of PTH levels'-'. Recent reports also indicate a high prevalence of osteopenia in subjects with 
growth hormone deficiency (GHD) of both childhood'·' and adult onset'·1O. Other 
investigators showed an increased susceptibility for fractures in this group, which is 
compatible with the inverse relationship between bone mineral density (BMD) and fracture 
riskil-ll . Also a positive correlation between circulating insulin-like growth factor (IGF-I) and 
BMD in individuals with acquired GHD has been reported14.15 . Based on these observations 
clinical studies were initiated to establish the potential effects of GH replacement therapy on 
bone turnover and bone massl6-18. Several reports indicate that GH replacement results in a 
considerable increase of bone turnover as indicated by an increase of markers of bone 
resorption and bone fonnation I8.23 • This increase in bone remodeling might result in an 
increase of remodeling space with a subsequent loss of bone mineral mass. This indeed was 
observed in a group of GHD adults we have followed on GH replacement therapy for six 
months". However, long-term treatment with GH up to 30 months leads, after an initial 
downwards trend, to a sustained increase of bone mineral content (BMC) as measured in the 
axial and appendicular skeleton25-28 • In other words long-tenn GH replacement therapy 
appears to result in a favourable shift in the balance between bone resorption and bone 
formation. In the present study we investigated the effects of GH replacement therapy in a 
group of GHD patients in combination with an inhibitor of bone resorption, the 
bisphosphonate pamidronate. Given the fact that bone turnover is initiated with bone 
resorption, we added in the present study pamidronate two weeks after the initiation of GH 
replacement therapy. 
Taken together, the present study performed in GHD subjects compares the effects of GH 
alone and GH with pamidronate on parameters of renal phosphate handling, bone turnover 
and bone mineral mass. 
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MATERIALS AND l'vlETHODS 
Patients. 
Eight patients with long-standing GHD were treated with GH alone for six months". The 
baseline characteristics of the six patients who agreed to enter the second part of the study 
three years later are shown in Tables 9.1 and 9.2. Age of onset of GHD was between 13 and 
19 years of age. Two patients received GH treatment during childhood (no.4 and 6) more 
than 10 years earlier. In the first study period patients I, 3 ,4 and 6 received 25 Jig/kg.day 
with a maximum of 1.48 mg (4 U) per day. Patient 2 received only half this dose (12.5 
Jig/kg.day). This lower dose was given because this patient already spontaneously complained 
of signs and symptoms of fluid retention. Patient 5 received 18 Jig/kg.day. She complained 
of fluid retention in the initial part of the study at which time the dose was reduced. Patients 
received GH replacement therapy for six months at the same dose in Ule two study periods. 
rhGH (Humatrope) was generously supplied by Eli Lilly Co., Indianapolis, IN .. In the 
second study period, from day 16 onward, the patients were cotreated with parnidronate 150 
mg per day orally. Measurements were performed at baseline, 1 month, 3 months and six 
months in the first study period and again at baseline, two weeks, 3 months and six months 
in the second study period. During and in between both treatment periods conventional 
pituitary replacement therapy remained unaltered. 
The aims and methods of the study were explained to the patients, and written informed 
consent was obtained before the study, which was approved by the ethics committee of the 
University Hospital Dijkzigt (Rotterdam, The Netherlands). 
Bone mass measurements. 
Lumbar bone mass (lumbar vertebrae, L2-lA) was measured, during the first study period 
using Dual-Photon Absorptiometry (DPA, Novo BMC-Lab 22a scanner). In the second study 
period a Lunar DPX Bone Densitometer (Lunar Corp., Madison, WI) was used. The short-
term coefficients of variation (CV) in normal subjects for DPA and DXA were 2.3% and 
1.1 % respectively29,30 correlation between both methods, as measured on the same day, was 
high (based on 252 lumbar spine measurements, r=0.984, jl=1.29 ± 0.015, P < .OOl). 
The results are expressed as BMC (g hydroxyapatite (Ha». Quality assurance including 
calibration, was performed routinely every morning. No drift was observed during both study 
periods. 
Single-Photon Absorptiometry (SPA) of the right forearm was perfonned at the distal and 
proximal sites using a Nuclear Data 1100a scannerl. The (fat-corrected) results are expressed 
as BMC (arbitrary units (U) per cm). The CV in our institution is 1.9% for the distal site 
and 1.0% for the proximal site". 
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Measurements and laboratory tests. 
Routine methods were used for the measurements of total alkaline phosphatase (APase) and 
inorganic phosphate (Pi). The renal tubular reabsorption maximum of phosphate corrected 
for glomerular filtration rate (TmP/GFR) was calculated according to Bijvoet". Serum 
osteocalcin and the carboxy terminal propeptide of type I collagen (PICP) were determined 
by commercially available kits (INCSTAR Corp., Stillwater, MN and Orion Diagnostica, 
Espoo, Finland respectively). 
24-hour Urinary excretion of hydroxyproline (Organon Technika, Oss, The Netherlands) 
expressed as nunol OH-proline per mol creatinine was assessed at each visit. Prior to urine 
collections patients were on a gelatine free diet for three days. 
25-hydroxyvitamin D, (25-(OH)D,), I,25-dihydroxyvitamin D, (I,25-(OH),D,) and intact 
PTH (1-84) were determined using commercially available kits (INCST AR Corp., Stillwater, 
MN). 
Statistical analysis. 
Paired T-tests were performed to analyse the effects on renal phosphate handling, bone 
turnover parameters and BMC between the two periods as well as within the two study 
periods. Results are expressed as mean ± SEM. P < .05 was considered significant. 
Table 9.1 Baseline clinical and biochemical characteristics of the six patients included 
in the study 
Patient no. OH daily dose (pg) Sex Cause of pituitary Diagnosis:! 
deficiency 
1480 m Craniopharygeoma TAGDI 
2 740 f Idiopathic TAG 
3 1480 f Craniopharygeoma TAG 
4 1288 m Congenital TAG 
5 1110 f Craniopharygeoma TAG 
6 1480 m Craniopharygeoma 
• T, thyroid deficiency; A, adrenal defiCiency; G, gonadal deficiency; 01, diabetes insipidus. 
b Peak OH. maximal GH level after iv injection of GHRH (l p.g/kg BW). 
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RESULTS 
All patients gained weight during the three years interval. Since height did not change, this 
also resulted in a significant increase of BMI (Table 9.1). PTH levels were significantly 
different at the beginning of the two study periods. Although none of the other parameters 
differed significantly, there was a tendency to a somewhat lower bone turnover and higher 
BMC at the beginning of the second study period (Table 9.2). 
GH replacement therapy was well tolerated. In the second study period, one patient was 
treated with furosemide 20 mg for two weeks in the tllird and fourth week of GH therapy 
because of tense feeling in the fingers due to mild edema. Also in the second study period 
two of the six patients complained of gastrointestinal discomfort after the initiation of 
pamidronate. This disappeared spontaneously within two weeks. 
The rise of IGF-I levels in the second study period was similar to that reported for the first 
study period". 
Biochemical measurements. 
Despite the higher baseline serum PTH levels during combined treatment, the rise of PTH 
levels was more prominent than during treatment with GH alone (Fig. 9.IA). The increase 
of PTH levels was significantly higher on combined treatment (P < . OS). A similar trend 
was observed for I ,25-(OH),D,levels, although no significant difference between treatment 
periods could be observed (Fig. 9.IB). 25-(OH)D, levels did not change in either treatment 
period (results not shown). Serum phosphate increased from 1.19 ± 0.03 to 1.48 ± 0.03 
mrnollL in the first study period and from 1. \0 ± 0.03 to 1.35 ± 0.03 mrnollL in the 
second study period (P < .05 baseline vs six months). TmP/GFR increased in both treatment 
periods, with a less prominent rise during combined treatment, reaching significance at three 
months (Fig. 9.1C). Although the correlation between serum IGF-I and TmPIGFR was 
highly significant (P < .001) during both treatment periods, addition of pamidronate 
weakened this relationship (r=0.75 vs r=0.44) (Fig. 9.2). 
In both treatment periods an increase in markers of bone formation (ie. osteocalcin, APase 
and PICP) was observed. However, versus baseline the increase of the biochemical markers 
of bone turnover was markedly blunted in the second study period from the moment that GH 
replacement therapy was combined with pamidronate (Fig. 9.3 A-C). 
Urinary hydroxyproline as a measure of bone resorption rose significantly in both treatment 
periods. It reached a maximum after 1 month during treatment with GH alone, whereas an 
attenuated response was observed after addition ofpamidronate (Fig. 9.3D). 24-hour Urinary 
calcium excretion increased significantly, but was not significantly different between the two 
periods (data not shown). 
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Table 9.2 Clil/ical al/d biochemical characteristics of the patiellls 
characteristic GH (period I) GH + APD (period II) 
mean range mean range P 
Age (yr) 33.7 25-46 36.7 28-49 
Height (em) 162.3 137-182 163.2 138-181 NS 
Weight (kg) 73.3 47-95 80.8 52-102 0.004 
BMI (kg/m,) 27.6 18.1-33.8 30.3 19.8-36.2 0.007 
Serum calcium (mmollL)" 2.21 2.16-2.23 2.17 2.08-2.42 NS 
Serum phosphate (mmoI/L) 1.19 1.11-1.28 1.10 0.98-1.22 NS 
1.25-(OH),D, (pmollL) 80 57-103 77 54-114 NS 
PTH (pg/mL) 20 13-32 26 15-32 0.017 
TmP/GFR (mmol/L) 1.0 0.8-1.2 1.1 0.9-1.2 NS 
APase (U/L) 71 39-150 58 37-97 NS 
Osleocalcin (Jlg/L) 4.1 2.6-7.5 3.2 1.2-8.0 NS 
Procollagen I (Jtg/L) 85.7 56-116 72 21-139 NS 
Urinary OH-proline (mmol/mol 20.8 9.6-39.4 23.5 10.2-60.0 NS 
creat) 
BMC SPAOlST(U/cm) 30.9 18.4-42.6 32.9 25.2-42.2 NS 
BMC SPApROX(U/cm) 33.8 22.3-44.5 34.7 25.5-44.9 NS 
NS: no significance between groups 
a serum calcium corrected for serum albumin. 
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Bone mineral content. 
The baseline date for bone mineral mass are shown in Table 9.1. The changes of the bone 
mass measurements during the two treatment periods are shown in Fig. 9.4. Only BMC data 
are shown, because bone mineral density data showed similar changes. 
Lumbar spine. In the first treatment period there was a significant decrease in BMC after 
three and six months of GH replacement therapy (-1.5 ± 1.3% and -3.1 ± 1.5%, 
respectively). In the second treatment period there was an increase in BMC, which already 
reached significance versus baseline at six months (3.8 ± 2.0%). The difference between the 
periods was already nearly significant at three months and reached significance at six months 
(P = .052 and P = .04 respectively) 
Distal foreann. In the first treatment period there was a significant decrease in BMC as 
measured in the distal foreann at three months. At six months BMC was still lower vs 
baseline, however not significantly (-4.8 ± 2.0% and -0.5 ± 3.4%). In the second treatment 
period there was an increase at three and six months (2.5 ± 0.7% and 4.5 ± 1.8%). The 
difference between the periods was significantly different at three months, but not at six 
months of therapy (P = .036 and P = .239 respectively). 
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Proximal foreann. The initial decline in BMC in the first treatment period was significantly 
greater than in the second treatment period. After six months in the second treatment period 
BMC levels were above baseline (-1.4 ± 0.6% and -1 ± 1.2% in the first period versus -0.3 
± 0.4% and 1.2 ± 1.1% at three and six months, respectively). Changes were not 
significantly different between periods. 
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DISCUSSION 
Our study indicates that addition of pamidronate to GH replacement therapy in GHD adults 
attenuates the GH-induced increase of the renal phosphate threshold and prevents the initial 
bone loss as observed during treatment with rhGH alone. 
As observed during the first study period GH induced a pronounced increase in renal 
phosphate reabsorption. This increase was not accompanied by changes of the phosphate 
regulating hornlOnes PTH and 1,25-(OH),D,. Therefore, a direct effect of GH or IGF-I on 
renal phosphate handling is more likely, which is also supported by the high correlation 
observed between IGF-I and TmP/GFR. Also recent in vivo and in vitro studies"'" suggest 
a similar mode of action. That GH does not affect the PTH-induced phosphaturic response 
is provided by the observation that the rise of PTH levels, as observed after the addition of 
pamidronate, is accompanied by a lowering of the renal phosphate threshold. In other words 
it appears that the GH-induced increase in phosphate reabsorption is counteracted by a PTH-
induced decrease. Based on these observations it is unlikely that GH at the level of renal 
phosphate handling acts as a PTH-antagonist'. 
Recent studies also indicate that GH or IGF-I stimulates renal la-hydroxylase activity'. In 
the first study period we did not observe a significant rise of l,25-(OH),D, levels, which 
might be explained by the prominent increase of serum phosphate levels during GH 
treatment. It is known that hyperphosphatemia is a potent inhibitor of la-hydroxylase 
activity". The lower phosphatemic response after addition of pamidronate might, therefore, 
explain the trend towards higher 1,25-(OH),D, levels during the second study period. Of 
course, it is also possible that this represents a direct effect of the raised PTH levels on the 
renal la-hydroxylase. 
When we compare the pretreatment values of biochemical markers of bone turnover and bone 
mass between both study periods, there appears to be a tendency to a somewhat lower bone 
turnover and a somewhat higher BMC at the start of the second study period. Nevertheless, 
the differences in these markers did not reach significance, which exclude an important 
"carry-over" effect of GH treatment from the first to the second study period. The somewhat 
higher bone mass at the start of the second study period could be related to the increase in 
body weight between both study periods. Several studies have shown a positive relationship 
between body weight and bone mineral measurements. 
As shown by the results obtained during the first study period GH leads to an increase in 
bone turnover. During an initial phase the GH-induced increase in the number of activated 
bone remodelling units will result in a larger bone surface undergoing bone resorption and 
subsequently will result in bone loss. An initial decrease in BMC was indeed found during 
treatment with GH alone in our patients, as well as by others". During a second phase the 
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coupling between bone resorption and formation will result in a new balance, which will limit 
bone loss". However, Vandeweghe et al observed that longterm treatment with rhGH, 
beyond six months, even resulted in an increase of bone mass. Therefore, this suggests that 
besides an increase in activation frequency of bone remodelling units, longterm rhGH 
treatment may result in a loss of synchronization between resorption and formation with an 
apparant shift towards bone formation. 
Several studies in postmenopausal women have shown that a reduction of bone turnover. as 
can be induced by pamidronate, is accompanied by a transient increase of bone mass (for 
review see Heaney33), However, in the present study treatment with pamidronate only 
attenuated the GH-induced increase in bone turnover, but did not result in a reduction below 
pretreatment level. Therefore, it is unlikely that the observed gain in BMC during additional 
pamidronate treatment can simply be explained by the so-called "transient". A shift of the 
bone balance towards formation is more likely. As stated above this shift towards formation 
may be related to GH treatment. It is known that IGF-I can stimulate osteoblast-like cells". 
Furthermore the effects of GH treatment can be indirect via an increase in muscle mass and 
physical activity. However, an anabolic effect on bone of the raised PTH levels during 
pamidronate treatment can not be excluded. Although the mechanism for the anabolic action 
of PTH is poorly understood, GH is required for its effect in animals". As the volume to 
surface ratio of trabecular bone is higher than that of cortical bone, changes in bone turnover 
are more reflected in trabecular bone. This also explains the more pronounced change of 
BMC at the distal radius and lumbar spine, compared to the proximal forearm. 
This study shows that the effects of GH-replacement therapy and bisphosphonates on renal 
phosphate handling are partly antagonistic and that these effects are probably not mediated 
through PTH. GH therapy results in an increased bone turnover and consequently in bone 
loss. Inhibition of bone turnover with the bisphosphonate pamidronate, prevents this initial 
loss and even results in an increase of bone mass. Additional studies are needed to see 
whether pamidronate interacts with long-term effects of GH on bone mass in GHD patients. 
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Nonnal DXA bone mass values in Dutch women 
SUMl\IARY 
Objective. 
To investigate in healthy nonnal Dutch women the age-associated changes in bone mineral 
density (BMD) and the effect on bone mass of menopause and potential risk factors. 
Methods. 
In 260 healthy Dutch women BMD was measured in the lumbar spine and three regions of 
the proximal femur (Ward's triangle, femoral neck and trochanter), using Dual Energy X-ray 
Absorptiometry (DXA). The subjects were interviewed using a structured questionnaire on 
age, reproductive history and gynaecological status, height, weight and consumption of 
tobacco and alcohol. 
Results. 
In 125 premenopausal women a small age-related bone loss was observed at both the lumbar 
spine and proximal femur, while in postmenopausal women (n= 135) a 2-3 times higher age-
related loss was observed. Expressed in years since menopause this postmenopausal loss was 
found to be exponential (P < .001). After adjustment for age there appears to be a 
relatioruhip between actual age of menopause and BMD at the lumbar spine and femoral 
neck. After adjustment for age and actual age of menopause we observed a small negative 
effect of breast feeding, whereas parity, current alcohol use and smoking showed no 
additional effect on BMD in this cohort. For all women (n=260) a highly significant 
correlation between BMD and BMI was found. 
Conclusions. 
In healthy Dutch women we observed a small premenopausal and an accelerated 
postmenopausal bone loss in both the lumbar spine and proximal femur. Except for 
breastfeeding no other risk factors could be identified. 
INTRODUCTION 
A low bone mineral density (BMD) has been identified as a major detenninant of the 
occurrence of non-traumatic fractures1-4. As the incidence of both hip and vertebral fractures 
increases with age, much attention have been paid to age-related bone 10SS'·I'. During the last 
decade Dual Photon Absorptiometry (DPA) was the most widely used technique for the 
measurement of bone mineral mass. The new generation densitometers use instead of an 
isotope source (DPA) an X-ray tube (Dual Energy X-ray Absorptiometry (DXA)). This has 
resulted in a significantly improved scan precision and has decreased radiation dose and 
scanning time I9.21 . 
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For the interpretation of bone mass data in women it is important to emphasize that, besides 
age and menopausal state, also other determinants like body mass index (BMI), nutritional 
factors (e.g. calcium, vitamin D, alcohol), medication (e.g. glucocorticoids, thiazides, 
thyroid honnone) and smoking may influence bone mass22-28 , In addition genetic, 
geographical, cultural and socia· economic factors may also explain the differences observed 
in BMD's within and between populations"·". Therefore, it is important that for a proper 
interpretation of bone mass measurements, values assessed in normal healthy women of the 
same population are available. 
In the present study we have measured spine and hip BMD in 260 healthy Dutch women, 
aged 20-80 years, to determine normal ranges for the different measurement sites. In 
addition, the influence of potential risk factors was analysed. 
SUBJECTS M'D METHODS 
Subjects. 
All subjects were recruited from a call for volunteers in a national television programme, as 
part of an international multi-centre study to cross-calibrate bone mineral mass measurement 
data obtained with different DXA-machines (COMAC-BME)'I. Only healthy ambulatory 
caucasian white women were included in the study. Subjects with known structural and/or 
metabolic bone diseases, arthritis or neurologic conditions were excluded. Subjects who were 
recruited were given a questionnaire, comparable to the one used in the MEDOS study". 
Those who reported in the questionnaire previous hyper(para)thyroidism, hysterectomy or 
oophorectomy before the age of 50, menopause before the age of 45 and subjects who had 
been treated with oestrogens, androgens, fluoride, vitamin D, corticosteroids or thiazide 
diuretics were also excluded. Women, who ceased menstruating for more than 6 months were 
classified as postmenopausal. The other women were classified as premenopausal. 
Besides exclusion criteria, the questionnaire contained questions about whether the women 
had given birth (parity) and if so, how many children were born and whether they had fed 
their children by breast. Also questions about smoking (present or past) and current alcohol 
usage (number of days/week) were included. 
Of the five hundred and eighty women who completed the questionnaire, finally two hundred 
and sixty women were considered eligible to enter the study (total exclusion 55 %). The age 
ranged from 20 to 80 years. One hundred and thirty five women were considered 
premenopausal. Informed consent was obtained from all volunteers. 
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Bone mass measurements. 
BMD was detennined using DXA (Lunar DPX-L, Lunar Radiation, Madison, Wisconsin) 
according to the instructions of the manufacturer19 • The measurement sites were the lumbar 
vertebrae 2-4 (L2-4) and in the left proximal femur the femoral neck (Fneck), Ward's 
triangle and trochanteric region. BMD is expressed in gram hydroxyapatite/cm' (gHa/cm'). 
Quality assurance including calibration with the standard of the machine was perfonned 
routinely every morning. No drift was observed during the whole study period (= 3 months). 
All measurements were performed by one of three experienced persons using the same 
instrument. 
Short-tenn precision was assessed by measuring BMD in 10 persons two times. 
The coefficient of variation (± S.D.) for lumbar BMD was 1.1 ± 0.2 %. The coefficients 
of variation in the femoral neck, Ward's triangle and trochanteric region were 1.4 ± 0.2, 
2.1 ± 0.3 and 2.3 ± 0.3 %, respectively. 
Data analysis. 
Means and standard deviations (SD) or standard errors of the mean (SEM) of anthropometric 
and BMD data were calculated in five year-age strata for pre- and postmenopausal women. 
Adjustment for mean body mass index (EMI, kg/m') was made by using multiple regression 
analysis. Age-associated changes of BMD, after adjustment for BMI, were analysed by 
means of linear regression analysis. in which a division in pre- and postmenopausal women 
was made. In addition regression with a polynomial model (quadratic) in the postmenopausal 
women was performed to detect a non-linear association between years since menopause 
(YSM) and BMD. 
The measure of YSM represents a mixture of age and age of menopause and equals, after 
adjustment for age, age of menopause (AOM). Therefore, we decided to analyse the effect 
of AOM on BMD by adding this variable to the model, thereby separating the effect of age 
and menopause completely. 
By using stepwise multiple regression analysis the effects on BMD of parity, breastfeeding, 
smoking (package-years; calculated amount of years in which 1 package of cigarettes/day has 
been smoked) and current alcohol use (number of days/week on which alcohol was used) 
were analysed after adjustment for age, BMI and AOM. 
Statistical computations were made using Statgraphics (Statistical Graphics Corporation, Inc., 
Maryland, USA). 
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RESULTS 
Characteristics of the subjects. 
General characteristics of the study group as a whole and after division between pre- and 
postmenopause are presented in Table 10.1. 
Of all the women. 195 (75 %) had given birth (number of children 2.2 ± 1.0 (range 0-6». 
Of these 195 women. 147 (75 %) had breastfed their children for a period of 1 month or 
more (number of children breastfed 1.1 ± 1.1. (range 0-6». Of all the women 69 (27 %) 
used at present no alcohol, 147 ( 56 %) used 1-3 times a week alcohol and the rest (44 
women, 17 %) used four or more times per week alcoholic drinks. With respect to smoking 
the following numbers were obtained: 108 (42 %) women had never smoked, 102 (39 %) 
had smoked in the past (package-years 7.9 ± 7.2 (range 1-38» and 50 (19 %) were current 
smokers (package-years 14.7 ± 10.2 (range 1-41». 
Table 10.1 Dala of wlwle group 
All Premenopausal Postmenopausal 
Number (n) 260 125 135 
Age (years) 49.7 ± 13.3 39.1 ± 10.0 59.5 ± 7.0 
range 20·80 20 - 55 45 - 80 
Age of menopause 50.4 ± 2.5 
range 45 - 56 
Years since menopause 9.4 ± 6.6 
range 0-30 
BMI (kgim,) 24.5 ± 4.0 23.4 ± 4.1 25.5 ± 3.6 
range 17.5 - 42.5 17.6 - 42.5 17.5 - 42.5 
Age-associated bone mineral mass. 
In Table 10.2, the distributions of BMI and the bone mass measurements at the various sites 
are listed according to age and menopausal state. For height a significant decline was noted 
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Table 10.2 Characteristics of the women, stratified by age and menopausal state. 
PREMENOPAUSAL POSTMENOPAUSAL 
Group (age) 20-25 26-30 31~35 36-40 41-45 46-50 51-55 regression 46-50 51-55 56-60 61-65 66-70 71+ regression 
coefficient' coefficient' 
N 17 14 16 10 26 22 20 10 28 47 22 17 10 
age,years 
mean 22.6 28.0 33.5 37.8 42.8 47.4 52.4 49.1 53.2 58.1 62.9 67.6 74.6 
sd 1.6 1.7 1.1 1.6 1.6 1.3 1.5 1.0 1.6 1.5 1.5 1.3 3.4 
menopausal age 
mean 47.8 50.3 50.6 51.0 50.7 51.0 
sd 1.7 2.1 2.6 2.2 2.5 3.0 
years since menopause 
mean 1.9 3.0 7.5 11.9 16.9 23.4 
sd 1.1 2.6 2.7 3.2 2.4 3.5 
BM!. Kg/m' 
mean 22.2 25.4 22.1 25.0 23.3 23.8 23.1 .0184 24.9 25.9 25.9 24.7 25.1 25.9 .0004 
sd 5.6 5.1 1.7 6.9 4.0 2.6 2.5 3.7 4.5 3.4 3.5 3.4 2.5 
BMD (gHalcm') 
L2-4 
mean 1.279 1.318 1.203 1.350 1.217 1.199 1.218 -.0031" 1.195 1.168 1.102 1.047 1.027 1.009 -.0084" 
sd .118 .132 .127 .127 .152 .148 .143 .174 .186 .171 .131 .136 .130 
Femoral neck 
mean 1.010 1.076 0.927 1.021 0.916 0.941 0.965 -.0031" 0.986 0.916 0.863 0.844 0.794 0.816 -.0056" 
sd .102 .132 .100 .170 .112 .097 .115 .115 .139 .141 .113 .071 .089 
Ward's triangle 
mean 0.983 1.064 0.849 0.956 0.832 0.832 0.867 -.0061" 0.892 0.822 0.737 0.711 0.670 0.714 -.0069" 
sd .142 .189 .137 .180 .122 .114 .129 .142 .160 .154 .123 .083 .083 
Trochanteric region 
mean 0.797 0.882 0.752 0.850 0.777 0.815 0.815 -.0005 0.875 0.804 0.782 0.773 0.749 0.732 -.0037' 
sd .094 .118 .095 .163 .105 .115 .109 .159 .139 .129 .117 .116 .120 
* P < .05, ., P < .001 (difference from zero). 'regression coefficient: coefficient from univariable regression analysis. 
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in the premenopausal as well as in the postmenopausal group. 
For all sites of measurement, except for the \Vard's triangle, a significant difference between 
the slopes, representing the relation between age and BMD, of the pre- and postmenopausal 
women was found (P < .01). Compared to the premenopausal group a 2-3 times higher 
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apparent loss was found in the postmenopausal women, at the various sites measured, except 
for the Ward's triangle. In Fig. 10.1 the BMI-adjusted BMD values for the lumbar spine and 
femoral neck are depicted. 
For the premenopausal women the calculated apparent loss per year was 0.2 % for the 
lumbar spine, 0.2 % for the femoral neck, 0.4 % for the Ward's triangle whereas no loss 
in the trochanteric region was observed. For the postmenopausal women a calculated loss per 
year of 0.8 % for the lumbar spine, 0.8 % for the femoral neck, I % for the Ward's triangle 
and 0.6 % for the trochanteric region was found, respectively. 
Comparing the youngest premenopausal group with the oldest postmenopausal group a loss 
of 20 % for the trochanteric region and of up to 27 - 30 % for the other sites was observed. 
In Table 9.3 the various regression coefficients of the multivariable analyses are presented 
for the pre- and postmenopausal group respectively, showing a significant contribution to the 
BMD of age and BM! in the premenopausal and of age and BMI and AOM in the 
postmenopausal group. 
Bone density and menopause. 
During the first 10 years after menopause we found an exponential decline of the BMD at 
all sites measured (Fig. 10.2). For our study population, it was calculated that in the first 10 
years after the menopause approximately 60 - 70 % of total postmenopausal loss occurred. 
By using multiple regression analysis the BMD values of the postmenopausal women were 
corrected for age. By using this approach the BMD at a given age of menopause can be 
predicted. The data shown in Fig. 10.3 depict the expected BMD of the lumbar spine and 
femoral neck of a woman at the age of 59.6 years (that is, the mean age of postmenopausal 
women in our group) as a function of the age of menopause. It is clear from these data that 
an earlier time of menopause will result in a lower BMD at a given age, compared to women 
with a later time of menopause. 
Bone mineral density and other variables. 
In all four skeletal regions studied the BMD showed a highly significant correlation with the 
BM!. This applied to the premenopausal (r = 0.30 - 0.42, P < .00l) as well as to the 
postmenopausal group (r = 0.28 - 0.47, P < .001). BMI was correlated neither with age 
nor with AOM. 
Using multiple stepwise regression analysis we looked at the effects of the following 
variables after adjustment for age and years since menopause: parity, breastfeeding, smoking 
(package- years) and current use of alcohol (days/wk). Only for breastfeeding a small but 
significant effect was found in the lumbar spine (P < .05) and the femoral neck (P < .05). 
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Table 10.3 Results of regression analysis' 
Univariable analysis: 
Premenopausal: 
ic age P 
12-4 1.365 -0.0031 <.05 
Fneck 1.089 -0.0031 <.01 
Postmenopausal: 
ic age P 
12-4 1.597 -0.0084 <.001 
Fneck 1.198 -0.0056 <.001 
Multivariable analysis 
Premenopausal: 
ic age P BMI P 
12-4 1.011 -.0034 <.01 0.0156 <.001 
Fneck 0.823 -.0032 <.01 0.0116 <.001 
Postmenopausal: 
ic age P BMI P 
12-4 1.234 -.0085 <.001 0.0144 <.001 
Fncck 0.823 -.0057 <.001 0.0146 <.001 
ic age P BM1 P AOM P 
L2-4 0.003 -.0115 <.001 0.0118 <.001 0.0293 <.001 
Fneck 0.415 -.0066 <.001 0.0138 <.001 0.0098 <.001 
• Intercept (ic (g/cm~). age (gIcrn2/year). BMI (g/cm2/(kglm~) and AOM (g/cm2/year) coefficients and P-values from univariable and multivariable 
regression analysis, stratified by site of measurement and menopausal state. 
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DISCUSSION 
The aim of the present study was to detenrune for the Dutch female population, age-related 
changes in BMD as measured with DXA . In addition, the influences of various potential risk 
factors on bone mass have been studied. 
In the premenopausal women we observed a small (0.2 - 0.3 %/yr) although significant bone 
mineral loss in the lumbar spine and proximal femur. These results are comparable to those 
obtained by others, using similar [l3] and other bone mass measurement techniques [15-17]. 
For the postmenopausal women we observed a three times higher age-related bone loss in 
the lumbar spine and a two times higher loss in the proximal femur. The apparent total bone 
loss in the lumbar spine of about 30 % appears comparable to that found in a previous study 
of our group using DPA'. 
In the first ten years after the menopause, bone loss in both the lumbar spine and proximal 
femur appears to be exponential. For the population studied about 60-70 % of total 
postmenopausal bone loss seems to occur during this period. This implies a postmenopausal 
loss of about 15 %. OUf results, therefore, indicate an important menopause-related bone loss 
superimposed on the age-related bone loss8.9. Also other investigators obtained similar results 
for a comparable cohort'. 
Our data also indicate that an early menopause is a risk factor for osteoporosis. From the 
regression between actual age of menopause and BMD we calculated that a one year later 
onset of the menopause compensates for two years of age-related bone mineral loss. 
In this cross-sectional study, the strict exclusion criteria used will have resulted in a certain 
degree of selection bias. However,the use of these criteria is the only way to minimize the 
interference of potential confounders like degenerative changes of the spine34 , immobilization 
and metabolic bone diseases. Therefore, our data represent healthy Dutch women. Of course 
this is different from a population based study like the Rotterdam Study. 
This Rotterdam study clearly shows the confounding effect of osteoarthritis on lumbar spine 
BMD measurements, and indicates that in elderly subjects, hip measurements give a better 
impression of BMDI8. In cross-sectional studies, like our investigation, cohort effects may 
also affect the slope of the regression, between age and BMD, upwards if one assumes that 
younger persons will have lower age-adjusted BMD's compared to older persons. In this 
respect life style factors as physical activity and diet could play an important role"'''. 
Furthermore, this may explain the apparent increment of BMD when the results are ploUed 
against YSM (Fig 10.2 A and B, right hand party of the curves). 
The highly significant correlation between BMD and BMI, as also found by several other 
investigators21.24.15, can be explained by the endogenous production of estrogen in fat tissue". 
Because the correlation with BMI was also found in premenopausal women other factors such 
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as increased weight bearing may also be of importance. 
Of Ole additional potential risk factors (parity, breast feeding, cumulative smoking and current 
alcohol use) we examined, only for breastfeeding a small but significant negative effect on 
bone mineral mass was observed. In another cross-sectional study in healthy Dutch women 
also a negative effect of breastfeeding was found and it was concluded that duration of 
breastfeeding was of more importance than parity". On the other hand a recent prospective 
study of one year recently showed a fast decrease of bone density in breastfeeding women, 
but this loss was regained within a year". 
We noticed no effects of smoking or use of alcohol. In our group 19 % of the women were 
current smokers. This is somewhat lower than the percentage of smokers (40 %) in large 
health interview surveys in the Netherlands". In our group 73 % of the women used alcohol 
once a week or more. This is comparable to the normal Dutch population, in which 70 % 
uses alcoholic drinks once a week or more". Another study showed a more important effect 
of tobacco or alcohol (ab)use". In this study however the subjects under 
investigation used on the average much higher amounts of alcohol and nicotine than the group 
we studied. 
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Discussion of the major conclusions 
DISCUSSION OF TIlE MAJOR CONCLUSIONS 
The central theme of this thesis is the question whether combination of an antiresorptive drug 
(estrogen or pamidronate) with a potential stimulator of bone formation (nandrolone 
decanoate) or bone turnover (growth hormone) might result in a larger increase in bone mass 
than the use of the antiresorptive agent only. 
Nornlally bone formation and bone resorption are coupled, but in the treatment of 
osteoporosis the ideal situation would be a shift in the balance betweeen the two processes 
in favour of the bone formation. In terms of bone mineral mass, a transient (positive) effect 
of bone mineral mass can be expected from an anti-resorptive agent, which will only be 
temporary until a new equilibrium has been established. When uncoupling can be established 
a more continuous increase of the bone mineral mass would be expected. 
It is important to distinguish a situation of uncoupling from a state of low bone turnover. 
With a low bone turnover state the number of bone multicellular units (bmu's) is diminished, 
but at the level of the bmu's the process of turnover can still be coupled. This implies, that 
with a drug that decreases bone turnover, remodelling space will be filled in, but ultimately 
a new steady state will be reached. Even when there is a negative balance at the bmu level, 
this mechanism will lead to some increase in bone mass although after the new steady state 
is reached again bone loss can occur'. With uncoupling at the level of the bmu an additional 
effect on bone fonnation is warranted with of course no effect on bone resorption. In other 
words a specific stimulation of the activation of osteoblasts will induce a certain degree of 
uncoupling. The response to treatment with fluoride is a typical example of stimulation of 
bone fonnation. 
Looking at our HRT + Nandrolone - trial no evidence has been obtained to support that 
uncoupling really took place. What is actually seen is an apparent correction by nandrolone 
of a fall in bone mass during the third year of HRT. This might be due to a waning effect 
of the estrogen-antiresorptive effect and a perseverance of a nandrolone-antiresorptive effect. 
In a theoretical model this effect has been described by Adami and Kanis'. This waning effect 
was also present in the biochemical parameters, in which an increase of some of the 
biochemical bone turnover parameters was observed during the third year of treatment in the 
HRT-group, whereas in the HRT + ND group bone turnover was still suppressed. 
Another explanation for the differences, occurring during the third year of treatment, would 
be an indirect effect of nandrolone on bone mass by inducing an increase of skeletal muscle 
mass. During the fourth year of follow-up, in which no treatment was given, both groups 
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showed comparable changes in bone mineral mass as well as in bone turnover parameters. 
Bone resorption as well as formation parameters showed a rapid (coupled) increase. This 
implies that the extra effect ofnandrolone-decanoate (during the third year) is only temporary 
and tend to disappear shortly after treatment has stopped. 
Taken together; ND appears not to be a stimulator of bone formation, but has to be looked 
upon as an anti-resorptive agent. The effects of ND in the presence of HRT are rather late, 
indicating that HRT itself induces a maximal anti resorptive effect, during the first two years 
of treatment. 
GH is a clear example of a stimulator of bone turnover, as is also supported by the studies 
described in this thesis (chapter 8 and 9). 
In postmenopausal osteoporotic women, treatment with the combination of pamidronate and 
GH for half a year showed no effects on bone mineral mass. Only minor effects on bone 
turnover parameters were found. However, these rather small effects did indicate a small 
increase in bone formation, i.e. osteocalcin as well as procollagen-l were increased with no 
effects on bone resorption parameters (Fig. 8.4). It is possible that a shift of the coupling at 
the bmu level in the direction of bone formation could explain this observation. However, 
the rather small changes in bone formation indices with no change in bone resorption 
parameters might explain that no changes in the bone mineral mass were observed in the 
patients treated with GH + pamidronate. 
In the patients treated with pamidronate-only the decrease in bone turnover, as shown by a 
decrease in bone turnover parameters, resulted in the expected gain of bone mineral mass. 
It remains possible that the treatment period and the period of follow-up were too short to 
observe an increase in bone mineral mass in the patients treated with the combination of GH 
+ pamidronate. 
Also in GH-deficient adults treated with rhGH, vandeWeghe et a!. showed an increase in 
bone mineral mass after a follow-up period of up to three years, whereas in the first year a 
decrease in bone mineral mass was observed, although bone formation indices were 
increased3. 
In our GH-deficient patients, who were treated with a combination of GH and pamidronate 
as well (no control group with pamidronate-only was studied), several differences were 
found. 
A possibly important difference between both patient groups is the increase mainly in 
cancellous bone in the GH-deficient group, whereas initially treatment with GH and 
pamidronate resulted in a small decrease of bone mineral mass in the osteoporotic women 
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studied (Fig. 9.4, cf Fig 8.1). 
It is important to realise that both patient groups can not be analysed together, as the 
osteoporotic patients were not GH-deficient according to their serum IGF-I levels. 
A possible explanation for the more important changes in the GH-deficient patients is a more 
significant shift of bone fonnation at the level of the bnlU. Furthennore, pamidronate 
inhibited the GH-induced increase in remodelling space. 
In a recent study in which elderly sheep were treated with human PTH (1-34), also no 
increase of bone fonnation was found in the presence of the anti-resorptive agent tiludronate4 . 
This seems comparable to the results found in our osteoporotic women, treated with a 
combination of GH and pamidronate. One might speculate that the anabolic effect of GH or 
PTH on bone is not maintained when a bisphosphonate is coadministered. Because 
bisphosphonates are selective inhibitors of osteoclastic bone resorption that do not directly 
affect osteoblastic bone fonnation, it is suggested that activation of bone resorption may be 
a prerequisite for an anabolic agent to be active. 
Another possible explanation for the differences found between both groups is the way in 
which medication was initiated. The osteoporotic women started with the combination of GH 
and pamidronate at the same moment, whereas the GH-deficient patients were treated initially 
with GH-only for two weeks. From then onwards pamidronate was added. In this scheme at 
first activation is stimulated and thereafter resorption is counteracted. It is possible that in 
the osteoporotic women the anti-resorptive agent already had induced a diminished turnover, 
after which GH could not act anymore as a stimulator of activation. This might implicate a 
very rapid effect of pamidronate on bone turnover. 
The additional treatment with GH resulted in a positive effect of GH on lean body mass and 
a decrease in fat mass. This represents the anabolic effect of GH, as has been observed in 
many other studies in which GH-deficient patients were treated with GH. Only few results 
are available in healthy people, but these results also indicate an increase in lean body mass 
and a decrease in fat mass5. 
The studies presented in this thesis support the view that bone turnover parameters are better 
indicators of a response to treatment than early follow-up BMD measurements. In all the 
studies presented differences in bone turnover parameters were visible as early as 3 months, 
whereas the earliest changes in bone mineral mass measurements were found after 6 months 
of follow-up at the earliest. 
When various study results are translated to a single patient it is important to take into 
account some variables. The two main variables with respect to bone mass meaurements or 
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bone turnover parameters are the coefficiency of variation (CV) of the method and the rate 
of change in the measurement results induced by treatment. 
AltllOUgh the bone mass measurements have a high precision it is not feasible to examine the 
short-term effects of treatment because of the rather small changes induced. 
For example a period of follow-up for I year is necessary for bone mass measurements with 
a CV of 2 % and a change in bone mass of 5 %. 
Although the CV for the various bone turnover parameters is much higher than for the bone 
mass measurements the required duration of foHow-up to obtain significant changes is shorter 
because of the higher rate of change. 
For example a period of follow-up of about 0.5 year is needed when changes in the order 
of 20 - 40 % are present with a CV for the method of 5 - 15 % 
At present no really good discriminative single biochemical measurement with respect to 
people at risk for fractures is available. In the future new medications or combinations of 
medications will be developed for the treatment of established osteoporosis. Another subject 
of future research will have to be the assessment of the value of the various parameters 
measured longitudinally with respect to the effects of treatment. Until those results are 
available, we will have to use a variety of measurements, bone mineral mass as well as 
biochemical measurements, to predict and follow the effect of treatment in an individual. 
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Osteoporosis is a disease, in which a lot of interest has been shown during recent years. This 
is for a large part the result of the increasing age of the population, because the occurrence 
of osteoporosis increases with age. 
Next to U,e diminishment of the amount of bone also a diminished stuctural quality of the 
bone occurs in osteoporosis. The ultimate result of osteoporosis, is an increased incidence 
of fractures, especially fractures of the hip, spine and wrist, 
Osteoporosis can be divided in a primary and secondary form, the secondary being the result 
of an underlying disease. Primary osteoporosis is related to a lot of risk factors, but the most 
important cause is occurrance of the menopause. With the loss of estrogen production, an 
increased resorption of bone occurs, which leads to a decline in bone mineral mass. Because 
this Joss of estrogen production is important for the genesis of osteoporosis, the incidence of 
osteoporosis in women is higher than in men. However, because also other factors are 
important, osteoporosis is not strictly a disease of women. 
The fractures, especially the hip fractures, induce a high morbidity and also a rather high 
mortality. 
For the above mentioned reasons, it is certainly worthwhile to try to prevent the occurrence 
of osteoporosis. Next to the prevention of osteoporosis it is also necessary to prevent further 
bone loss in patients with established osteoporosis. 
In c/zapler 1 several risk factors and epidemiological aspects of osteoporosis are described. 
Because a low or decreased bone mass is one of the most important factors for the 
development of fractures, it is important to be able to measure the bone mass as accurately 
as possible. Whereas in the past only few possibilities were available to measure bone mass, 
during U,e last two decades a number of measuring methods have been developed. These 
techniques are able to assess the bone mass in a non-invasive manner. Unfortunately, 
however, these techniques do not give a good impression of the connectivity of the cancellous 
bone, another important factor for the strength of bone. In c/zapler 2 the various bone mass 
measurement techniques are discussed. In conclusion, it can be stated that, at present, various 
methods are available with a high precision, a good accuracy and a very low radiation dose. 
These important facts have made it possible to follow the bone mass in a longitudinal 
manner, that is to describe the natural and pathological course of bone mass, as well as the 
effect of various treatment schemes to try to increase bone mineral mass. Next to the 
measurements, which are dependent on a radioactive source or on x-rays also the use of 
ultrasound techniques for the measurement of bone mass is discussed. 
By measuring several biochemical markers of bone mineral metabolism in serum or urine, 
it is possible to investigate and follow bone turnover. These markers can be divided into two 
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groups, one related to bone fonnation, the other related to bone resorption. When the 
menopause is reached an increase of bone turnover occurs, as is apparent from the increase 
of the various bone turnover parameters. 
The various markers of the bone turnover can be followed during treatment. In general the 
bone fonnation and resorption are coupled, which means, that with a decrease in bone 
resorption also the bone fonnation is subsequently diminished. As to biochemical parameters 
until now, no "golden standard" is available. Therefore, it is necessary to use a combination 
of the various markers of bone turnover to get a reasonable impression of the bone turnover 
activity. This can be strengthened by having measurements longitudinally. 
In recent years several attempts have been made to find a good treatment to prevent 
osteoporosis or to find a treatment, which can be used for established osteoporosis. The 
ultimate goal for the treatment of osteoporosis is to prevent or decrease the number of new 
fractures. In chapter 4 the various treatment schemes, as they are or have been used, are 
presented. With respect to the prevention of the development of osteoporosis, the most 
extensively used treatment, with good results, is estrogen substitution. Estrogen substitution 
has then to be started within a few years after the menopause. About other preventive 
regimens very few data are available. 
A number of studies have been published on the treatment of established osteoporosis, 
although the results were varying. Generally tlley were positive with respect to increasing 
bone mineral mass. In chapter 4 the design of several treatment schedules is presented in 
tables. The role of estrogens is also paramount here. Finally a brief overview about 
osteoporosis in men and corticosteroid induced osteoporosis as well as the treatment of both 
disorders is presented in chapter 4. 
The investigations, which are presented in this thesis, were aimed at a combination of several 
medications and the effects of these combinations on bone mass measurements as well as 
biochemical parameters of bone turnover. The goal was to investigate, whether it was 
possible with the various medications to induce uncoupling between bone resorption and bone 
formation. Nonnally resorption and fonnation are coupled to one another. If uncoupling 
between formation and resorption could be reached it was hypothesized that a more important 
and more sustained effect on bone mass could be reached. 
In chapter 6 the effects of honnone replacement therapy (HRT) for two years with or without 
the addition of nandrolone decanoate (ND), an anabolic steroid, are described. A prominent 
increase of bone mineral mass was observed, in the lumbar spine as well as in the foreann 
Bone turnover was suppressed as measured with biochemical parameters. Between both 
treatment groups no differences were observed, and no indication as to whether formation 
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and resorption were uncoupled were found. 
Chapter 7 describes the effects in the same groups of patients, after the treatment was 
continued for another (third) year. Also the effects after one year of discontinuation of 
treatment were studied. During the third year of treatment a difference in bone mass occurs 
between both groups, i.e. the group treated with HRT alone showed a little decline in bone 
mineral mass values, whereas the other group, treated with ND, in addition to HRT showed 
a continuous rise of bone mineral mass, measured with two independent methods. A possible 
explanation for this observation, is the waning effect of HRT, thereby showing more clearly 
the effect of ND. Another explanation might be, the anabolic effect of ND, especially on 
muscle mass, and thereby inducing indirectly an increase in bone mineral mass. After 
treatment had been stopped for one year, a comparable decline in bone mineral mass in both 
groups was observed, although the group also treated with ND had a higher value of bone 
mass after this year of follow-up. Also biochemical parameters showed a comparable pattern 
in both groups after treatment was withdrawn, Le. a rather high increase in bone turnover 
parameters. The virilizing effects of ND were noticeable at various sites. During tlle use of 
ND changes of the voice occurred, which were only partly reversible after the treatment was 
withdrawn. Muscle mass, extrapolated from serum creatinine values, increased. Also the 
amount of hemoglobin increased, as a result of increased erytropoiesis. The positive effect 
of HRT on plasma lipids was blunted by the addition of ND. 
In conclusion, the combination of HRT and ND seems not to be a combination to be used 
routinely in the treatment of postmenopausal osteoporosis. Only minor positive effects of 
addition of ND with respect to bone mineral mass were found during the third year of 
treatment, while on the other hand some side effects were observed in the group treated with 
ND in addition to HRT. 
In chapter 8 the effects of another anti-resorptive agent namely a bisphosphonate, 
pamidronate, on the bone mineral mass and bone turnover parameters are described in a 
group of patients with postmenopausal osteoporosis. The patients were treated with growth 
hormone (GH) in a placebo-controlled manner, as a stimulator of bone turnover. The results 
showed a decrease of bone resorption when treatment with pamidronate only was given, 
which resulted in an increased bone mass. In the group, in which the patients were also 
treated with GH, in addition to pamidronate, this effect on bone mineral mass was not found. 
The biochemical parameters in this group (GH plus pamidronate) did not show many 
changes, when compared to the group, treated with pamidronate only. Next to the effect on 
bone mineral mass and bone turnover also the effects on body composition are described. In 
the GH-treated group, a clear effect of GH was shown, i.e. a decrease of fat tissue and an 
increase of lean body mass (indicating an increase of muscle mass). Several hypotheses about 
the differences between both treatment groups are discussed in this chapter. 
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In c/zapler 9 again effects of GH, combined with the administration of pamidronate are 
presented. In this study, growth hormone deficient patients were studied. The same group 
of patients was also treated with GH-only 3 years ago. The results, previously obtained, were 
compared with results obtained in the same group, now treated with a combination of GH 
and pamidronate. When the patients were treated with GH and pamidronate an increase in 
bone mass was observed. In the earlier study, a small decrease in bone mass was found. The 
additional administration of pamidronate seems to antagonize this loss. It is important to 
emphasize that the bisphosphonate treatment was started two weeks after treatment with GH 
had begun. This may be an important difference with respect to the treatment in the 
postmenopausal women, in whom both medications were started at the same time. The effect 
on bone turnover parameters with the combined treatment of GH and pamidronate was less 
than with the treatment of GH alone. This is probably due to the anti-resorptive effect of 
pamidronate. 
In c/zapler 9 also the effect of GH and GH combined with pamidronate on the calciotropic 
hormones: parathyroid hormone, 25-(OH) Vit D, and 1,25-(OH), Vit D, and their effect on 
the tubular reabsorption of phosphate are discussed. It is conCluded, that GH induces an 
increase in tubular reabsorption of phosphate, which can be counteracted by simultaneous 
administration of pamidronate. 
In c/zapler 10 the normal values of bone mineral mass, in the lumbar spine as well as in the 
proximal femur, are presented, measured in a group of 260 healthy Dutch females, by means 
of DXA. Also an analysis with respect to risk factors was performed. In the premenopausal 
women a small age-related loss was observed in the lumbar spine as well as in the proximal 
femur. In the postmenopausal women a far greater age-related loss (2-3 times) at the various 
sites of measurement. was found. With respect to risk factors, especially an early menopause 
was shown to be an important risk factor, whereas also breast feeding had a small negative 
effect on bone mineral mass. 
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Osteoporose is een ziektebeeld, dat de laatste jaren volop in de belangstelling is komen te 
staan. Dit is vooral een gevolg van de toenemende vergrijzing van de bevolking, aangezien 
het optreden van osteoporose toeneemt met de leeftijd. 
Bij osteoporose treedt naast een vermindering van de hoeveelheid bot, ook een verminderde 
structurele kwaliteit van het bot op, waardoor het uiteindelijke resultaat van de osteoporose 
of 'botontkalking', namelijk een toename van het aantal fracturen, en dan met name heup-, 
wervel- en onderarmfracturen, voor een ieder duidelijk zichtbaar wordt. 
Osteoporose kan worden onderverdeeld in een primaire en secundaire vonn, waarbij de 
secundaire vorm veroorzaakt wordt door een onderliggende ziekte. Primaire osteoporose is 
gerelateerd aan een groat aantal risicofactoren, maar de Yoomaamste oorzaak is het optreden 
van de menopauze. Bij het verliezen van de oestrogeenproduktie, treedt een sterke toename 
van de botafbraak op, hetgeen leidt tot afname van de botmassa. Aangezien dit verlies van 
oestrogeen produktie, belangrijk voor het ontstaan van osteoporose, is ook de incidentie van 
osteoporose bij vrouwen veel hager dan bij mannen. Aangezien er echter oak andere factoren 
een rol spelen is osteoporose ruet een geslachtsgebonden ziektebeeld. 
De fracturen, met name de heupfracturen, leiden tot een hoge morbiditeit en uiteindelijk ook 
een relatief hoge mortaliteit. Het is dan ook zeker de moeite waard om het optreden van 
osteoporose te proberen te voorkomen. Naast het voorkomen van osteoporose is het oak 
noodzakelijk om bij patienten met osteoporose een verdergaande botafbraak te voorkomen. 
In hoojdstllk 1 worden de diverse risicofactoren en epidemiologische aspecten van 
osteoporose verder toegelicht. 
Aangezien een lage of verlaagde botmassa een van de belangrijkste factoren is voor het 
optreden van fracturen is het van belang deze botmassa zo nauwkeurig mogelijk te kunen 
vaststellen en te kunnen vervolgen. In het veri eden waren slechts beperkte mogelijkbeden om 
de botmassa vast te kunnen stellen beschikbaar. De laatste twee decennia zijn er een aantal 
meetmethoden ontwikkeld. Deze technieken zijn in staat op een niet-invasieve wijze een 
indruk te geven van de botmassa. Helaas zijn deze meetmethoden ruet in staat een uitspraak 
te doen over de samenhang van het bot, een factor ook belangrijk voor de sterkte van het 
bot. In hoojdstuk 2 zijn de diverse botmassametingen besproken. Concluderend kan gesteld 
worden dat er momenteel een aantal verschillende methoden met een hoge precisie en 
gevoeligheid beschikbaar zijn. Deze hoge precisie en gevoeligheid alsmede een lage 
stralingsbelasting, heeft er toe geleid, dat ook in longitudinale studies het natuurlijk en 
pathologische beloop van de botmassa of een effect van behandeling kan worden vastgesteld. 
Naast de meetmethoden welke afbankelijk zijn van radioactieve straling of rontgenstraling 
wordt ook de toepassing van ultrageluid als mogelijkbeid om botmassa te bepalen besproken. 
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Door middel van het vervolgen van diverse merkstoffen van botmineraal metabolisme in het 
bloed of in de urine, is het mogelijk een uitspraak te doen over de ombouwactiviteit of 
turnover van het bot. Deze merkstoffen zijn onder te verdelen in 2 groepen, de ene groep 
is gerelateerd aan botaanmaak, de andere aan botafuraak. Bij het optreden van de menopauze 
treedt een toe name van de botombouwactiviteit op, hetgeen zich uit in stijging van de 
verschlllende merkstoffen. 
De merkstoffen kunnen worden vervoIgd bij het toepassen van verschillende behandelingen. 
In het algemeen zijn de aanmaak en afuraak van bot gekoppeld, dit betekent dat bij een 
afname van de afuraak vervolgens ook de aanmaak wordt geremd. In hoofstuk 3 worden de 
verschillende biochemische merkstoffen van de botombouw besproken. Totnogtoe is er helaas 
geen "gouden standaard" beschikbaar, zodat in ieder geval voorlopig nog een combinatie van 
de aanwezige merkstoffen moet worden gebruikt om inzicht te krijgen in de 
botombouwactiviteit. 
De afgelopen jaren is men op zoek geweest naar een goede behandeling om het optreden van 
osteoporose te voorkomen, dan wei cen behandeling toe te passen bij het aanwezig zijn van 
osteoporose. De behandeling van osteoporose heeft als doel het optreden van fracturen te 
voorkomen dan weI het aantal te verminderen. In "oofds/llk 4 worden de verschillende 
behandelingsschema's, zoals deze zijn toegepast, besproken. Wat betreft het voorkomen van 
osteoporose, is de rueest beproefde methode met goede resultaten, het toevoegen van 
oestrogenen. Dit dient dan binnen enkele jaren na het bereiken van de menopauze gestart 
worden. Over andere preventieve behandelingen is slechts weinig bekend. 
Voar de behandeling, bij het aanwezig zijn van osteoporose, zijn een groot aantal studies 
verricht met wisselende resultaten. In lwofds/llk 4 wordt de opzet van de verschillende 
behandelingsschema's in cen aantal labellen toegelicht. Naast oestrogenen zijn cen groat 
aantal andere medicamenten toegepast. Uiteindelijk wordt in lwofdstuk 4 ook kort ingegaan 
op het voorkomen en de behandeling van osteoporose bij mannen, en osteoporose bij het 
gebruik van corticosteroi'den. 
De in dit proefschrift beschreven onderzoeken, richtten zich op de combinatie van de diverse 
medicanlenten en het effect hlervan op zowel de botmassametingen als ook de biochemische 
botombouwactiviteit. Het doel was om te onderzoeken of het mogelijk was met verschillende 
medicamenten de koppeling tussen aanmaak en atbraak te doorbreken en op die manier een 
verdergaand en aanhoudend effect op de botmassa te bewerkstelligen. 
In llOofds/uk 6 worden de effecten van homlOnale replacement therapie (HRT), gedurende 
twee jaar behandeling, al dan niet gecombineerd met nandrolone-decanoate (ND), een 
anabool steroid, beschreven. Hierbij werd een duidelijke toename van de botmassa 
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waargenomen, zowel in de lumbale wervelkolom als aan de onderarm. De biochemische 
parameters toonden een onderdrukking van de botombouw. Tussen de beide groepen konden 
geen duidelijke verschillen worden waargenomen, en op grond van de gevonden resultaten 
kon dan ook van ontkoppeling tussen formatie en resorptie niet worden gesproken. 
Hoofdstuk 7 beschrijft de effecten in dezelfde groep patienten, waarbij de behandeHng van 
beide groepen gedurende een derde jaar wordt gecontinueerd. Tevens wordt het effect van 
het staken van de therapie na 1 jaar beschreven. Gedurende het derde jaar treedt er een 
verschil op in botmassa tussen beide groepen, waarbij de groep, behandeld met HRT een 
geringe daHng in de botmassa verloont, maar de andere groep, welke naast HRT oak met ND 
behandeld een aanhoudende stijging vertoont, gemeten met twee verschillende methoden. Een 
mogeHjke verklaring voor deze observatie is, dat het effect van HRT verdwijnt, waardoor 
het effect van ND zichtbaar wordl. Een andere verklaring is dat het anabole effect van ND, 
met name op de spieren, de oorzaak is van cen toename van de botmassa. 1 jaar na het 
staken van de therapie in beide groepen, toonden beide groepen een vergeHjkbaar verHes van 
botmassa, waarbij de groep behandeld met ND op een hoger niveau van botmassa zit, dit 
tengevolge van een hogere botmassa na het derde jaar. Ook de biochemische parameters 
gedurende het vierde jaar van follow-up tonen een vergelijkbaar beloop in beide groepen, 
nameHjk een forse stijging van de botombouw parameters. 
Het viriliserende effect van ND was waameembaar op verschillende plaatsen. Bij het gebruik 
van ND traden forse stemveranderingen op, welke deeIs reversibel waren na het staken van 
de behandeHng. Spiermassa, gemeten aan een stijging van het serum kreatinine gehalte, 
toonde een toename. Het hemoglobine gehalte steeg fors bij het gebruik van ND. Dit laatste 
kan worden toegeschreven aan een positief effect van ND op de erytropoiese. Het positieve 
effect van HRT op de plasmalipiden werd teniet gedaan door toevoeging van ND. 
Concluderend Hjkt het niet ge[ndiceerd de combinatie van HRT en ND in de behandeling van 
osteoporose routinematig toe te passeD. 
In IlOofdstuk 8 worden de effecten van een bisfosfonaat, pamidronate, op de bot massa en 
botombouw weergegeven in ceo groep patienten met postmenopausale osteoporose. Dit 
bisfosfonaat is cen botresorptieremmer. Tevens werden de patienten placebo-gecontroleerd 
behandeld met groeihormoon (GH) als stimulator van bottumover. De resultaten toonden een 
goede remming van de botresorptie met pamidronate, gecombineerd met placebo, gepaard 
gaande met een forse toename van de botmassa. In de groep welke werd behandeld met GH 
en pamidronate werd dit effect op de botmassa niet waargenomen. De biochemische 
parameters in deze groep waren minder duideHjk gewijzigd in vergeHjking met de placebo-
behandelde groep. Naast de effecten op botmassa en botombouw activiteit werd ook naar de 
Hchaamssamenstelling van beide groepen gekeken. In de groep behandeld met GH was een 
duideHjk effect zichtbaar van dit GH, namelijk afname van de hoeveelheid vetweefsel en 
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toename van de vet vrije massa (~ o.a. spier). Over de verschillen, zoals deze tussen heide 
groepen werden waargenomen, zijn diverse hypothesen op te stellen welke in de discussie 
van het hoofdstuk worden toegelicht. 
In hooidstuk 9 worden opnieuw de effecten van GH in combinatie met pamidronate 
beschreven, echter nu in GH deficiente patienten. Dezelfde groep patienten was in het 
verI eden (3 jaar terug) met aileen GH behandeld geweest. De resultaten welke toendertijd 
werden verkregen werden nu vergeleken met de huidige resultaten. Hierbij bleek dat met de 
combinatie van GH en pamidronate een toename van de botmassa optrad. Bij het eerdere 
onderzoek (aileen behandeHng met GH) werd een geringe afname van de botmassa 
waargenomen. De toevoeging van pamidronate lijkt dit verlies tegen te gaan. Het is van 
belang te benadrukken, dat de toediening van pamidronate pas twee weken na de start met 
GH werd gestart. Dit is een duideHjk verschi! met de behandeling van de postmenopauzale 
vrouwen met osteoporose, waar beide medicamenten tegelijkertijd werden gestan. Het effect 
op de biochemische botombouw parameters was bij de behandeHng met zowel GH als 
pamidronate minder uitgesproken dan eerder. Dit wordt waarschijnlijk veroorzaakt door 
remming van de botresorptie door pamidronate, waarbij er in de eerdere studie aileen een 
anabool hormoon, GH, werd gegeven. 
In IlOoids/uk 9 wordt oak het effect van GH en pamidronate op de diverse calciotrope 
hormonen; parathyroid hormoon, 25-(OH) Vit D, en 1,25-(OH), Vit D, en hun effect op de 
terugresorptie van fosfaat in de nier besproken. Geconcludeerd wordt GH een toename van 
de renale fosfaat terugreabsorptie geeft, hetgeen kan worden tegengegaan door geHjktijdige 
toediening van parnidronate. 
In hooids/uk 10 worden de normaalwaarden van bot massa, van zowel de Iumbale 
wervelkolom als de heup gepresenteerd, zoals deze in een groep van 260 gezonde 
Nederlandse vrouwen met behulp van DXA werden verkregen. Tevens werd een analyse 
verricht naar risicofactoren. In de premenopauzale groep vrouwen werd een gering van de 
Ieeftijd afhankeHjk verHes van de botmassa w.argenomen in zowel de wervelkolom als in de 
heup. Bij de postmenopauzale vrouwen werd een veel duidelijker (2-3 x zo groat) 
Ieeftijdsafhankelijk botmassa verHes waargenomen. Met be trekking tot risicofactoren bleek 
een menopauze op jonge leeftijd een fors risico met zich ruee te dragen, tenvijl ook 
borstvoeding een gering negatief effect op de botmassa had. 
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Het verrichten van het in dit proefschrift beschrevcn onderzoek zou niet rnogelijk zijn 
geweest zonder de hulp van cen groat aantal personen. Ik wil dan ook cen ieder. die met 
ideeen en suggesties bij de realisatie van dit proefschrift behulpzaam is geweest, bedanken. 
Allereerst Prof. dr. J.C. Birkenhager, die de onderzoeken begeleidde en mij uitgebreid van 
advies heeft gediend bij het optreden van problemen, zoals deze bij klinische studies kunnen 
optreden. Met name van zijn zeer uitgebreide kennis op het gebied van calcium en 
botstofwisseling werd dankbaar gebruik gemaakt. 
Dr. H.A.P. Pols, Huib, jou wil ik natuurlijk bedanken voor aile nuttige en stimulerende 
adviezen. Ondanks het feit, dat bepaalde resultaten en artikelen vaak later (te laat ?) gereed 
waren heb je nooit afgehaakt, waarvoor mijn hartelijke dank. Dankzij jou gingen oak de 
namen van de onderzoekers in 'bottenland' spreken. 
Mw. D.H. Birkenhager-Frenkel wil ik bedanken voor de introductie in de 
bothistornorfometrie. Hierdoor kreeg ik inzicht in de dynamische veranderingen in het bot 
door osteoblasten en osteoclasten, waarbij duidelijk zichtbaar wordt dat bot niet een 'dade' 
substantie is maar zeer aktief weefsel. Oak werd hierdoor duidelijk wat het optreden van 
osteoporose betekende voar het trabeculaire en corticale bot. 
Het verpleegkundig personeel van de balansafdeling, tegenwoordig Clinical Research Unit, 
vocr hun gastvrije ontvangst van aile patienten. Nag jaren na afloop van de onderzoeken, 
vertelden zij op de diverse polikliniken, hoezeer zij de persoonlijke benadering op de 
balansafdeling hebben gewaardeerd. 
Mw. J. van Vuure, hartelijk dank voor het maken van aile administratieve afspraken, 
waardoor het mogelijk was de klinische trials, waarbij planning van het grootste belang is, 
goed af te ronden. 
Mw. C. van Aller, Cootje, bedankt voor aile bloedafnames, en met name voor het perfect 
en zeer geordeod bewaren van aile monsters in de diepvriezers, waardoor het bij herhaling 
mogelijk was aanvullende bepallngen te verrichten. Oak voar de invoer van een groat deel 
van de data was jij een onmisbare steun. 
Het personeel van de afdeling nucleaire geneeskunde voor hun gastvrijheid. Marcel van de 
Pluijrn en Jopie Hensen, bedankt voor aile uiUeg met be trekking tot het verrichten van de 
metingen en het berekenen hiervan op zowel de DPA- als DXA-machine. 
Jopie Hensen was samen met Gre van de Wacht en Agnes de Lange, altijd bereid zowel voor 
de patienten, als voor de 'noffilalen', tijd in te ruimen, zodat de scans op korte termijn 
konden worden verricht. 
Van het laboratorium inwendige geneeskunde III wil ik met name Cock Buurman en Gert-Jan 
van de Bemd bedanken, die steeds weer bereid waren de grote hoeveelheden bloed en 
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urinemonsters met voorrang te behandelen. Bij herhaling kwam ik langs met de vraag of er 
'nog eventjes' een honderdtal aanvullende bepalingen konden worden verricht. Vrijwel 
zonder uitzondering waren jullie in staat dit op zeer korte termijn te doen. 
Dr. Paul Mulder, voor alle statistische bewerkingen en het begrijpelijk maken van de vaak 
uitgebreide uitdraaien, 'telefoonboekdikte'. 
Douwe Aigra voor zijn statistische bewerking en adviezen bij het norrnaalwaarden project, 
waardoor de interpretatie van diverse varia belen werd verduidelijkt. Ook het begrip 
'confounders' heb ik door hem beter leren te begrijpen. 
Van de afdeling radiodiagnostiek Cees van Kuijk, voor het maken en berekenen van alle CT 
scans bij de patienten, welke behandeld werden in de nandrolone-decanoateioestrogeen-
progestageen trial. De rontgen foto's van de thoracale en lumbale wervelkolom werden op 
vakkundige en gestandaardiseerde wijze gemaakt door Wiebeke van Leeuwen. 
Niek Valk, bedaok ik voor zijn hulp bij de berekening en interpretatie van de 
lichaamssamenstelling bij de studies met toediening van groeihormoon. 
Aangezien mijn eigen artistieke talenten beperkt zijn. ben ik Marisa Klaster dank 
verschuldigd voor het uiteindelijke bereikte resultaat met betrekking tot de omslag van dit 
proefschrift. 
De beschreven studies in dit proefschrift hadden natuurlijk nooit plaats kuonen vinden lOnder 
de medewerking van de patienten en de gelOnde vrijwilIigers. 
Oak de diverse verwijzers, zowel binnen maar ook buiten het Dijkzigt ziekenhuis zijn van 
groot belang geweest bij het verkrijgen van te includeren patienten voar de diverse studies. 
Pieter Postema en Rob Vos wil ik hartelijk bedaoken voor hun belangrijke rol als paranimf, 
maar ook voor hun collegialiteit en gezellige perioden tijdens de opleiding tot internist en 
daarbuiten. 
Mijn ouders wil ik in bedaoken voor de mogelijkheden, welke zij mij geboden hebben. 
Zonder hun onvoorwaardelijke steun tijdens mijn studie en daama was ik nooit op dit punt 
aangekomen. 
Lieve Ema, aangezien jij zelf de promo tie perikelen in het verleden al had meegemaakt. vond 
ik bij jou altijd een gewillig oor om frustraties te uiten. Hiema kon met frisse moed verder 
worden gegaan. Waarvoor daok. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 7 september 1964 te Genemuiden. Na het 
behalen van het Atheneum B diploma aan de Rijksscholen Gemeenschap te Meppel, werd in 
1982 met de studie geneeskunde aangevangen aan de Erasmus Universiteit te Rotterdam. In 
1989 werd het artsexamen afgelegd. Aansluitend was hij tot 1990 werkzaam als 
wetenschappelijk medewerker bij de afdeling Inwendige Geneeskunde III van het Academisch 
Ziekenhuis "Dijkzigt" te Rotterdam (hoofd Prof. Dr. J.C. Birkenhiiger) op de afdeling 
Klinische Pathologie (Mw. D.H. Birkenhiiger-Frenkel), waarbij de basis voor dit proefschrift 
werd gelegd. Vanaf januari 1990 was de schrijver werkzaam als arts-assistent op de afdeling 
Inwendige Geneeskunde III en per I december 1990 werd de opleiding tot internist 
aangevangen op dezelfde afdeling (hoofd Prof. Dr. J.C. Birkenhager). Op I september 1995 
werd gestart met de opleiding in het kader van het aandachtsgebied Endocrinologie. Het 
onderzoek zoals beschreven in dit proefschrift werd deels op de Balans-afdeling (Clinical 
Research Unit, hoofd Prof. Dr. J.e. Birkenhiiger) en deels op de afdeling Nucleaire 
Geneeskunde (hoofd Prof. Dr. E.P. Krenning) verricht, in samenwerking met de afdeling 
Radiodiagnostiek (hoofd Prof. Dr. H.E. Schlitte). 
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